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1. Er zijn goede indirecte bewijzen dat transforming growth factor-03 een multi-
fuctioneel gedrag vertoont in vivo. 
2. De afname van de TGF-/? productie door estrogeen vindt niet noodzakelijkerwijs 
plaats op het post-transcriptionele niveau zoals geconcludeerd werd door Knabbe 
er al. (1987), maar kan worden verklaard door de aanwezigheid van verscheidene 
genen voor TGF-/? iso-vormen, die verschillen in hun transcriptionele regulatie. 
Knabbe er al., Cell 48, 417-428 (1987). 
3. De waarneming van Arrick ef al. (1990) waarin de MCF-7 borstkankercellen geen 
TGF-/72 en TGF-/83 mRNA expressie vertonen, is mogelijk te wijten aan de 
aanwezigheid van estrogeen in het serum en het estrogene effect van fenolrood 
in de media gedurende de celgroei. 
Arrick et al., Cancer Res. 50, 299-303 (1990). 
M.-H. Jeng, pers. communicatie. 
4. Bepalingen van de juiste relatieve biologische activiteit tussen de verschillende 
TGF-/0 iso-vormen voor een bepaald celtype dienen te worden uitgevoerd onder 
a2-macroglobuline-vrije condities in het groeimedium. 
Danielpour en Sporn, J. Biol. Chem. 265, 6973-6977 (1990). 
5. De activine iso-vormen spelen zeer waarschijnlijk een belangrijke rol in de inductie 
van mesoderm gedurende de gewervelde embryogenese. 
Smith ef al., Nature 345, 729-731 (1990). 
Van der Eijnden-Van Raaij et al., Nature 345, 732-734 (1990). 
Thomson ef al., Cell 63, 485-493 (1990). 
6. De door Pribilla ef al. gedeeltelijk gezuiverde hittebestendige remmer van protein 
kinase C is het EDTA, dat was toegevoegd in de homogenisatie buffer. 
Pribilla et al., Eur. J. Biochem. 177, 657-662 (1988). 
Zevgolis et al., Eur. J. Biochem. 788, 203-204 (1990). 
7. Adjuvant therapie met tamoxifen zou mogelijk van voordeel kunnen zijn voor 
estrogene-receptor negatieve borstkankerpatienten. 
Breast Cancer Trials Committee, Lancet 2, 171-175 (1987). 
8. De expressie van de NM23 gen blijkt geassocieerd te zijn met een goede 
prognose in geval van borstkanker. 
Bevilacqua et al., Cancer Res. 49, 5185-5190 (1989). 
Hennessey étal., J. Natl. Inst. 83, 281-286 (1991). 
9. Als bij een rechtzaak de rechtspleging gebaat is bij een getuigenis, die gebruik 
maakt van "DNA finger printing", is een kritische wetenschappelijke inspectie van 
het bewijsmateriaal noodzakelijk. 
Neufeld and Colman, Scientific Am. 262, 46-653 (1990). 
10. In studies waarin de bevindingen direct de volksgezondheid betreffen is het van 
groot belang dat de onderzoekers hun resultaten, voordat deze aan de pers 
worden medegedeeld, laten beoordelen door collega's. 
11. Er kan een belangenconflict ontstaan wanneer klinische onderzoekers, die de 
toxicologie en effectiviteit van nieuwe medicijnen evalueren als betaling effecten 
(opties) ontvangen. 
12. In de biotechnologische industrie zijn de beloften voor medische doorbraken en 
de financiële verwachtingen van investeerders niet altijd in overeenstemming 
geweest met de technische realiteit. 
13. Als onderzoeker denkt men soms eindelijk het licht aan het einde van de tunnel te 
zien, maar in plaats daarvan blijkt het een tegemoetkomende trein te zijn. 
Stellingen behorend bij het proefschrift: 
Molecular Characterization of Transforming 
Growth Factor-/ff3 
Peter ten Dijke, Wageningen, 27 November 1991. 
1. Good circumstantial evidence exists that transforming growth factor-#3 has multi-
functional properties in vivo. 
2. The decrease of the TGF-0 production by estrogen does not necessarily occur at 
the post-transcriptional level as concluded by Knabbe et al. (1987), but can be 
explained by the existance of multiple closely related genes of TGF-0S, that are 
differently transcriptionally regulated. 
Knabbe ef al, Cell 48, 417-428 (1987). 
3. The observation by Arrick ef al. (1990) that MCF-7 breast cancer cells do not 
express TGF-02 and TGF-/?3 mRNA, is possibly due to the presence of estrogen 
in the serum and the estrogenic effect of phenol red in the media during cell 
growth. 
Arrick ef al., Cancer Res. 50, 299-303 (1990). 
M.-H. Jeng, personal communication. 
4. For true relative potency of the biological effects of the different TGF-/? isoforms, 
the activity measurements should be performed under o2-macroglobulin-free 
conditions in the media. 
Danielpour and Sporn, J. Biol. Chem. 265, 6973-6977 (1990). 
5. Activins are likely to play a key role in mesoderm induction during vertebrate 
embryogenesis. 
Smith etal., Nature 345, 729-731 (1990). 
Van der Eijnden-Van Raaij ef al., Nature 345, 732-734 (1990). 
Thomson ef al., Cell 63, 485-493 (1990). 
6. The partially purified heat resistant and low M.W. inhibitor of protein kinase C 
isolated by Pribilla ef al. (1988) is the EDTA, that was included in the 
homogenization buffer. 
Pribilla ef al., Eur. J. Biochem. 177, 657-664 (1988). 
Zevgolis ef al., Eur. J. Biochem. 188, 203-204 (1990). 
7. Adjuvant therapy with tamoxifen may be benefitial for estrogen-receptor negative 
breast cancer patients. 
Breast Cancer Trials Committee, Lancet 2, 171-175 (1987). 
8. The expression of the NM23 gene appears to be associated with good prognosis 
in breast cancer. 
Bevilacqua etal., Cancer Res. 49, 5185-5190 (1989). 
Hennessey ef al., J. Natl. Inst. 83, 281-285 (1991). 
9. If justice is to be served in courts of law with forensic testimony using DNA finger 
printing, critical scientific review of the evidence is neccesary. 
Neufeld and Colman, Scientific Am. 262, 46-53 (1990). 
10. In studies in which the findings suggest a direct effect on human health care, the 
researchers should be particular careful to submit their results to thorough peer 
review before releasing it to the news media. 
11. A conflict of interest is created when clinical investigators, evaluating the toxicity 
and efficacy of new drugs, are reimbursed by stock(options). 
12. In the biotechnology industry the promises for medical break throughs and the 
financial expectations of investors have not always been in line with the technical 
realities. 
13. As a researcher one sometimes thinks finally to see the light at the end of the 
tunnel, but instead one is fooled by a train coming towards you. 
Propositions that are part of the thesis: 
Molecular Characterization of Transforming 
Growth Factor-/83. 
Peter ten Dijke, Wageningen, 27 November 1991. 
Aan mijn ouders 
Voor Midory 
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CHAPTER ONE 
Scope of the Investigation 
SCOPE OF THE INVESTIGATION 
Normal tissue homeostasis is controlled by a critical balance of positive and 
negative modulators. Chapter 2 gives an overview of the molecular aspects of growth 
control, in particular the role of growth factors and oncogene and anti-oncogene 
products. Uncontrolled growth of cancer ceils may result from either an abrogation of 
growth stimulatory or a deficiency of growth inhibitory pathways. Mediators of growth 
inhibition include secretory polypeptide growth inhibitors, like transforming growth factor 
ß (TGF-/?) and nuclear proteins, like the retinoblastoma gene product. Early studies on 
organogenesis suggested the presence of growth inhibitors (chalones) to regulate the 
growth of organs. Postulating that growth inhibitory proteins might have potential in 
cancer therapy, we began to analyze human tissues for the presence of novel tumor 
inhibitory factors. Purification of these activities and physico-chemical characterization 
suggested a relatedness to TGF-/?. The biochemistry and cell biology of TGF-/? will be 
reviewed in Chapter 3. 
At the start of the investigation, only one TGF-y? had been identified. Our 
subsequent results indicated that a family of TGF-/? proteins exists. Conventional 
purification of these TGF-yS-like activities provided only limited quantities of material for 
analysis. We therefore adopted an alternative strategy which included the isolation of the 
cDNAs for TGF-/?-like factors using TGF-01 as a probe, assuming that related molecules 
might possess sufficient sequence similarity to cross-hybridize to a TGF-/?1 probe. 
Differential hybridization of a Southern blot with human genomic DNA probed with TGF-
/?1 cDNA suggested the presence of a related gene, which we termed TGF-/83. The 
research described in this thesis includes the molecular cloning and expression of TGF-
03. Furthermore, experiments were carried out to gain insight into the effects of TGF-
03 on cell growth and differentiation and its mechanism of action, including initial studies 
to gauge the potential therapeutic uses of this factor. 
In Chapter 4, we report the cloning of the human TGF-/Ö cDNA and the encoded 
TGF-/83 protein is compared with other members of the TGF-/? family. In Chapter 5 the 
interspecies conservation of TGF-03 is examined and the chromosomal location of the 
human TGF-/Ö gene is determined. In Chapter 6, the recombinant expression and 
purification of TGF-/?3 is described. The purified TGF-/J3 protein has potent growth 
modulating effects on a number of normal as well as tumor cells. The studies in Chapter 
7 were performed to assess the effect of TGF-/J3 on osteoblasts and to characterize the 
specific binding of TGF-/83 to bone cells. TGF-^3 appears to be a potent regulator of 
functions associated with bone formation. Crosslinking studies showed that TGF-/73 and 
TGF-/?1 associate in a similar fashion with three cell surface binding proteins, which have 
been characterized as putative receptor types I and II and a membrane-bound 
proteoglycan, termed betaglycan. The different TGF-/? isoforms appear to have different 
potencies on MvlLu mink lung epithelial and fetal bovine heart endothelial cells. In 
Chapter 8, we investigate the role of TGF-0 receptors and serum factors as determinants 
of the cell-specific responsiveness to the three homodimeric isoforms. The induction of 
mesoderm in Xenopus laevis animal cap expiants by TGF-/J3 is discussed in Chapter 9. 
Finally, in Chapter 10 we review the therapeutic applications of growth factors for wound 
healing. 
CHAPTER TWO 
Molecular Mechanisms of Cell Growth Control: 
Role of Peptide Growth Factors and Oncogene Products 
MOLECULAR MECHANISMS OF CELL GROWTH CONTROL: ROLE OF GROWTH 
FACTORS AND ONCOGENE PRODUCTS 
Peter ten Dijke 
Oncogene Science, Inc., Manhasset, NY, USA 
I. Introduction 
Growth Factors 
a. Discovery and nomenclature 
b. Biochemistry of growth factors 
c. Multiple effects of growth factors 
III. Growth Factor Receptors 
a. Biochemistry of growth factor receptors 
b. Receptors with protein tyrosine kinase activity 
IV. Signal Transduction Pathways 
a. Cytoplasmic second messengers 
b. Modulation of gene expression 
V. Oncogenes and anti-oncogenes 
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b. Tumor suppressors and anti-oncogenes 
c. Interplay between positive and negative growth control 
VI. Growth Factors in Early Embryogenesis 
a. Growth factor expression in pre-implantation embryos 
b. Growth factors regulating embryonic stem cell proliferation and differentiation 
c. Mesoderm induction by growth factors 
VII. Concluding Remarks 
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I. Introduction 
Cellular proliferation and differentiation are controlled, in part, by a complex 
network of interacting growth factors. After cell secretion, growth factors can bind 
specifically to high affinity cell surface receptors, typically on adjacent cells (paracrine) or 
on the producer cell itself (autocrine) and exert a local effect (Sporn and Todaro, 1980). 
Following growth factor-receptor interaction, activated second messengers release 
intracellular signals, which initiate a complex cascade of responses. Ultimately, these 
signals lead to the nucleus and change the expression of target genes. Certain genes 
may be activated or repressed to modulate cell proliferation or differentiation. Other 
molecules involved in cellular communication (but not discussed in this review) are 
extracellular matrix proteins, which mediate direct cell-cell contacts (Loewenstein, 1987), 
steroid and non-steroid hormones, which bind to nuclear receptors(Evans, 1988). 
A number of mediators involved in inter- and intra-cellular signaling mechanisms 
are products of oncogenes (Heldin and Westermark, 1984) or anti-oncogenes (Sager, 
1989; Klein, 1987). Oncogenes were first identified in the genome of acutely oncogenic 
RNA tumor viruses. In 1976, Stehelin et al., showed that a viral transforming gene, or 
oncogene, was in fact derived from the host cell genome (Stehelin ef a/., 1976). The 
normal cellular form of the gene has been termed proto-oncogene. Thus far, more than 
50 oncogenes have been identified (Bishop, 1987; Varmus, 1989). Proto-oncogenes can 
be activated into transforming oncogenes by qualitative or quantitative changes in the 
protein product. Whereas oncogenes classically act in a growth stimulating fashion, anti-
oncogenes appear to have growth inhibitory activities and have been implicated in 
neoplasia when inactivated (Sager, 1989; Klein 1987). Thus far, only a few have been 
identified, and their properties will be reviewed. Several oncogenes and anti-oncogenes 
have been associated with particular forms of cancer (Bishop, 1989). 
The complex interactions between inter- and intracellular signaling molecules, 
oncogenes and anti-oncogenes have been important for our understanding of the 
molecular pathways regulating normal cell growth, as well as those leading to neoplastic 
growth. This review will focus on the role of growth factors and their mechanism of action 
in growth control. Growth factors exhibit multifunctional activities and can participate in 
a variety of diverse physiological processes, such as embryogenesis, immune response, 
hematopoiesis, inflammation, tissue repair and remodeling. In this review, however, only 
the role of growth factors in early mammalian embryogenesis is discussed. 
II. Growth Factors 
a. Discovery and Nomenclature 
Growth factors can be described as a group of small, soluble molecules, usually 
proteinaceous in nature, that bind to specific high affinity cell surface receptors to regulate 
cell proliferation and differentiation. Normally, growth factors are present in intracellular 
spaces at low concentrations and are released from storage upon exposure to the 
appropriate environmental stimuli. The autocrine and paracrine action of growth factors 
confines their effect to neighboring cells (Sporn and Todaro, 1980), in contrast with the 
more classical endocrine hormones which circulate in the blood. However, it has become 
apparent that this classification is somewhat arbitrary. 
Growth factors were initially discovered in the conditioned medium of tumor cells 
and in tissue extracts. The first to be detected was nerve growth factor (NGF), produced 
by mouse sarcoma cells and found to stimulate neurite proliferation (Levi-Montalcini and 
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Hamburger, 1951). Efforts to purify NGF from mouse submaxillary glands which led to 
the identification of another growth factor termed epidermal growth factor (EGF), which 
was also present in this tissue. EGF, which stimulates the premature eyelid opening and 
tooth eruption in newborn mice, was purified using this in vivo effect as an assay (Cohen, 
1962). Other growth factors such as platelet-derived growth factor (PDGF)(Ross et al., 
1974) and transforming growth factor (TGF) were initially detected using in vitro assay 
systems (DeLarco and Todaro, 1978). 
Historically, growth factors were named after the biological assay that lead to their 
identification. For example, to describe growth factors with effects on the immune 
system, the term interleukin or cytokine is often used, while the name colony stimulating 
factors (CSFs) has been given to factors that stimulate bone marrow cells to proliferate 
and differentiate into colonies. However, there is no clear distinction, as many growth 
factors have been found to be multifunctional, not only regulating growth of multiple cell 
types, but also affecting differentiation and functional activities (Sporn and Roberts, 1988). 
Other names, like panregulins, have been proposed for growth factors, but are not widely 
used (Sporn ef a/., 1986). Another implication of the multifunctional ability of growth 
factors is that many growth factors have been and will be rediscovered. Upon isolation 
and sequence determination of a factor with certain biological activities, it sometimes 
occurs that the factor has previously been isolated and characterized. 
b. Biochemistry of Growth Factors 
The structural characteristics and biological effects of a number of growth factors 
are listed in Table 1. Sequence determination has shown that many are structurally 
related. EGF is a member of a family of proteins which includes TGF-o (Marquardt et al., 
1983), amphiregulin (Shoyab era/., 1989) and poxvirus growth factors (Brown era/., 1985; 
Chang et ai, 1987). These molecules bind to a 170 kD receptor with a protein-tyrosine 
kinase activity (Downward ef a/., 1984). Members of this family stimulate proliferation of 
a large number of cell types including epithelial, fibroblastic and endothelial cells 
(Nakagawa ef a/., 1985). The FGF family of growth factors consist of not only of acidic 
and basic FGF (Abraham ef a/., 1986; Gimenez-Gallego et ai, 1985), but also includes the 
hst/ks (Taira et al., 1987; Dickson and Gordon, 1987) and int-2 proto-oncogene products 
(Smith ef a/., 1988b), FGF-5 (Zhan ef a/., 1988), FGF-6 (Maries ef a/., 1989) and KGF or 
FGF-7 (Finch ef a/., 1989). The FGF-family members are mitogenic for cells of 
mesodermal origin and may bind to multiple receptos types, with different affinities 
(Gospodarowicz ef a/., 1986). Three different isoforms of PDGF are formed by homo- or 
hetero-dimerization between a 124 amino acid A chain and a 140 amino acid B chain 
(Stroobant and Waterfield, 1984; Heldin ef a/., 1986; Hammacher ef a/., 1988; Bowen-
Pope ef a/., 1989). The isoforms PDGF-AA, PDGF-BB and PDGF-AB interact differently 
with two receptor types, both of which contain an intrinsic protein-tyrosine kinase activity 
(Hart ef a/., 1988; Heldin ef a/., 1988). Three TGF-/? homodimeric isoforms are present 
in humans, which are formed from two polypeptide chains of 112 amino acids sharing 
approximately 70% amino acid sequence identity (Derynck ef a/., 1985; de Martin ef a/., 
1987; ten Dijke ef a/., 1988). All three proteins interact with high affinity, but different 
potencies, to three cell surface proteins, present on most cells (Cheifetz ef a/., 1987). 
Recently, the type I and type II receptors have been implicated in signal transduction of 
TGF-/?s, and appear to account for many, if not all, of the actions of these molecules 
(Boyd and Massague, 1989; Laiho ef a/., 1990a). TGF-ySs affect the proliferation of 
multiple cell types and can stimulate as well as inhibit cell proliferation (Roberts and 
Sporn, 1990). The colony stimulating factors (CSFs) are growth factors for hematopoietic 
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cells, controlling their survival, proliferation and differentiation (Clark and Kamen, 1987). 
CSFs are not related structurally, act through different receptors, and are classified 
according to the type of mature blood cell soft agar colony to which they give rise. Thus, 
G-CSF and M-CSF support colonies of granulocytes and macrophages, respectively; GM-
CSF and multi-CSF (also termed IL-3) stimulate the colony growth of two or more distinct 
phenotypes. The interleukins act as signaling molecules between the various leucocyte 
cell types (O'Garra, 1989 a,b). Interleukins also exhibit little structuraly homology to one 
another. 
Different members of a growth factor family with similar in vitro activities may have 
different in vivo activities, as different spatial and temporal expression patterns may lead 
to different physiological functions. Furthermore, in vitro sources of growth factors do not 
necessarily correspond to in vivo sources. For example, TGF-/? expression is often 
induced when cells are kept in continuous culture, possibly related to its stimulatory action 
on extracellular matrix formation which facilitates growth on plastic. Also, the in vitro 
biological effects cannot automatically be translated to in vivo activities. TGF-/?s inhibit 
the growth of endothelial cells in vitro. However, they are potent angiogenic factors in 
vivo, the probable mechanism being the chemoattraction of macrophages which are 
activated to secrete angiogenic factors (Roberts ef a/., 1986). 
c. Multiple effects of growth factors 
Many growth factors have multiple effects on cell proliferation and differentiation, 
which appears to be context dependent (Sporn and Roberts, 1988). The presence of 
other growth factors, the cell type and state of differentiation can all modulate the action 
of a particular growth factor. A prototype of a multifunctional growth factor is TGF-/?. In 
combination with TGF-o or EGF, TGF-yff stimulates the growth of NRK cells in soft agar, 
whereas TGF-/? inhibits the growth of NRK cells in monolayer culture (Anzano ef a/., 
1982). TGF-/? stimulates soft agar growth of fibroblasts transfected with a myc oncogene, 
but inhibits growth of these cells in the presence of EGF (Roberts ef a/., 1985). TGF-0 
also stimulates cell proliferation of fibroblasts from very early stage fetuses, but inhibits 
proliferation of fetal fibroblasts from the later gestational stage (Hill ef a/., 1986). 
Growth factors have been suggested to form the signaling components of an 
intercellular language, whose meaning is controlled by context (Sporn and Roberts, 1988). 
The amount of information that can be communicated between cells increases 
enormously when combinations, instead of individual growth factors, are used. However, 
the detailed mechanisms that result in multifunctional effects and the pathways which 
allow these complex interactions to be coordinated are poorly understood. 
Their multifunctionality, together with their potency (typically in the pico Molar 
range) clearly necessitate a tight control of their action in a localized region. A number 
of growth factors are produced in an inactive latent form. For TGF-yff, either activation by 
specific proteases or acidification is necessary to obtain a biologically active protein after 
secretion (Lawrence ef a/., 1985; Lyons etal., 1988). A growth factor, following receptor 
binding, can be inactivated by internalization and degradation by lysosomal proteases 
(Carpenter, 1987). Alternatively, binding proteins or scavenger proteins, like o2-
macroglobulin can inactivate certain growth factors (James, 1990). 
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III. Growth Factor Receptors 
a. Biochemistry of growth factor receptors 
Growth factors act through specific cell surface receptors. Radiolabeled 
biologically active growth factors are often used for labeling of the receptors and to 
characterize their presence, number and affinity on the cell surface. For purification of the 
receptor, a growth factor affinity purification step is often employed. As some growth 
factor receptors have protein tyrosine kinase autophosphorylation activities (Ushiro and 
Cohen, 1980) affinity chromatography using a phosphotyrosine antibody has also been 
used in the receptor purification, eg. the PDGF receptor (Yarden, ef a/., 1986). After 
purification and partial sequencing or antibody generation, the receptor gene can be 
cloned by screening cDNA (expression) libraries with oligonucleotide probes or 
antibodies. Alternatively, direct cloning of the receptor can be achieved by for example, 
screening cDNA library-transient transfected COS cells with radiolabeled ligand and 
autoradiography. 
Two types of growth factor receptors have been structurally characterized and they 
can be classified according to the presence or absence of discrete domains. One class 
of receptors have a characteristic seven membrane spanning motif, such as the ß-
adrenergic receptors (Dixon era/., 1986) and the mas proto-oncogene product (Jackson 
era/., 1988). The N-terminus and C-terminus, located on the extracellular and intracellular 
sides of the plasma membrane, respectively, are connected by a polypeptide chain which 
crosses the membrane seven times. The ligand interacts with the transmembrane helices 
and extracellular loops, while G-proteins (see also part IV on signal transduction) interact 
with the intracellular loops and mediate transduction of the extracellular stimulus to the 
intracellular effector, eg. adenylate cyclase (Sibley ef a/., 1987). The other class of 
receptors are single-chain transmembrane glycoproteins, with a glycosylated extracellular 
ligand binding domain, a hydrophobic transmembrane region, and typically, an 
intracellular domain which possesses an intrinsic enzymatic activity which directly 
mediates the intracellular signal production. Within this class different receptor sub-
groups can be distinguished according to their structural domains and sequence 
homologies (Ullrich and Schlessinger, 1990). 
A number of receptors with a single transmembrane region contain cysteine rich 
repeats on the external domains, such as the EGF receptor family (EGF-R (Lin ef a/., 
1984; Ullrich ef a/., 1984), HER-2/neu (Bargman ef a/., 1986), HER-3 (Kraus et al., 1989) 
and Xmrk (Wittbrodt ef a/., 1989)), with 2 repeats per monomer and the insulin receptor 
family (l-R (Ullrich ef a/., 1985), IGF-R (Ullrich ef a/., 1986) and IRR (Shier and Watt, 1989)) 
with two repeats per disulfide-linked heterotetramer. A number of receptors contain 
multiple immunoglobulin like repeats such as the PDGF receptors A and B (Yarden ef a/., 
1987), CSF-1 (Sherr ef a/., 1985) and the c-kit proto-oncogene product (Yarden ef a/., 
1987) which possess 5 repeats, and the FGF receptors, also termed the fig and bek 
proto-oncogene products with 3 such repeat structures (Ruta et ai, 1989; Pasquale and 
Singer, 1989). The recently identified hematopoitin receptor superfamily (including the 
receptors for erythropoietin, IL-2, IL-3, IL-4, IL-6, IL-7, G-CSF, GM-CSF, growth hormone 
and prolactin) share a characteristic 4 cysteine residues and a Trp-SerX-Trp-Ser sequence 
motif (Cosman ef a/., 1990). The TNF receptor shares homology with NGF receptor in 
their extracellular domains (Schall ef a/., 1990; Loetscher ef a/., 1990). The functional 
significance of the homologous structures is unknown, but suggests that they have 
evolved from ancestral genes. 
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Sequence analysis of the cytoplasmic domain has shown that many growth factor 
receptors posses protein-tyrosine kinase activity, such as EGF-R, IGF-R, PDGF-R and 
FGF-R, which appears essential for their function (Ullrich and Schlessinger, 1990). 
Receptors which lack protein tyrosine kinase activity may associate with other proteins 
having tyrosine kinase activity or other activities. 
Some receptors are complexed with oligomeric GTP-regulatory proteins (G-
proteins) which serve to couple receptors to intracellular effector molecules (Gilman, 
1987). G-proteins are a multi-gene family, composed of a, ß and Y subunits. The a-
subunit appears to be the active moiety, while the ß and y subunits serve to regulate the 
a subunit. Receptor stimulation causes the exchange of the bound GDP on the G-protein 
for GTP. Subsequently, the activated GTP:G-protein complex activates enzymes that 
generate second messengers such as cAMP. The G-proteins possess an intrinsic 
GTPase activity (Gibbs et al., 1984), which terminates this activation. Regulatory proteins 
have been identified that stimulate the GTPase activity, termed GAPs (GTPase activating 
proteins) (Traheg era/., 1988; Vogel et al. 1988). 
The number and affinity of receptors is an important control point for signal 
regulation. The expression of growth factor receptors can be regulated at both the 
transcriptional and translational level. The affinity of the receptor can also be regulated 
by post-transcriptional modification leading to conformational receptor changes creating 
subclasses of receptors. The binding of ligand to the receptor often leads to decreased 
receptor numbers, a process known as down-modulation (Green and Olefsky, 1982). 
One mechanism involved in this process appears to be an increased rate of receptor 
degradation. After binding of the growth factors with their receptors, the complex is 
internalized and may either be targeted to the lysosomes for degradation (as for EGF) 
(Carpenter, 1987) or recycled to the cell surface (as for insulin)(Oka et al., 1984). 
Different receptors are also able to regulate each other, a process known as receptor 
cross-talk or transmodulation, which involves changes in receptor distribution and affinity 
between the cell surface membrane and intracellular compartments. For example, 
addition of PDGF to cells can decrease the affinity of the EGF receptor for its ligand 
(Bowen-Pope et al., 1983). A detailed description of structure and function of each 
receptor family is beyond the scope of this review. However, the function and regulation 
of receptors with protein-tyrosine kinase activity are discussed in more detail. 
b. Receptors with Protein-Tyrosine Kinase Activity 
Some growth factor receptors possess an intrinsic protein-tyrosine kinase activity 
(Ullrich and Schlessinger, 1990). Upon ligand binding, the signal is transmitted across 
the plasma membrane and activates the tyrosine kinase activity of the intracellular domain. 
The mechanism whereby the signal is transmitted is not clear. One model proposes that 
growth factors induce dimerization of the receptor (Schlessinger, 1988; Williams, 1989; 
Heldin and Westermark, 1990). Either the ligand binding may induce a conformational 
change in the extracellular domains, as shown for the monomeric ligand EGF or the 
dimeric ligand itself as shown for PDGF, may lead to receptor dimerization. The receptor 
dimerization presumably stabilizes the interaction of the two cytoplasmic domains with a 
concomitant activation of the protein tyrosine kinase activity (Yarden and Schlessinger, 
1987). Dimerization may also occur between structurally similar receptors leading to 
hybrid receptors, which could generate different signals. Heterodimerization of the EGF 
receptor and the p185 — protein has been observed to modulate EGF receptor function 
(Goldman ef ai, 1990; Wada ef a/., 1990) The presence of different dimeric ligand 
isoforms, as is the case for PDGF, can also lead to distinct receptor signaling 
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(Hammacher et al., 1989). Homology comparison between family members shows that 
the transmembrane region is less conserved than the extra- and intra-cellular regions, 
suggesting that it may have only a minor function, if any, in signal transmission. Based 
on the structure of the transmembrane region it appears unlikely that a conformational 
signal could be transmitted directly through this region; more likely, this domain functions 
as an anchor of the receptor to the membrane. It is of interest, however, that a single 
point mutation in the transmembrane domain of the HER-2/neu receptor was found to be 
sufficient for activation of protein tyrosine kinase function (Stern et al., 1988) and to confer 
transforming potential to the receptor, possibly by inducing receptor dimerization (Weiner 
era/., 1989). 
IV. Signal Transduction Pathways 
a. Cytoplasmic Second Messengers 
After a growth factor binds to its receptor, many rapid changes can occur in the 
cell, including stimulation of inositol formation (Berridge, 1987), Ca2+ influx (Moolenaar 
et al., 1984), activation of Na+/H+ exchange (Pouyssegur et al., 1985) and protein 
phosphorylation of cellular substrates. While there has been an explosion of information 
in this area in recent years, the events leading to the modulation of gene expression 
remain poorly understood. It appears that many ligand-receptor systems activate 
common second messengers. The two best characterized are the cAMP and inositol 
phosphate pathway. Activation of adenylate cyclase yields cAMP, which in turn activates 
a cAMP dependent protein kinase (Edelman er al., 1987). Phospholipase C stimulates 
the hydrolysis of a membrane lipid phosphatidyl inositol 4,5-diphosphate (PIP2) yielding 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3)(Berridge, 1987). Subsequently, 
DAG can activate protein kinase C (PKC) and IP3. IP3 triggers a transient release of Ca + 
from intracellular compartments which elicits a number of rapid metabolic changes. 
Activation of ion channels, such as the Na+/H+ antiporter occur by virtually all growth 
promoting agents (serum, growth factors, vasopressin, bradykinin, etc). However, it 
remains controversial if changes in pH and cation concentration act as a second 
messenger system or merely serve to compensate for pH changes resulting from 
increased rate of glycolysis. 
Recently, it was shown that both PDGF and EGF receptors associate with 
multiprotein complexes consisting of phosphatidyl inositol kinase (Coughlin era/., 1989) 
and phospholipase C (Kumjian era/., 1989; Morrison era/., 1990), a GTPase activating 
protein (GAP)(Kaplan era/., 1990), which is involved in the control of ras activity, and the 
c-rar" proto-oncogene product, which is a serine/threonine kinase (Kaplan er al., 1990; 
Morrison et al., 1989) and members of c-src family oncogene products (c-src, c-fyn and 
c-yes) which are tyrosine kinases (Kypta ef ai, 1990). Upon ligand stimulation these 
proteins are phosphorylated and activated. 
b. Modulation of gene expression 
One of the principal mechanisms of growth factor action is to control gene 
transcription. Ultimately, the transcription of the growth factor target genes is controlled 
by the interaction of RNA polymerase II with specific transcription factors. These 
transacting factors recognize and bind specific DNA sequence (cis-acting) elements in the 
promoter/enhancer region of the gene. The type, number and spacial array of cis 
elements allows a unique combination of factors to regulate each gene. The organization 
of the cis elements together with their occupation by the appropriate transacting factors 
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ultimately determines the transcription rate (Mitchell and Tjian, 1989). Via cytoplasmic 
second messengers, the status of the transacting factors changes (see discussion below) 
resulting in either a positive or negative change in the rate of transcription (or activity) of 
a relatively small number of primary response gene products. Many of these primary 
response genes themselves encode transcription factors, such as members of the jun (c-
jun, jun B and jun D)(Maki ef al., 1987; Nakabeppu er al., 1988; Ryder er al., 1988) and 
fos proto-oncogene families {c-fos, fra-1, fos-B)(Cohen and Curran, 1988). Their protein 
products can in turn activate or repress the transcription of secondary response genes, 
resulting in a cascade of regulated transcriptional modulation. 
Growth factors with quite different and multiple biological activities induce the 
transient expression of a relatively small number of common early response genes 
(perhaps 50-100)(Herschman, 1989). For example, upon addition of serum, PDGF, EGF 
or NGF, the expression of the early response gene c-fos is rapidly stimulated (Greenberg, 
and Ziff, 1984; Kruijer era/., 1984; Bravo etal., 1985; Kruijer era/., 1985). A number of 
potential mechanisms operate to obtain growth factor and cell specific responses. By 
influencing the number and array of synergizing or antagonizing transcription factors, the 
transcription rate of different genes will alter differently. Many single promoter elements 
interact with different structurally related, often dimeric transcription factor complexes 
(Jones, 1990). Members of the Jun family bind as homodimers or heterodimers with 
members of the Fos family to a DNA sequence termed the AP-1 binding site (Kouzarides 
and Ziff, 1989). Dimerization is mediated by the so called basic leucine zipper motif 
(Landschultz etal., 1988). Different complexes may have different effects on transcription 
possible by binding to DNA with different affinities or specificities; Jun A, but not Jun B, 
can activate the transcription from a AP-1 site containing promoter; Jun B can, in fact, 
decrease the activation mediated by Jun A (Chiu etal., 1989; Schutte etal., 1989). Some 
transcription factors contain a basic helix-loop-helix (HLH) motif, which also mediates DNA 
binding and dimerization (Davis et al., 1990). This motif has been identified in two 
proteins (E12 and E47) that bind to a specific DNA sequence found in immunoglobulin 
enhancers (Murre etal., 1989) and in a number of genes involved in muscle development 
(Myo D, Myf 5 and myogenin)(Davis ef a/., 1987; Braun et al., 1989; Edmonson and 
Olson, 1989; Wright et al., 1989). Recently, a gene encoding a protein termed Id was 
discovered and found to contain the HLH motif without the basic DNA binding region 
(Benezra ef a/., 1990). The Id protein is able to dimerize with Myo D but fails to bind to 
DNA, suggesting a role as a dominant negative regulator. The latter mechanism again 
illustrates the complexity of interactions made possible by using unique combinations of 
common transcription factors. 
The observation that in the presence of protein synthesis inhibitors gene 
expression can still be regulated suggests that transcription factors are regulated post-
translationally; ie. in their phosphorylation or glycosylation states. The c-jun proto-
oncogene product is phosphorylated after activation of protein kinase C (Angel ef a/., 
1987). The modified transcription factor may be altered in the affinity or in the sequence-
specific DNA binding characteristics. Alternatively, the interaction with other proteins in 
the transcription complex can be affected. This mechanism may be found for the 
glycosylated p67 serum response factor (SRF) of the fos gene, which interacts in a 
ternary complex with another glycosylated protein (p62 CTF) and the serum response 
element (SRE) (Herrera ef a/., 1989; Schröter ef a/., 1990). 
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V. Oncogenes and anti-Oncogenes 
a. Oncogenes 
Oncogenes can be defined as modified cellular (or viral) growth regulatory genes 
whose altered protein products, acting alone, or more typically in combination with other 
gene products, can lead to cell transformation. Proto-oncogenes can be activated by 
qualitative and/or quantitative changes in their gene products. Transduction of proto-
oncogenes by acutely transforming retroviruses can result in overexpression, truncation 
or internal mutations leading to a constitutive biological activity (Bishop, 1987). The 
transforming protein from the Rous sarcoma virus, pp60 v-src, was the first described 
transduced cellular oncogene (Stehelin et ai, 1976). To date, at least 20 distinct cellular 
genes have been identified through their derivative viral oncogenes present in a retroviral 
genome. Many exhibit constitutive protein-tyrosine kinase activity (Hunter and Cooper, 
1985). Proto-oncogenes can also be activated by point mutation in the coding region, 
as exemplified by the human ras oncogene (Tabin ef a/., 1982; Santos ef a/., 1982). 
Another more frequent activation mechanism is increased expression by direct gene 
amplification, as found for the N-myc gene (Schwab era/., 1984). In animals, an increase 
in gene expression has also be observed following retroviral insertion whereby the strong 
transcriptional promoter of the virus stimulates expression of an adjacent proto-oncogene 
(Nusse and Berns, 1988). The /nf-1 and int-2 proto-oncogenes were discovered in such 
a manner, in association with the mouse mammary tumor virus (MMTV)(Nusse and 
Varmus, 1982; Peters ef a/., 1983). Chromosome translocations provides yet another 
mechanism for activation of proto-oncogenes, the paradigm being the reciprocal 
translocation of the human c-abl proto-oncogene from chromosome 9 to 22 (Groffen ef 
a/., 1984). This translocation results in a novel fusion protein with constitutive tyrosine 
kinase activity. 
The finding in 1978 by DeLarco and Todaro that certain tumor cells and oncogene 
transformed cells often produced their own growth factors (termed transforming growth 
factors), resulted in an important link between oncogene and growth factor research. 
This discovery lead Sporn and Todaro to suggest that one mechanism for malignant cell 
transformation was the ability of the transformed cell to produce and respond to its own 
growth factors. Support for this hypothesis was obtained with the sequence 
determination of the v-sis oncogene from simian sarcoma virus (SSV), which showed 
sequence homology to the PDGF B chain (Doolittle ef a/., 1983; Waterfield ef a/., 1983), 
suggesting that growth factors can function as oncogenes. 
Subsequently, it was shown that growth factor independence can also be achieved 
by alterations in the structure of receptors, which can uncouple signal transduction from 
ligand binding, providing a mitotic signal in the absence of growth factors. The oncogene 
v-ero B, with intrinsic tryosine kinase activity is a truncated version of the EGF receptor 
(EGF-R), which lacks most of the external EGF binding domain (Downward et ai, 1984). 
The \i-fms oncogene is a mutated version of the CSF-1 receptor (Sherr ef ai, 1985). 
Point mutations induce or stabilize a conformational change that is equivalent to ligand 
binding (Roussel et ai, 1988; Woolford ef ai, 1988). 
Based upon structural similarities and biochemical properties, ras proteins 
presumably function as G-proteins (Hurley ef ai, 1984). The point mutations reduce the 
GTPase activity of ras, thereby maintaining the ras protein longer in its GTP active state. 
Alterations in the activity of cytoplasmic signal transducers can also lead to a loss of 
growth control by uncoupling it from the need for exogeneous stimuli. The src family of 
oncogenes (including yes, fgr, fps/fes, ros and abl) have an intrinsic constitutively active 
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TABLE 2: Proto-oncoaenes and Their Products" 
Oncogene 
Proto-oncogene 
Product (in kDa) 
Secreted 
s/s 
hst 
int-2 
Plasma membrane 
a. transmembrane 
erbB 
fms 
neu 
met 
ros 
kit 
trk 
ret 
eck 
elk 
eph 
b. membrane-associated 
H-ras 
K-ras 
N-ras 
src 
yes 
fps/fes 
abl 
fgr 
hek 
lyk 
fyn 
tkl 
lyn 
p32/PDGF-B 
p22/FGF-like factor 
p27/FGF-like factor 
p170/EGF receptor; PK-Tyr 
p170/CSF-1 receptor; PK-Tyr 
p185/receptor; PK-Tyr 
p140/receptor; PK-Tyr 
p250/receptor; PK-Tyr 
p145/receptor; PK-Tyr 
p140/receptor; PK-Tyr 
p150-170/receptor; PK-Tyr 
p130 receptor; PK-T 
p130/receptor; PK-Tyr 
p130/receptor; PK-Tyr 
p21:G-B 
p21;G-B 
p21;G-B 
pp60; PK-Tyr 
p61; PK-Tyr 
p92; PK-Tyr 
p142; PK-Tyr 
p57; PK-Tyr 
p57; PK-Tyr 
p56; PK-Tyr 
p60; PK-Tyr 
p50; PK-Tyr 
p58; PK-Tyr 
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TABLE 2: Proto-oncoaenes and Their Products8 (Cont'd) 
Oncogene 
Proto-oncogene 
Product 
Cytoplasm 
IV. Nucleus 
mos 
raf/mil 
myc 
fos 
jun 
erbA 
myb 
ets 
rel 
ski 
p53 
p37; PK-Ser/Thr 
p74; PK-Ser/Thr 
p58; TR/DB 
p55; TR 
p39; TR/DB 
p46; TR/DB/THR 
p75; TR/DB 
p50; TR/DB 
p68; TR/DB 
p100; TR? 
p53; TR/DB 
Abbreviations: (PK-Tyr) protein-tyrosine kinase; (PK-Ser/Thr) protein-
serine/threonine kinase; (TR) transcriptional regulator; (DB) DNA binding; (G-B) 
GTP/GDP binding protein; (THR) thyroid hormone receptor. 
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TABLE 3: Anti-oncoaene (Putative) Tumor Suppressor Genesa 
Anti-oncogene/ 
Tumor Suppressor 
Protein Product and 
Biochemical Properties 
Rb-1 (retinoblastoma gene) 
WT-1 (Wilms' tumor gene) 
p53 
c-ert>A 
K-rev 
NM23 
Thrombospondin (fragment) 
DCC (deleted in colorectal 
cancer) 
p105; TR/DB 
? ;TR/DB 
p53; TR?DB 
p46; TR/DB 
p21 ; antagonist ras 
p17; metastasis inhibitor 
p140; angiogenesis inhibitor 
? ; adhesion molecule 
Abbreviations: (TR) transcriptional regulator; (DB) DNA binding 
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protein tyrosine kinase activity, providing a continuous intracellular mitogenic stimulus 
(Hunter, 1989). A number of oncogene products, including fos, myc, myb, ski and jun 
are located in the nucleus and are implicated in aberrant control of gene expression or 
DNA replication (Eisenman, 1989). Thus, proto-oncogenes appear to form the growth 
stimulating proteins in the signaling pathways in normal growth control (Table 2) (Bishop, 
1987). 
b. Tumor suppressors and anti-oncogenes 
Studies with somatic cell fusions between malignant and normal cells were the first 
indication that normal cells contained genes that suppressed the malignant phenotype 
(Stainbridge ef a/., 1982). Normal human fibroblasts fused with HeLa cells were found to 
be non-tumorigenic, while revertants of these hybrids had lost one or more chromosomes 
(Stainbridge ef a/., 1982). Presumably, in tumor cells both alleles of these tumor 
suppressing genes (also termed anti-oncogenes) were lost, functionally inactivated or their 
gene expression reduced. Further support for the existence of tumor suppressor genes 
came from studies on hereditary predisposition to cancer (Knudson, 1985; Hansen and 
Cavenee, 1987). Cytogenetic and restriction fragment length polymorphism (RFLP) 
studies indicated chromosomal deletion or loss of heterozygosity at certain chromosomal 
regions in tumors, such as chromosome 13 in pediatric retinoblastoma (Cavenee ef a/., 
1983) and chromosome 11 in Wilms tumors (Orkin ef a/., 1984; Fearon ef a/., 1984; 
Koufos ef a/., 1984). The retinoblastoma (Rb-1) gene was cloned by chromosome 
walking using RFLP marker for the suppressor gene locus (Friend ef a/., 1986; Fung ef 
a/., 1987; Lee ef a/., 1987). The Rb-1 gene encodes a nuclear phosphoprotein of 105 
kDa with affinity for DNA, suggesting an involvement in the regulation of transcription or 
DNA replication. Defective Rb-1 alleles were not only detected in retinoblastoma, but also 
in other tumor types, including osteosarcomas (Weichselbaum ef a/., 1988), small cell 
lung carcinomas (Harbour ef a/., 1988) and mammary carcinomas (Lee ef a/., 1988). 
Functional evidence for identity of Rb-1 gene was obtained when the wildtype Rb-1 gene 
was introduced into retinoblastoma and osteosarcoma cells lacking an intact Rb. Upon 
introduction of Rb-1, cell growth was inhibited in vitro and cells lost tumorigenicity in vivo 
(Huang ef a/., 1988). Recently, a possible candidate for the Wilms Tumor (WT) gene on 
human chromosome 11 (band 13) was cloned, using similar techniques as used for Rb-
1. This WT gene encodes a zinc finger protein, with a potential role in transcriptional 
regulation (Rose ef a/., 1990; Call ef a/., 1990). 
To contrast the tumor suppressor genes or anti-oncogenes with the dominant 
acting oncogenes, the name recessive oncogenes has been proposed. However, recent 
observations suggest that at least some anti-oncogenes do not act in a recessive fashion. 
Some familial tumors, such as adenomatous polyposis and multiple endocrine neoplasia 
type 2 develop without loss of the normal allele. A dosage effect appears to be important 
with reduction to half the normal dose leading to hyperproliferation (Vogelstein ef a/., 1988; 
Nelkin ef a/., 1989; Landsvater et al., 1989). 
Recently, two genes, p53 and v-erbA, originally classified as oncogenes, appear to 
act in a dominant negative fashion over their normal counterparts, and have growth 
suppressive activity. The (anti)oncogene p53 was discovered through the direct 
association of p53 protein with DNA tumor virus proteins (Lane and Crawford, 1979; 
Linzer and Levine, 1979). p53 was first shown to immortalize primary cells and 
collaborate with the ras oncogene in transforming of these cells, a characteristic for 
oncogene function (Eliyahu ef a/., 1984; Jenkins ef a/., 1984; Parada ef a/., 1984). 
However, a mutated form of p53, rather than wildtype p53, was used in these 
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experiments. Wildtype p53 lacks any transforming potential and is in fact capable of 
inhibiting the transforming activity of ras and mutant p53 combination or a mixture of ras 
and EIA (Finlay ef a/., 1989). p53 protein has been shown to oligomerize (Eliyahu ef a/., 
1989; Finlay ef a/., 1989). The dominant negative effect of a large excess of mutant p53 
over wildtype may be attributed to the formation of hetero-oligomers, which render the 
wildtype p53 inactive. 
The oncogenes v-erbA and v-erbB were originally identified as the two cellular 
genes co-transduced by avian erythroblastosis virus (Vennstrom and Bishop, 1982). 
Whereas v-erbA alone is not an efficient inducer of transformation of erythroid progenitor 
cells, v-erbA enhances transformation efficiency of other oncogenes (v-erbB, v-Ha-ras, 
v-src and v-fms) by blocking differentiation (Gandrillon era/., 1987). c-erbA is an altered 
form of the normal cellular receptor for thyroid hormone, which acts as a DNA binding 
transcription factor (Sap era/., 1986; Weinberger era/., 1986). Upon ligand binding the 
wildtype receptor modulates the expression of target genes to induce cell differentiation. 
In the presence of ligand, the v-erbA oncogene does not modulate gene expression and, 
in fact, competes with wildtype receptor binding, resulting in a dominant negative effect 
on cell differentiation (Damm et al., 1989; Sap era/., 1989). 
Whereas the anti-oncogenes described above have an intracellular location, a 
number of secreted factors, including TGF-jff, TNF and IFN (see also section on growth 
factors) have a growth inhibitory action on certain target cells (Wang and Hsu, 1986). 
The mechanism by which the signals transduced from the cell surface receptors of these 
growth inhibitors through the cytoplasm to the nucleus are poorly understood. 
The identification of tumor suppressor genes (or more general, growth inhibitors) 
has proven far more difficult than the growth stimulating oncogenes. Typically, an 
oncogene can score positive in transfection-transformation assays; transfection of 
extracted tumor DNA into the mouse fibroblast cell line NIH-3T3, can result in the 
formation of transformed cell foci. Using comparable gene transfer techniques for the 
cloning of tumor suppressor genes, one has to select for rare, slow growing transfected 
cells in a background of fast growing transformed ones. Strategies for isolating of tumor 
(or transformation) suppressor genes (other than Rb-1, WT, p53, c-erbA), have been 
based upon molecular and functional differences between the normal and tumor cell. For 
example, the cDNA from the Kirsten-ras-revertant gene (Krev-1) was isolated from a 
human fibroblast cDNA expression library by virtue of its revertant-inducing activity in the 
v-Ki-ras transformed NIH 3T3 cells (Kitayama era/., 1989). The predicted Krev-1 protein 
is structurally related to ras proteins, with GTP-binding domains on the putative effector-
interaction domain (Table 3). 
c. Interplay between positive and negative growth control 
Recently, it was shown that both Rb and p53 anti-oncogene products form stable 
complexes with the oncogenic proteins of DNA tumor viruses. pRb complexes with SV40 
large T antigen, EIA of adenovirus and E7 protein of human papillomavirus (Whyte ef al., 
1988; DeCaprio ef al., 1988; Dyson ef al., 1989; Egan ef al., 1989). p53 binds to E1b of 
adenovirus, as well as to SV40 T antigen (Lane and Crawford, 1979; Linzer and Levine, 
1979; Sarnow ef al., 1982). in vitro mutation studies with these viral proteins have 
demonstrated that the interaction domain of pRb with the viral protein is required for 
transformation (DeCaprio ef al., 1988). Interestingly, these domains are also the most 
frequently sites for naturally occurring mutations found in tumors(Hu ef al., 1990). 
Complexing of the viral proteins with the anti-oncogene products of Rb and p53 may 
block the normal growth inhibitory actions of these proteins on the untransformed cell. 
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The phosphorylation state of pRb is cell cycle dependent (DeCaprio et al., 1989; 
Buchkovich et al., 1989; Chen er al., 1989; Mihara et al., 1989). The under 
phosphorylated pRb form prevails during the G1 phase of the cell cycle and presumably 
is the active form, contributing to growth suppression. The potent secreted growth 
inhibitor TGF-01 interferes with the cell cycle at late G1 (Heimark era/., 1986; Shipley et 
al., 1986). Recently, TGF-01 was shown to block pRb phosphorylation in mink cells 
(Laiho et al., 1990b). Apparently, therefore, TGF-/9 and pRb may function via a common 
growth inhibitory pathway. In keratinocytes, growth inhibition by TGF-/81 appears to 
involve down-regulation of c-myc proto-oncogene expression through inhibition of 
transcriptional initiation (Pietenpol et al., 1990b). This effect was diminished in 
keratinocytes transfected with DNA tumor viruses. Viruses with mutant transforming 
protein that fail to bind pRb (and other cellular proteins) do not show this effect (Pietenpol 
er al., 1990a). This suggests that pRb, or another protein that interacts with the viral 
protein binding domain mediates TGF-yS induced down-regulation of c-myc in 
keratinocytes. 
Both the epidemiology of cancer and genetic analysis of tumors indicate that 
tumorigenesis is a multi-step process. Mutations in multiple genes either causing the 
activation of the proto-oncogenes or the inactivation of tumor suppressor genes (or anti-
oncogenes) or their combination are necessary to transform a normal cell into a tumor 
cell (Land er al., 1983). For example, in colorectal cancer, tumorigenesis proceeds 
through a series of clinical stages, ie. hyperproiiferation, three stages of adenomas, 
carcinoma and metastasis. Each of these stages correlate with concomitant genetic 
alterations, including ras activation and loss of the tumor suppressor genes, p53 (Baker 
era/., 1989), DCC (an acronym for Deleted in Colorector Carcinoma) and an unidentified 
gene(s) on chromosome 5 (Fearon etal., 1990; Fearon and Vogelstein, 1990) 
VI. Growth Factors in early Embryogenesis 
a. Growth factor expression in preimplantation embryos 
During embryogenesis, extensive proliferation and differentiation occurs. Growth 
factors and their signal response elements are likely to play an important role in this 
process. In early mammalian development, the direct study of growth factors involved 
in growth and differentiation is difficult, as the embryo consists of only a few thousand 
cells with multiple cell types, and is rather inaccessible within the maternal uterus. 
Therefore, a number of model systems have been developed to study growth factors in 
early embryogenesis. 
Preimplantation mouse embryos develop in vitro independently of exogenous 
added growth factors, suggesting that endogenously produced factors are sufficient to 
support growth (Biggers, 1971). Using a technique termed mRNA phenotyping (based 
upon the polymerase chain reaction of cDNA with growth factor specific primers) growth 
factor expression can be detected in individual blastocysts. PDGF-A, TGF-o, IGF-II and 
TGF-/?1 transcripts were found in blastocytes, while EGF, bFGF, NGF and G-CSF were 
absent (Rappolee et al., 1988). Initially, the amount of PDGF-A and TGF-o transcripts 
were high, but disappeared at the 2 cell stadium suggesting that they were maternally 
derived. The expression reappeared once expression in the zygotic genome was 
initiated. TGF-/?1 expression appears only after fertilization. The transcripts were 
translated as immunofluorescence studies indicated the presence of TGF-01, PDGF-A and 
TGF-o proteins. This suggests a role for growth factors in the growth and differentiation 
of early mammalian embryos. 
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b. Growth factors regulating embryonic stem cell proliferation and differentiation 
Embryonic stem (ES) cells are the totipotent cell lines established from early 
embryos. When ES cells are injected into a blastocyte they can contribute to all adult 
tissues, including the germ-cell lineages. In contrast, embryonal carcinomas (EC) cells, 
derived from spontaneous or experimentally-induced teratocarcinoma tumors, have only 
a limited differentiation capacity and induce tumors when introduced into embryos (Martin, 
1980). Some EC cells are blocked in their differentiation and can be kept in continuous 
culture. These cells form a useful source for the isolation of growth factors involved in 
early mammalian development. For example, embryonal carcinoma-derived growth factor 
(ECDGF), a member of the FGF family, was isolated from the conditioned media of 
murine PC13EC cells (Heath and Isacke, 1984; Heath ef al., 1989). 
Differentiation of EC cells is accompanied with changes in growth factor 
expression. For example, retinoic acid induces differentiation of PC13 into PC13END 
(resembling extra-embryonic mesoderm) with a concomitant increase in IGF expression, 
and a cessation of ECDGF expression (Heath and Rees, 1985; Heath and Shi, 1986). 
During retinoic acid induced differentiation of the EC cell line, Tera-2 clone 13, PDGF-A 
expression was reduced, but TGF-/71 expression increased (Weima ef a/., 1988). The 
expression levels of these two growth factors may possibly be essential for the 
transformed phenotype and differentiation state of EC cells. 
When grown in isolation, ES cells differentiate spontaneously. ES cell differentiation 
can be prevented by growing these cells on certain mitotically inactivated heterologous 
feeder layers (Smith and Hooper, 1983; Koopman and Cotton, 1984), such as the Buffalo 
rat liver (BRL) cells (Smith and Hooper, 1987). An ES differentiation inhibitory activity 
(DIA) was purified from the conditioned media of the BRL cells, which can substitute for 
the feeder layer in continuous cultures of ES cells (Smith et al., 1988a). When cells are 
grown in the absence of DIA, they differentiate into cells with mesodermal characteristics. 
Treatment with retinoic acid in the presence of DIA results in the differentiation into cells 
with characteristics of parietal endoderm (Heath era/., 1988). The differentiation pathway 
appears to be dependent on the combination of regulatory factors and most likely is 
determined by target cell and microenvironment. In vivo, DIA may function as a switch 
between self-renewal and stem cell differentiation. Structural and functional 
characterizations of DIA (Smith ef ai, 1988a) has shown a relatedness (if not identity) of 
DIA to two other factors described previously; human interleukin for DA cells 
(HILDA)(Godard ef a/., 1988) and leukemia inhibitory factor (LIF)(Gearing ef a/., 1987; 
Gough ef al., 1988). HILDA/LIF has been shown to act by binding to high affinity cell 
surface receptors on mature hemopoietic cells, as well as ES cells. As with many growth 
factors, one factor appears to have pleiotropic functions, retarding the differentiation of 
ES cells (Williams ef al., 1988; Smith ef al., 1988a), supporting the growth of a murine IL-
3 sensitive cell line (DA2) and inducing the differentiation of M1 cells (Hilton ef al., 1988). 
c. Mesoderm induction by growth factors 
Jn the early embryo, mesoderm differentiates from ectoderm upon inductive 
interactions from the underlying endoderm. Most mechanistic studies have been 
performed with amphibian embryos, which are technically easier to manipulate than the 
inaccessible intra-uterine mammalian embryos. Ectoderm alone, dissected from the 
blastula otXenopus embryos, forms a mass of epidermal cells. However, when dissected 
ectoderm is combined with dissected endoderm, mesoderm is formed (Nieuwkoop, 1969). 
The endoderm derived signals appear to be diffusible and isolated growth factors have 
been shown to mimic the mesoderm inducing signals. When isolated Xenopus animal cap 
expiants are treated with FGF family members 
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(aFGF, bFGF, ECDGF, KGF and int-2 protein product)(Slack et al., 1987; Paterno et al., 
1989) and mammalian TGF-/9 family members (activin A, TGF-/92 and TGF-/Î3), mesoderm 
is formed (Smith et al., 1988c; Rosa et al., 1988; Smith et al., 1990; van den Eijden-van 
Raaij et al., 1990; ten Dijke, unpublished results). Different members of each family exhibit 
different potencies. Synergism is found between TGF-/? and the FGF family of growth 
factors (Kimelman and Kirschner, 1987). Furthermore, the type of mesoderm that is 
induced appears to be dependent on concentration. The role of these factors in the 
natural inductive process has not yet been directly demonstrated. However, genes 
homologous to both mammalian TGF-/8 (Weeks and Melton, 1987; Kondaiah et al., 1990) 
and FGF (Kimelman and Kirschner, 1987) have been identified from frog libraries, and are 
expressed in embryonal stages when mesoderm induction takes place. The Xenopus 
activin, TGF-/82 and TGF-/95 have been isolated from Xenopus XTC conditioned medium 
(Smith et al., 1988c; Roberts er al., 1990). FGF has been isolated from Xenopus blastula 
in an amount that would be sufficient for mesoderm induction in vivo (Kimelman et al., 
1988). The demonstration that mammalian growth factors can mimic amphibian 
mesoderm induction signals indicates a considerable evolutionary conservation of growth 
factors and suggest a role for those factors in early mammalian development. 
VII. Concluding Remarks 
Within recent years, substantial progress has been made in our understanding of the 
molecular mechanisms of cellular growth during tissue homeostasis and development. 
There appears to be a direct relationship between these processes as similar growth 
factor and receptor/signaling pathways are being utilized. However, many steps in the 
inter- and intracellular signaling pathways remain virtually unknown. 
As different pathways in the growth control process are elucidated, new insights 
will be obtained not only in the development of complex organisms from fertilized eggs, 
but also in the origins of uncontrolled growth. Understanding the pivotal role of growth 
factors in these processes will contribute to an improved diagnosis and prognosis, and 
will lead to the development of new strategies for therapeutic intervention and prevention 
of neoplasia. 
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I. Introduction 
Transforming growth factor (TGF) was a term originally used to describe an activity 
produced by murine sarcoma virus-transformed cells (De Larco and Todaro, 1978). 
Medium conditioned by these cells was able to confer morphological transformation and 
anchorage independence on certain target cells, which are characteristics that often 
correlate with tumorigenesis of cells in vivo (Cifone and Fidler, 1988). TGF induced 
transformation was shown to be reversible, as "transformed" cells reverted back to normal 
upon removal of TGF. Subsequently, similar transforming activities were also found in the 
conditioned media of other tumor cells (Todaro et al., 1980) as well as in normal tissues, 
particularly when epidermal growth factor (EGF) was added to the assay (Roberts era/., 
1981). Purification of this activity revealed that it was not a single biochemical entity, but 
was derived from two distinct proteins, termed TGF-a and TGF-/?. Both proteins alone 
were unable to induce soft agar growth of normal rat kidney NRK fibroblast, but act 
together synergistically (Anzano et al., 1983). 
TGF-a and TGF-/? are different molecules in structure and function. TGF-a is 
structurally related to EGF and competes with EGF receptor binding (Todaro et al., 1980). 
TGF-0 is a multifunctional dimeric protein of 25 kDa (for recent reviews see Roberts and 
Sporn, 1990; Lyons and Moses, 1990) and its structure, functions and mechanism of 
action are the topic of this review. TGF-/? may act to stimulate or inhibit cell proliferation 
and differentiation or regulate other functional processes. Multiple forms of TGF-/? have 
been identified which share similar, but not identical biological activities. Five true different 
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Figure 1 
Schematic representation of the human TGF-/?1 (Derynck etat., 1985), TGF-02 (de Martin 
et a/.,1987) and TGF-j83 (ten Dijke er al., 1988; Derynck er al., 1988). The relative 
positions of the N-glycosylation sites (N-CHO) and the potential fibronectin cellular 
recognition site (RGD) are indicated. The arrow heads indicate the cleavage sites following 
the signal peptide and preceding the C-terminal mature TGF-/33 sequences (shaded). The 
size of the precursor protein in amino acids is indicated between brackets. 
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TGF-/9 genes have been described in vertebrates. Moreover, TGF-/?s are part of a larger 
super family of structurally related, but functionally different proteins. TGF-ySs are 
produced by many different cell types and most cell types have high affinity specific 
receptors, suggesting a broad physiological importance. The clinical implications of the 
role of TGF-0S in disease and therapy are also discussed. 
II. Molecular Biology and Biochemistry of TGF-/?s 
Identification and Structure of TGF-A1 
TGF-01 was first purified to homogeneity from human platelets (Assoian er al.., 
1983), human placenta (Frolik era/., 1983) and bovine kidney (Roberts era/., 1983), using 
the normal rat kidney (NRK) fibroblast soft agar assay for detection. TGF-01 was 
identified as a disulfide linked dimer of 25 kDa. Upon reduction two identical subunits of 
12 kDa were obtained with no biological activity. The cloning and DNA sequencing of the 
human TGF-/91 cDNA revealed that TGF-/71 is synthesized as a larger pre-pro-precursor 
protein (Derynck era/., 1985) that undergoes at least two proteolytic cleavage steps for 
maturation in a biologically active protein. The pre-pro-TGF-01 contains a hydrophobic 
signal peptide of 29 amino acids at the N-terminus. The pro-TGF-/91 is further 
proteolytically processed at a tetrabasic RHRR cleavage site yielding the 112 amino acid 
C-terminal mature fragment. 
After secretion and processing the 25 kDa TGF-/?1 mature protein remains non-
covalently associated with the N-terminal precursor fragment (Gentry ef al., 1987). In 
vitro, both chaotropic agents and specific proteases can disrupt these interactions, 
releasing biologically active TGF-01 (Lawrence er al., 1985; Lyons er al., 1988). Plasmin 
was shown to cleave the N-terminal precursor fragment, which may result in a 
conformational change that destabilizes the latent complex (Lyons er al., 1990). The N-
terminal precursor fragment contains several N-linked glycosylation sites (Brunner era/., 
1988). Recently, it was shown that alterations in glycosylation can also lead to activation 
of latent TGF-01 (Miyazono and Heldin, 1989). 
TGF-fl-like factors 
TGF-0-like factors have been isolated many times, by virtue of its multifunctional 
character and the existence of multiple forms. In bovine bone two distinct forms were 
identified, using an assay that measures the induction of cartilage extracellular matrix 
proteins (Seyedin ef a/., 1985). Upon sequence determination cartilage-inducing factor 
A and B (CIF-A and CIF-B) were shown to be identical to TGF-01 and TGF-02, 
respectively (Seyedin ef a/., 1986; Seyedin ef a/., 1987). Subsequently, TGF-02 was 
isolated from porcine platelets (Cheifetz ef a/., 1987) and from several conditioned media. 
A potent T-cell suppressor factor secreted by glioblastoma cells (de Martin ef a/. 1987), 
a growth inhibitor secreted by monkey BSC-1 kidney cells (Hanks ef a/., 1988) and a 
TGF-/9-like factor from a prostatic adenocarcinoma cell line (Ikeda ef a/., 1987) were all 
shown to be identical to TGF-/92. 
The cDNAs for three different TGF-0S, termed TGF-/83 (ten Dijke ef a/., 1988a; 
Derynck ef a/., 1988; Jakowlew ef a/., 1988a), TGF-04 (Jakowlew etal., 1988b) and TGF-
05 (Kondaiah ef a/., 1990) have recently been isolated. Whereas TGF-/83, like TGF-01 
and TGF-/82 are found in mammals (see also figure 1), TGF-04 and TGF-05 have thus far 
only been identified in chicken and frog, respectively (Jakowlew etal., 1988b; Kondaiah 
etal., 1990). The TGF-/?3 protein was recently expressed in CHO cells transfected with 
TGF-03 cDNA expression plasmids (Graycar etal., 1989; ten Dijke etal., 1990b) and the 
TGF-/95 protein was isolated from medium conditioned by Xenopus cultured cells (XTC) 
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(Roberts et ai, 1990). The. TGF-/94 putative protein has not yet been isolated. 
Heterodimers may also be formed, as TGF-01.2, containing one TGF-/?1 and one TGF-
ß2 chain was identified in porcine platelets (Cheifetz era/., 1987). This increases even 
more the number of possible forms of TGF-/9, as multiple TGF-/9s are often expressed in 
one cell. 
As predicted from their cDNA sequence, each of the TGF-ySs are produced as 
larger precursor proteins with N-linked glycosylation sites in the precursor segments. All 
TGF-0s have a signal peptide sequence at the N-terminus, except TGF-04, which may 
function within the cell. Proteolytic processing at the tetra basic cleavage site yields for 
each TGF-/9 a mature protein of 112 amino acids, except TGF-04 which has a mature 
protein of 114 amino acids. The mature forms share between 70-80% sequence identity 
with a strict conservation of all nine cysteines. In most assays, TGF-^s have similar 
biological activities, including growth inhibition of MV1Lu mink lung epithelial cells and 
induction of NRK soft agar growth (Roberts er a/., 1990; Graycar ef a/., 1989; ten Dijke, 
era/., 1990b; Cheifetz era/., 1990). 
Transcriptional regulation 
Northern blot analysis and in situ hybridization studies reveal distinct temporal and 
spatial expression patterns for each TGF-yS, suggesting that each isoform is differently 
transcriptionally regulated. In the TGF-01 transcription unit two major transcriptional start 
sites are present with multiple positive and negative regulatory elements. Two Sp1 and 
three AP-1 binding sites have been identified in the human TGF-/S1 promoter regions 
(Kim ef a/., 1989). The ability of TGF-/91 (and also c-jun) to upregulate TGF-/M expression 
was found to be mediated by binding of AP-1 (Jun-Fos) complex in both promoter 
regions. The induction of c-jun by TGF-/9 and auto induction of c-jun may play a role to 
amplify and sustain the action of TGF-yff in normal physiological and pathological 
processes (Kim ef a/., 1990). The receptors for steroids and retinoids and may also play 
an important role in transcriptional regulation of TGF-ySs, as suggested by induction of 
TGF-/J2 by retinoic acid in primary cultures of mouse keratinocytes (Glick etal., 1990) and 
estrogen induced reduction of TGF-/S2 and TGF-/Î3 expression in estrogen receptor 
positive (ER+) breast cancer cells (Arrick ef a/., 1990). 
Evolutionary conservation 
TGF-/91 is very highly conserved in evolution. The C-terminal 112 amino acids of 
TGF-01 are identical in human (Derynck etal., 1985), porcine (Derynck and Rhee, 1989), 
bovine (Van Obberghen - Schilling ef ai, 1987), chicken (Jakowlew ef a/., 1988c) and 
simian species (Sharpies ef a/., 1987) and differ by only one amino acid in the murine 
form (Derynck ef a/., 1986). The same high degree of conservation is found for the 
mature forms of TGF-02 (de Martin ef a/., 1987; Madisen ef a/., 1988; Hanks ef ai, 1988; 
Cheifetz ef ai, 1987; Seyedin ef ai, 1985; Miller ef ai, 1989b)) and TGF-/S3 (ten Dijke ef 
ai, 1988a, ten Dijke etal., 1988b; Derynck et ai, 1988; Jakowlew et ai, 1988a; Miller ef 
ai, 1989a). The N-terminal domains for each TGF-0 are also highly conserved (-80-
90% amino acid sequence identity), suggesting that this part of the protein may have an 
important function, including proper folding, disulfide bond formation and in the export the 
TGF-/? mature protein (Gray and Mason, 1990). 
Comparing the gene structure of TGF-/M and TGF-/83 reveals that all intron-exon 
junctions are at the same positions, with the exception of the first intron, which differs by 
three nucleotides. This suggests that the TGF-/ffs originate from the same ancestral gene 
(Derynck et ai, 1987; Derynck et ai, 1988). The human genes f o TGF-01, TGF-/02 and 
TGF-/83 have been localized on different chromosomes (Fujii ef a/., 1986; Barton ef ai, 
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1988; ten Dijke et al., 1988b), suggesting that after amplification, these genes have 
dispersed and subsequently diverged in sequence. 
TGF-fl superfamily 
TGF-/?s form part of a larger superfamily of proteins that structurally as well as 
functionally are distantly related (see Table 1). The two forms of inhibin and the three 
forms of activin, which were first identified as gonadal proteins that regulate pituitary 
secretion of follicle stimulating hormone (Ling ef al., 1986; Mason er al., 1985) and the 
Mullerian inhibiting substance of MIS, which causes regression of the female rudiments 
in the developing male reproductive system (Cate era»'., 1986) share approximately 60% 
identity with the TGF-/? mature forms. An even more distantly related group, with 
approximately 30-40% identity with TGF-/? mature forms include the decapentaplegic gene 
complex (DPP-C) involved in dorsal-ventral pattern formation in the developing Drosophila 
embryo (Padgett ef a/., 1987), the Vg-1 gene product expressed in frog oocytes and 
possibly involved in mesoderm formation (Weeks and Melton, 1987), the mouse Vg-1R 
gene product (Lyons era/., 1989) and bone morphogenetic proteins (BMP's)fWodzney 
etal., 1988) which play a role in cartilage and bone formation. All members are produced 
as larger precursor proteins with their mature biologically active parts at the C-terminus 
and with seven of the nine cysteine residues conserved among all members. 
III. TGF-/? receptors and binding proteins 
TGF-fl receptors 
The action of TGF-/?s, like all growth factors, is mediated through binding to 
specific cell surface receptors. Virtually all cell types examined to date carry TGF-/? 
receptors, with the exception of retinoblastoma and pheochromocytoma cells, and bind 
TGF-/?s with affinities in the pico molar concentration range (Massague and Like, 1985; 
Wakefield ef a/., 1987; Kimchi ef a/:, 1988). By covalently linking radiolabeled TGF-/? to 
ceil surface molecules followed by Polyacrylamide gel electrophoresis of the affinity 
labeled complexes three distinct classes of cell surface proteins (in most cases) are 
identified, named receptor type I and II and a proteoglycan termed betaglycan. The 
relative distribution of the three cell surface proteins types varies per cell type (Massague 
etal., 1990). 
The TGF-/? receptor types I and II are glycoproteins which appear as 65 kDa and 
85-110 kDa affinity labeled complexes on reduced Polyacrylamide gels (Massague, 1985; 
Cheifetz ef a/., 1986) and have a high affinity for TGF-/?1 (Kd=5-50 pM) and are present 
in low numbers (300-400 binding sites) per ceil. The betaglycan is a heterogenous 
proteoglycan with a molecular weight of 280-300 kDa of affinity labeled complex 
(Massague, 1985) and consists of 200 kDa of glycosaminoglycan (GAG) chain mass and 
10 kDa of N-linked glycans attached to a heterogeneous core component of 100-120 kDa 
(Cheifetz ef a/., 1988a; Segarini and Seyedin, 1988). The GAG's are not required for 
functional expression of the receptor on the cell surface (Cheifetz and Massague, 1989). 
The affinity of TGF-/?1 for the proteoglycan is lower than for the glycoproteins (Kd=30 ~ 
300 pM) with up to 105 binding sites per cell (Cheifetz etal., 1987; Cheifetz etal., 1988a). 
The biological effects of TGF-/?s appear to be mediated by type I and/or type II receptors 
(Boyd and Massague, 1989; Laiho etal., 1990b) (see also mechanism of action). None 
of the receptor types show affinity for latent TGF-/9. A fourth receptor type has, thus far, 
only been detected in a pituitary tumor cell line and has a unique property among TGF-
/? receptor types in that it binds inhibin and activin (Cheifetz ef a/., 1988b). 
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OCCURRENCE 
Figure 2 
Latent forms of TGF-01. Latent TGF-/?1 secreted by recombinant cells is a non-covalent 
complex of the 75 kDa dimeric latency associated protein (LAP) derived from the TGF-
/?1 precursor and the processed dimeric 25 kDa TGF-/?1 (small latent complex). As 
secreted from cells and released from platelets, the large latent complex contains in 
addition a 135 kDa modulator protein, termed latent TGF-/? binding protein (LTBP). The 
complex of o2-macroglobulin with the mature dimeric TGF-/? is also latent and probably 
functions as a clearance mechanism, (from Wakefield et al., 1989, reprinted with 
permision of the authors). 
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TGF-l binding proteins 
TGF-/?s are synthesized as latent complexes with high molecular weights (Pircher 
era/., 1986)(figure 2). The TGF-01 latent complex isolated from platelets consists of the 
mature TGF-/71 (25 kDa) non-covalently associated with a disulfide-bonded complex of 
a dimer of the N-terminal propeptide of the TGF-01 precursor (75 kDa) (TGF-/?1 -latency 
associated peptide ) and a third component termed latent TGF-/91 binding protein 
(LTBP)(135 kDa)(Miyazono et al., 1988; Wakefield et al., 1988). In vitro TGF-01 can be 
released in a biologically active form from the latent complex by treatments with extreme 
pH values, chaotropic agents and proteases such as plasmin and cathepsin D and by 
enzymatic removal of the carbohydrate structures of TGF-^1 precursor (Miyazono ef a/., 
1990; Lawrence etal., 1985: Lyons era/., 1988). Recombinant TGF-/S1 expressed in CHO 
cells, is also produced in a latent form (Gentry ef ai., 1987; Wakefield ef a/., 1989). 
However, the LTBP was not associated with the latent complex (figure 2). Apparently, 
the N-terminal precursor region is sufficient to confer latency on the active TGF-/?1 and 
has been shown to function as a functional binding protein to regulate biological activity 
of TGF-£1 (Gentry and Nash, 1990). The latent complex which includes LTBP is termed 
the large latent complex, whereas the complex without LTBP is termed small latent 
complex (Wakefield ef a/., 1989). Recently, the LTBP cDNA was cloned from a fibroblast 
library (Kanzaki etal., 1990). Sequence analysis revealed the existence of 16 EGF-like 
repeats and three copies of an unknown motif. The LTBP did not bind or inactivate TGF-
/?1, also indicating that the binding protein is not necessary for TGF-/?1 latency. Possibly 
the binding protein could play a role in stabilization, targeting and activation of the latent 
complex (Kanzaki etal., 1990). 
In serum, another latent complex can be isolated, consisting of TGF-/7 and o2 
macroglobulin (O'Connor-McCourt and Wakefield, 1987; Wakefield, etal., 1988, Huang 
etal., 1988). This complex is different from the cell secreted latent JGF-ß complex in that 
it contains only processed mature TGF-/Î (figure 2). The latent platelet TGF-01 does not 
bind to o2 macroglobulin. Possibly, o2 macroglobulin may function as a scavenger for 
excess of TGF-/ffs, in order to restrict the action range of TGF-/ffs in vivo. 
TGF-yffs can also interact with a soluble form of the betaglycan, that lacks the 
membrane anchor (Andres etal., 1989). This form is secreted by some cells and found 
in low amounts in serum and in extracellular matrices. It is not known whether binding 
of TGF-^s to betaglycan inhibits the activity of the growth factor. Possibly, betaglycan 
may act as a storage or clearance system for biologically active TGF-/9s and play a role 
in cell to cell recognition and adhesion (Massague ef a/., 1990). Recently, decorin, a 
small proteoglycan, consisting of a core protein and a single glycosaminoglycan chain, 
was shown to bind TGF-/?1 and to neutralize its activity (Yamaguchi ef ai., 1990). TGF-
01 was shown to stimulate the synthesis of decorin, suggesting that it may function as 
a negative feedback mechanism. 
IV. Effects of TGF-/7S 
Effects on proliferation 
TGF-^s can both stimulate and inhibit cell proliferation. Whereas most 
mesenchymal derived cells are growth stimulated (Kimura etal., 1989; Hill etal., 1986; 
Centrella etal., 1987, Vivien etal., 1990; Battegay etal., 1990), epithelial (Coffey etal., 
1988a), endothelial (Baird and Durkin, 1986) and lymphoid (Kehrl etal., 1986a,b) cells are 
mostly inhibited by TGF-0S. However, both growth stimulation and inhibition by TGF-/9s 
have been observed for the same cell type in vitro. The particular effect of TGF-ySs 
appears to be dependent on not only cell type, but also cell culture conditions and 
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presence of other factors (Roberts and Sporn, 1990). Most of the published work on the 
effects of TGF-0S have been performed with TGF-01 and as all TGF-0S associate with the 
receptor types I and II and betaglycan, the results on TGF-/M will most likely, at least 
qualitatively, apply for the other TGF-£s (unless stated otherwise). 
TGF-01 was initially discovered as a growth stimulator of NRK in soft agar, in the 
presence of TGF-o (De Larco and Todaro, 1978). Human marrow fibroblasts and early 
passage fetal fibroblasts (Kimura era/., 1989; Hill ef a/., 1986) and other connective tissue 
cells, such as osteoblasts (Centrella ef a/., 1987), chondrocytes (Vivien ef a/., 1990) and 
smooth muscle cells (Battegay etal., 1990) are also growth stimulated by TGF-/?s, with 
low concentration being more myogenic than high concentrations. 
In vivo TGF-0S also stimulates mesenchymal cell growth. Subcutaneous injection 
of TGF-01 in neonatal mice stimulates the formation of granulation tissue consisting of a 
dense population of fibroblasts, macrophages and neovasculature (Roberts etal., 1986). 
TGF-/91 injected into rat femurs resulted in intramembranous bone formation and 
chondrogenesis (Joyce ef a/., 1990b). These results suggests a physiological role of 
TGF-/8 in wound healing and bone formation. Indeed, many cells involved in tissue repair, 
including activated marcrophages, lymphocytes and fibroblasts, express TGF-^s and the 
highest levels of TGF-£s in the body are found in platelets and bone (Roberts and Sporn, 
1990). Moreover, in a closed space/wound chamber model, the endogenous level of 
TGF-/? peaks during the phase of wound healing associated with maximal fibroblast and 
collagen synthesis (Cromack ef a/., 1987; Grotendorst ef a/., 1988). Expression of 
endogenous TGF-/S is induced in a bilateral femur fractures in the rat and correlated with 
areas of mesenchymal cell proliferation and differentiation into both osteoblasts and 
chondrocytes (Joyce ef a/.,%1990a,b). TGF-0 like activities are released after bone 
resorption and may regulate bone formation and resorption during remodeling. The 
acidic environment surrounding the osteoclast may provide a mechanism of activation of 
the secreted latent TGF-0S (Oreffo ef a/., 1989). 
The growth inhibitory action of TGF-/8S on many cells in vitro appears to function 
by its ability to antagonize the effects of other growth factors. For example, TGF-/71 
inhibits the proliferation of EGF stimulated keratinocytes (Coffey ef al., 1988a), inhibits the 
mitogenic effect of FGF on vascular endothelial cells (Baird and Durkin, 1986), inhibits the 
mitogenic effects of IL-2 on T and B lymphocytes (Kehrl ef al., 1986a, b), inhibits the 
mitogenic effect of PDGF on rat embryo fibroblasts (Anzano ef al., 1986). 
In vivo TGF-0S can also act as a growth inhibitor. For example, TGF-/71 in a slow 
release carrier, implanted in the mammary gland of mice caused the growth inhibition of 
epithelial ductal end buds (Silberstein and Daniel, 1987). Intravenously administered TGF-
01 and TGF-/S2 inhibited the liver regeneration following partial hepatectomy, suggesting 
a physiological role of TGF-0S in the quiescence of normal hepatocytes (Rüssel ef al., 
1988). 
Effects of TGF-/0S in vitro do not necessarily correspond with the in vivo effects. 
An example is the effect of TGF-/9s on endothelial cells. In vitro TGF-/91 inhibits 
endothelial cell growth in monolayer (Frater-Schroder ef al., 1986). In vivo TGF-/91 
stimulates the formation of new blood vessels (angiogenesis), possibly in part, by 
attraction and activation of macrophages, which release angiogenic factors (Roberts ef 
al., 1986). 
Other effects of TGF-fls 
TGF-/?s affect the differentiation of many cell types in vitro. TGF-01 is a potent 
regulator of myogenesis inhibiting the fusion into multinucleated myotubes and the 
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expression of muscle specific genes in myoblasts (Massague et ai, 1986; Olson et ai, 
1986). TGF-/71 also inhibits the differentiation of adipocytes (Ignotz and Massague, 1986), 
inhibits immunoglobulin secretion by B lymphocytes (Kehrl et al., 1986) and inhibits 
steroid production in Leydig cells and adrenocortical cells (Avallet et al., 1987; Feige et 
al., 1987) However, TGF-/?1 stimulates the differentiation of bronchial epithelial cells 
(Masui era/., 1986), keratinocytes (Reiss and Satorelli, 1987) and intestinal epithelial cells 
(Kurokawaef a/., 1987). 
Extracellular matrix (ECM) is produced by many cell types and in almost all cases 
TGF-ySs stimulate the EM formation, either by increasing the production and/or decreasing 
the degradation of the matrix. The transcription of multiple genes involved in ECM 
turnover is affected by TGF-/8s. TGF-/91 increases the transcription of genes encoding 
for matrix components such as type I and type III collagen, fibronectin (Ignotz and 
Massague, 1986; Ignotz era/., 1987) and chondroitin (Bassols and Massague, 1988) in 
several cell types, osteonectin (Noda and Rodan, 1987), osteocalcin (Noda, 1989) and 
osteopontin (Noda ef a/., 1988) in osteosarcomas and thrombospondin (Wrana et al., 
1986) and tenascin (Pearson era/., 1988) in fibroblast cells and matrix receptors such as 
integrins (Ignotz and Massague, 1987) in several cell types. Several growth factors 
including FGF and EGF induce the transcription of genes encoding metalloproteases like 
collagenase and stromelysin in fibroblasts. TGF-/M blocks the transcriptional induction 
of these genes (Kerr ef a/., 1988; Edwards ef ai, 1987). Moreover, TGF-^1 in 
combination with EGF stimulates tissue inhibitor of metalloproteinases TIMP expression 
(Edwards ef a/., 1987) and TGF-/?1 by itself can induce the synthesis of plasminogen 
activator inhibitor I (PAI-1)(Lund ef a/., 1987). 
TGF-/M is a potent chemoattractant for monocytes and fibroblasts (Wahl ef ai, 
1987; Postlethwaite ef ai, 1987) with an effective concentration below 10 pg/ml. This 
dose is much lower than what is required for regulation of proliferation and differentiation 
and extracellular matrix production. High concentrations of TGF-/91 are not chemotactic. 
The effect is also observed in vivo as a local injection of TGF-01 in several different tissue 
types results in Chemotaxis (Roberts ef ai, 1986; Wiseman ef a/., 1988; Mustoe ef ai, 
1987). 
TGF-yffs have immunosuppressive and anti-inflammatory effects; TGF-/91 is growth 
inhibitory for T and B cells (Kehrl ef ai, 1986a,b), inhibits the formation of lymphokine 
activated killer (LAK) cells (Küpper ef ai, 1988) and the generation of cytolytic T cells 
(CTC) (Jin ef a/., 1989). Furthermore, TGF-01 deactivates H202 and 02~ production (Tsunawaki ef a/. ,1988). 
Differential effects of TGF-fls 
Marked in vitro differences in biological potency of TGF-/9s have been observed 
in certain cell types. TGF-01 has been reported to be approximately 100 times more 
effective than TGF-^2 in the inhibition of colony formation by hematopoietic progenitor 
cells (Ohta ef a/., 1987) and endothelial cells are strongly growth inhibited by TGF-/?1 and 
TGF-,83, but not TGF-02 (Cheifetz ef a/., 1990). Furthermore, TGF-/92 and TGF-/83 induce 
Xenopus mesoderm formation, while TGF-01 alone does not show an effect (Rosa et ai, 
1988; ten Dijke ef ai, unpublished results). The in vitro differences in potency may be 
due to differences in recognition by receptors (Cheifetz ef a/., 1990) and in the 
susceptibility to antagonism or inactivation by extracellular factors (Danielpour and Sporn, 
1990). The in vitro differences between TGF-/ffs are likely to result in different in vivo 
actions. 
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V. Mechanism of Action 
TGF-0S have multifunctional properties affecting many cell types. Several 
mechanisms may contribute to the cell specific responses to this factor. The biphasic 
growth stimulatory effect of TGF-^s on chondrocytes, smooth muscle cells and 
osteoblasts appears to be mediated by a complex control of an autocrine PDGF-A loop. 
TGF-01 stimulates PDGF-A mRNA and the secretion of PDGF protein in AKR-2B 
fibroblasts (Leof ef a/., 1986). This together with the delayed kinetics of TGF-01 growth 
stimulation compared with the direct affect after addition of PDGF suggest that TGF-/?1 
acts by a PDGF mediated autocrine growth stimulatory loop. Moreover, Battegay ef a/., 
recently demonstrated that in smooth muscle cells neutralizing PDGF-A antibodies inhibit 
the induced proliferation by TGF-/?s. They also showed that high doses of TGF-/?s 
decrease the expression of PDGF-receptor a subunits, which are required for biological 
activity of PDGF-AA. This effect reduces the proliferative response of TGF-0S and 
correlates with high doses of TGF-0S being less mitogenic (Battegay era/., 1990). 
The action of TGF-/?s in other systems may also be, in part, due to receptor 
modulation. TGF-/01 decreases the number of high affinity EGF receptor in endothelial 
cells (Takehara ef a/., 1987), and decreases the number of high affinity receptors for EGF 
and FGF in EGF and FGF stimulated osteosarcoma cells (Mioh and Chen, 1989). 
Furthermore, TGF-/J1 inhibits IL-2 induced upregulation of IL-2 and transferrin receptors 
in IL-2 induced stimulation of T lymphocytes (Kehrl ef a/., 1986b), which correlates with 
the inhibitory effect of TGF-0 on T-cell clonal expansion. TGF-/?1 downregulates the 
expression of angiotensin II receptors on adrenocortical cells (Feige et al., 1987) and of 
hCG receptors on Leydig celJs (Avallet ef a/., 1987), which correlates with inhibitory effects 
on steroidogenesis in these cells. 
However, TGF-/?1 does not inhibit EGF receptor binding or any of the early growth 
factor induced events in EGF-stimulated keratinocytes (Coffey ef a/., 1988b). Apparently, 
TGF-/M interferes with EGF stimulated proliferation at sites more distal than the receptor 
level. TGF-01 rapidly reduces c-myc expression in keratinocytes (Coffey et ai, 1988b). 
c-myc expression appears to be essential for keratinocyte proliferation, as antisense c-
myc oligonucleotides inhibit keratinocyte growth with the same kinetics as TGF-/91 
(Pietenpol et al., 1990b). 
In some cases, the effects of TGF-/7s appear also mediated, by the stimulatory 
effect of TGF-yffs on the synthesis of extracellular matrix proteins, such as fibronectin. 
For example, exogenously added fibronectin inhibits the growth of endothelial cells (Madri 
etal., 1988) and inhibits the differentiation of myoblasts, chondrocytes and pre-adipocytes 
(Podleski ef a/., 1979; Rosen ef a/., 1988; Spiegelman and Ginty, 1983). TGF-01 has 
similar effects on these cell types. 
TGF-/9s mediate their action by binding to receptors. In most cells, three TGF-0 
binding cell surface proteins are identified termed types I and II and betaglycan (see also 
TGF-/9 receptors and binding proteins). Current evidence suggests type I and II receptors 
to be involved in receptor signal-transduction. The type I and II receptors are detected 
on all cells that respond to TGF-/S, whereas the betaglycan is not detectable in many 
epithelial, endothelial, lymphoid-derived and monocytic cells that respond to TGF-/9s 
(Segarini etal., 1989). Furthermore, some mutagenized mink cells selected for resistance 
to growth inhibition by TGF-/9 show no or anomalous binding to type I or type I and II 
receptors. The betaglycan is not affected (Boyd and Massague, 1989; Laiho ef a/., 
1990b). In receptor competition studies using l-TGF-01 tracer amounts, the binding 
to receptor types I and II can be much more efficiently competed by TGF-01 (and TGF-
ßS) than TGF-/J2 in all cell lines tested. Whereas this differential effect correlates with the 
activity of TGF-0S on hemapoietic progenitor and vascular endothelial cells, it is 
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inconsistent for many other effects of TGF-yff on cells which correspond similarly (with less 
than 5 fold difference in potency) to all three factors (including growth regulation by TGF-
/? of mink cells and osteoblasts). Recently, Cheifetz ef al. identified a subset of receptor 
types I and II on mink cells, which has a high affinity for TGF-/S2. This receptor subset 
could not be detected on vascular endothelial cells. This suggests that the cell specific 
differences in high affinity TGF-y92 receptors may lead to the cell specific differences in 
responsiveness to this isoform (Cheifetz ef al., 1990). 
The intracellular pathways of signal transduction after TGF-0 receptor binding 
through the cytoplasm to the nucleus and the effects on gene transcription are virtually 
unknown. Thus far no consistent involvement of TGF-/?s with any of the known signal 
transduction pathways has been established. Effects by TGF-01, appear to occur without 
activation of tyrosine protein kinases (Fänger ef al., 1986), S6 protein kinase (Like and 
Massague, 1986), protein kinase C (Daniel and Fen, 1988), phosphoinositol breakdown 
and activation of Na+/H+ antiporter (Chambard and Pouyssegur, 1987). The intracellular 
cAMP levels are not affected by TGF-01 (Kerr ef al., 1988), and although TGF-01 can 
activate phosphatidyl inositol turnover and induce Ca2+ fluxes in Rat-1 cells (Muldoon ef 
al., 1988) these are probably secondary responses. Recent studies suggest the 
involvement of GTP-binding proteins in the proliferative responses of TGF-/?1 in mouse 
AKR-2B fibroblasts (Murthy ef al., 1988). Pertussis toxin inhibits growth stimulation by 
TGF-/?1 and TGF-/?1 stimulates GTP-ase activity. Moreover, this study also showed that 
in the presence of Gpp(NH) the non hydrolysable analog of GTP, the receptor binding 
affinity of TGF-/?1 is reduced, providing strong evidence for a functional association 
between TGF-0 receptor and a G protein. 
Ultimately, the result of TGF-/S1 on target cells is the change in gene expression. 
The transcription of many genes is affected, including nuclear proto-oncogenes (c-myc, 
c-fos, c-jun and/unB) (Pertovaara ef al., 1989) genes encoding for growth factors (TGF-
ß, PDGFA and PDGF-B)(Van Obberghen-Schilling ef ai, 1988; Bascom ef al., 1989; 
Starksen ef al., 1987; Leof ef al., 1986) and growth factor receptors (EGF and PDGF 
receptors)(Fernandez-Pol ef al., 1987; Gronvald ef al., 1989), genes encoding for 
components of the immune response (IgE receptor, interferon y and IgK light 
chain)(Tanaka ef al., 1989; Esperik ef al., 1987; Briskin ef a/., 1988) and genes encoding 
for proteins involved in extracellular matrix formation (see effects of TGF-/?). Induction of 
gene expression can be within minutes of exposure, as is found with c-fos (Pertovaara 
ef al., 1989) or can start after a lag phase of 3-4 hrs, if the synthesis or modification of 
other factors is required. A number of mechanisms appear to be involved in 
transcriptional regulation of TGF-/?s. The induction of o(2) I collagen gene expression by 
TGF-/?1 is mediated by a nuclear factor-1 (NF-1) binding site in the collagen promoter 
(Rossi ef al., 1988). However, the autoinduction of TGF-/?1 and conduction of c-jun 
appear to be mediated by AP-1 binding sites (Kim ef al., 1990). The negative 
transcriptional response of TGF-/? on transin expression appears to be mediated by a 
Fos-containing protein complex that binds to a cis-acting element, termed TGF-/? inhibitory 
element (Kerr ef al., 1990). Post transcriptional effects on mRNA stability may also 
contribute to a change in mRNA expression (Raghow ef al., 1987; Penttinen ef al., 1988; 
Coffey ef a/., 1988b). 
The signal transduction of TGF-/?s from the receptor through the cytoplasm of the 
nucleus affecting gene transcription is poorly understood. The cloning and 
characterization of TGF-/? receptors will be important for a better understanding of this 
process. Additionally, the target genes that are directly transcriptionally modulated by 
TGF-/9s may provide valuable information. Intracellular factors that coordinately regulate 
the expression of TGF-/? modulated genes in a similar fashion as TGF-/?s themselves, 
possibly function as mediators in the signal transduction pathway of TGF-/?s. 
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VI. Expression of TGF-jffs during Mammalian Embryogenesis 
The in vitro effects of TGF-/9S (including Chemotaxis, regulation of growth and 
differentiation and stimulation of ECM), their expression during embryogenesis (see 
discussion below) and the presence of TGF-/? receptors and ability of embryonic cells to 
respond to TGF-0S (Rizzino, 1987; Hill era/., 1987; Centrella era/., 1987) suggest that 
IQF-ßs are likely to play a key role in the control of differentiation and cell specification 
in embryonic development. 
TGF-01 expression is found in mouse pre-implantation blastocysts after fertilization 
(Rappolee era/., 1988) and differentiated embryonal carcinoma (EC) cells and embryonic 
stem (ES) cells (which share characteristics with pluripotent cells of the inner cell mass 
in the blastula) express TGF-01 and TGF-02 (van Zoelen era/., 1989; Weima ef a/., 1989; 
Mummery ef a/., 1990). Northern blot analysis of RNA prepared from mouse embryos 
between 10.5 and 17.5 days post coitum (p.c) showed that TGF-01 expression increases 
over the 7 day period. The total TGF-/92 expression increased, although multiple TGF-
02 mRNA transcripts show differential regulation and TGF-/J3 expression increases 
between days 10.5 and 15.5 p.c. and TGF-/J3 expression decreases slightly at day 17.5 
(Miller ef a/., 1989, a,b). 
Measuring mRNA expression by in situ hybridization during mouse and human 
embryogenesis show that TGF-£s are expressed highly localized with different temporal 
and spatial patterns, though the expression of each different isoform occasionally overlap 
(Sandberg et al., 1988 a,b; Lehnen and Akhurst, 1988; Wilcox and Derynck, 1988; Pelton 
ef a/., 1989; Pelton ef a/., 1990; Gatherer ef a/., 1990). Comparing the expression of the 
three TGF-0 isoforms during the first trimester of human embryogenesis show that TGF-
ß~\ is expressed in hematopoietic, endothelial and osteogenic tissues. TGF-/92 and TGF-
#3 are expressed in a wide variety of mesenchymal tissues including areas of 
chondrogenic activity. TGF-/72 expression is also expressed in several epithelia and in 
neutral nervous system (Gatherer ef a/., 1990). Similar transcript distributions are found 
in murine embryos, suggesting a conservation of the gene regulatory elements for TGF-
ßs at these early stages. 
Comparing in situ hybridization of TGF-01 with immunolocalization studies in mice 
with aTGF-^1 antibody (Ellingsworth ef a/., 1986; Heine ef a/., 1987) both autocrine and 
paracrine modes of action have been proposed for TGF-01 (Lehnert and Akhurst, 1988). 
High levels of TGF-/S1 RNA and TGF-/S1 protein were found in tissues undergoing 
osteogenesis, hematopoiesis, vascularization and angiogenesis. Based upon the known 
biological activities of TGF-/M, a possible autocrine mechanism of action of TGF-/?1 is 
proposed for these tissues. In the more differentiated tissue, with both epithelial and 
mesenchymal tissues, like the developing hair follicles of the snout, the developing tooth 
bud, the submandibular salivary gland and the secondary palate, in situ hybridization 
detect TGF-01 in the epithelial cells, (Lehnert and Akhurst, 1988), whereas TGF-/?1 protein 
is detected in the underlying mesenchymal layer (Heine ef a/., 1987). A paracrine 
mechanism of action is proposed in which epithelial synthesized TGF-/M localizes in the 
mesenchyme, possibly to stimulate extracellular matrix deposition and to modulate 
mesenchymal condensation. The absence of TGF-01 protein in a tissue expressing high 
levels of mRNA may be explained that the TGF-/71 is synthesized in a latent form and is 
not recognized by the antibody. (Alternatively, the TGF-/81 antibody may recognize other 
members of the JQF-ß family). The roles of the various isoforms of TGF-0 during 
embryogenesis will be investigated when isoform specific antibodies and antibodies that 
can distinguish between latent and active form, become available. 
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VII. Clinical Implications of TGF-0S 
Pathological role of TGF-g in disease 
TGF-jffs are potent growth inhibitors for many cells, including epithelial and 
lymphoid cells. When a cell becomes refractory to growth inhibition by TGF-/?s, this may 
lead to malignant cell growth (Sporn and Roberts, 1985). Indeed, TGF-£s are not growth 
inhibitory for particular transformed cells, including transformed keratinocytes, leukemia 
cells and retinoblastoma cells (Shipley era/., 1986; Keller era/., 1989, Kimchi era/., 1988). 
Pharmacological agents that enhance the cellular secretion of TGF-/8S in a premalignant 
state, before the cells have become insensitive to TGF-/ffs, may be useful agents for 
chemoprevention of cancer. Retinoic acid in keratinocytes and tamoxifen in estrogen 
receptor positive (ER + ) breast cancer cells are able to upregulate the expression TGF-
ß (Glick et ai, 1990; Arrick era/., 199Ö). Interestingly, both agents have successfully been 
used in animals to prévent skin and breast cancer (Boone era/., 1990; Fentiman, 1990). 
This chemoprevention approach may, however, only be useful when it will be possible to 
diagnose patients at high risk for these type of cancers in a premalignant state. 
TGF-ySs are potent inducers of extracellular matrix formation in vitro and in vivo. 
Therefore, elevated expression and activity of TGF-/ffs could possibly lead to excessive 
connective tissue deposition as seen in fibrotic disorders, including keloids, cirrhoris, 
pulmonary fibrosis, and scleroderma. Elevated levels of TGF-/? expression have been 
observed in pulmonary fibrosis (Raghow et al., 1989; Khalil et al., 1989) and in hepatic 
fibrosis (Czaja ef a/., 1989). The JGF-ß2 levels correlated with the severity of intraocular 
fibrosis (Connor ef a/., 1989). These results suggest a possible role for TGF-/9s in the 
pathogenesis of diseases in which fibrosis is a factor and the possibility of therapeutic 
intervention using inhibitors of the action of TGF-/9s. Indeed, recent data suggest that 
antagonists of TGF-/?1 may be useful in the prevention of glomerulonephritis, a kidney 
disease in which excess extracellular matrix deposition results in impaired filtration and 
loss of protein retention. TGF-/71 is directly implicated in the matrix deposition associated 
with this disease as antibodies directed against TGF-01 were able to reverse this 
experimentally induced glomerulonephritis in rats (Border era/., 1990). 
Therapeutic opportunities of TGF-ls 
TGF-/9s are regulators of proliferation, differentiation and other cell functions in a 
wide variety of cell types. Physiologically TGF-^s are thought to play an important role 
in embryogenesis, tissue repair, immunomodulation and inflammation. This suggests a 
number of potential therapeutic applications of TGF-^s (Sporn ef a/., 1989) which are 
described below. Until recently, little was known about the in vivo effects of TGF-/? as 
animals studies with TGF-/?, extracted from tissues, have been very expensive to perform. 
However, the large amounts of protein necessary for animal and clinical studies have 
become available with the recent recombinant expression of TGF-/te. Multiple animal 
studies using this material have already shown promising results (Sporn and Roberts, 
1989). 
TGF-/9S have been shown to stimulate wound repair in a variety of animal models. 
In a model for deep wounds using wire mesh chambers inplanted subcuteneously in 
rats, TGF-/71 stimulated the formation of granulation tissue (Sprugel ef a/., 1988: Sporn 
et al., 1983). TGF-/01 also accelerated the healing and increased tensile strength of 
incisonal wounds in rats (Mustoe et ai, 1987), which are analogous to surgical wounds. 
TGF-01 was very effective in impaired healing models induced by adriamycin (Lawrence 
ef a/., 1986). This may have important clinical relevance as a wide variety of clinical 
conditions exist, where patients exhibit significant impaired wound healing including 
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patients undergoing systemic drug therapy on glucocorticoids or cancer chemotherapy 
and patients with vascular insufficiencies such as diabetic ulcers or sickle cell disease (ten 
Dijke and Iwata, 1989). 
Several observations indicate that TGF-/?s could also possibly enhance bone repair. 
TGF-/?1 injected "under the periosteum of uninjured newborn rat femurs initiated 
intramembranous bone formation (Joyce era/., 1990a,b). Injection of TGF-/?1 onto the 
periostea of parental bone of neonatal rats stimulated the formation of periosteal woven 
bone (Noda and Camilliere, 1989). 
In vitro TGF-/?s have potent immunosuppressive and anti-inflammatory effects. In 
vivo administration of TGF-/9s can suppress myeloid and lymphoid cell proliferation (Goey 
ef a/., 1989; Fontana er al., 1989). Therapeutically, the immunosuppressive activity of 
TGF-/? may be useful for treatment of autoimmune diseases and in preventing graft versus 
host disease. Systemic administration of TGF-/? to mice was shown to prolong the heart 
graft survival significantly (Palladino ef a/., 1990). Additionally, the potent reversible 
growth inhibition of hematopoietic cells by TGF-/? may be used to protect these normal 
cells during chemo-radiotherapy of neoplastic disease. The action of TGF-/?s as anti-
inflammatory agents was demonstrated when TGF-/?1 and TGF-/S2 increased survival of 
rats injected with pathogenic E. coli, suggesting that IGF-ßs may prevent septic shock 
due to bacterial infections. Possibly, the TGF-/& are decreasing the production of TNF-
a, which is a key mediator in septic shock (Palladino era/., 1990). 
Clearly, TGF-ySs hold a therapeutic promise for many clinical conditions and may 
provide solutions to illnesses that are currently not amenable to effective treatment. 
However, for appropriate use of TGF-/?s as therapeutic agents, further understanding of 
the molecular and cellular mechanisms that determine their (patho)-physiological role and 
pharmacological activity is essential. 
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ABSTRACT We report here the complete amino acid 
sequence of another member of the type ß transforming growth 
factor gene family, deduced from the nucleotide sequence of 
three overlapping cDNA clones. The C-terminal 112 amino 
acids share »80% sequence identity with type ßl and ßl 
transforming growth factors, with many of the remaining 
differences being conservative substitutions. By analogy to type 
ßl and type ßl transforming growth factors, we predict the 
protein to be synthesized as a 412 amino acid precursor that 
undergoes proteolytic cleavage to produce the mature poly-
peptide. 
In contrast to the rapid accumulation of information over the 
past few years regarding positive regulators of cell growth (1-
3), only limited progress has been made in efforts to identify 
regulatory factors that maintain tissue homeostasis by means 
of growth inhibition. Two growth inhibitors that have been 
the focus of considerable attention in recent years are trans-
forming growth factor types 01 and 02 (TGF-01 and TGF-02). 
TGF-/31 was first identified by its ability to induce colony 
formation of certain rodent cell lines in soft agar (4, 5). 
Subsequently, however, TGF-01 was found to act as a potent 
growth inhibitor of a variety of cell lines (6). Both TGF-/31 
and -ßl are synthesized as precursors that undergo dimeri-
zation and proteolytic cleavage to produce the biologically 
active polypeptide. In their mature forms, which consist of 
the C-terminal 112 amino acids, TGF-/31 and -ßl exhibit 71% 
sequence identity. TGF-/8s have been proposed to effect 
tissue repair, wound healing, bone formation, and embryonic 
development (7-9). Abnormalities in TGF-/3 function have 
been implicated in both immunosuppression and cellular 
transformation (8). 
In analyzing human tissues and cell lines as potential 
sources of tumor inhibitory factors, we discovered that ex-
tracts from umbilical cord contain multiple growth inhibitory 
activities, which we termed tissue-derived growth inhibitors 
(TGIs) (10). One of these TGI activities was purified to 
homogeneity and appeared to be indistinguishable from 
TGF-/31, whereas the initial characterization of a second TGI 
revealed a distinct but closely related protein. Conventional 
purification of this activity provided only limited quantities of 
material for analysis. An alternative strategy was to isolate 
the cDNA sequences for this TGI* using TGF-/31 cDNA as 
a probe, predicting that the inhibitor could possess sequence 
similarity to TGF-01. 
MATERIALS AND METHODS 
Oligonucleotide Synthesis. Oligonucleotides, synthesized 
by the phosphoramidite method with an Applied Biosystems 
(Foster City, CA) model 380 A synthesizer used as specified 
The publication costs of this article were defrayed in part by page charge 
payment. This article must therefore be hereby marked "advertisement" 
in accordance with 18 U.S.C. §1734 solely to indicate this fact. 
by the manufacturer, were purified by Polyacrylamide gel 
electrophoresis and desalted on a Waters SEP-PAK C18 
cartridge. 
DNA Labeling and Hybridization Methods. Nick-transla-
tion of DNA restriction fragments and filter hybridizations 
were done as described (11). The specific activities of the 
probes were >2.5 X 108 cpm//ig. Oligonucleotides were 
phosphorylated using [-y-32P]ATP and T4 polynucleotide 
kinase (12). Specific activities were >2 x 106 cpm/pmol. 
Filters were prehybridized for 2 hr in 2.5 x SSC (1 x SSC = 
0.15 M sodium chloride/0.015 M sodium citrate, pH 7)/10x 
Denhardt's solution ( l x Denhardt's solution = 0.02% 
polyvinylpyrrolidone/0.02% Ficoll/0.02% bovine serum 
albumin)/0.1% NaDodS04, followed by 2 hr at 65°C in hybrid-
ization mixture [5 x SSC/50 mM sodium pyrophosphate/10 x 
Denhardt's solution/10% dextran sulfate/single-stranded DNA 
at 250 /ig/ml/7% (wt/vol) NaDodSOJ. Hybridization with the 
labeled oligonucleotide probes was performed overnight in 
hybridization mixture at 45°C. The filters were washed with 3 x 
SSC/lOx Denhardt's solution/0.5% NaDodS04 and exposed 
to Kodak XAR-2 film at -70°C with a DuPont Lightning Plus 
intensifying screen. 
Construction of a cDNA Library from the Human A673 
Rhabdomyosarcoma Cell Line. Poly(A)+ RNA was prepared 
from A673 cells (CRL 1598, American Type Culture Collec-
tion) by twice passing total RNA, isolated by the lithium 
chloride method (13), over an oligo(dT)-cellulose column 
(14). Before cDNA synthesis, the RNA was treated with 
RNase-free DNase (Promega Biotec, Madison, WI) in the 
presence, of the ribonuclease inhibitor RNasin (Promega 
Biotec). Starting with 5 /ig of poly(A)+ RNA, a random-
primed cDNA library of approximately 2 x 106 clones was 
constructed in AgtlO, with the Amersham cDNA Synthesis 
System Plus according to the manufacturer's procedures 
[which are based on the method of Gubler and Hoffman (15)]. 
Subcloning and DNA Sequencing. EcoYÜ inserts from pos-
itive clones were subcloned in both orientations either in M13 
sequencing vectors or in pGEM vectors (Promega Biotec) 
from which deletion clones were generated by Exonuclease 
III digestion (16). Sequencing was done according to the 
dideoxynucleotide chain-termination method (17). 
RNA Analysis. Poly(A) + RNA was purified by oligo(dT)-
cellulose chromatography of total RNA isolated from umbil-
ical cord and various cell lines by the lithium chloride method 
(13). Ten micrograms of poly(A)+ RNA were fractionated on 
a 1% agarose gel in the presence of formaldehyde and then 
transferred to nitrocellulose (12). Radioactive labeling of the 
probes was done by the random-priming method (18). Blots 
Abbreviation: TGI, tissue-derived growth inhibitor; TGF-01, -ßl, 
and -03, transforming growth factor type ßl, type 02, and type 03, 
respectively. 
*To whom reprint requests should be addressed. 
tThe sequence reported in this paper is being deposited in the 
EMBL/GenBank data base (IntelliGenetics, Mountain View, CA, 
and Eur. Mol. Biol. Lab., Heidelberg) (accession no. J03241). 
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were prehybridized in 50% (vol/vol) formamide/50 niM 
sodium phosphate, pH 6.5/5 x SSC/2.5X Denhardt's 
solution/salmon sperm DNA at 250 /ig/ml/poly(A) at 10 
/ig/ml for 4 hr at 55°C. Hybridization was performed in 
prehybridization mix/50% (wt/vol) dextran sulfate, 4:1, for 
12 hr at 55°C. The filters were washed in SSC buffered with 
20 mM sodium phosphate, pH 6.5/1 mM EDTA/0.1% 
NaDodS04. Six 20-min washes were carried out at 65°C, 
stepwise lowering the concentration of SSC from 0.3 x to 
0.1 x to 0.03 x . Filters were exposed to Kodak XAR-2 film 
with a DuPont Lightning Plus intensifying screen at -70°C. 
RESULTS AND DISCUSSION 
Identification and Sequence Analysis of a TGI cDNA. Based 
on the published sequence of TGF-01 cDNA (19), we syn-
thesized a 25-mer oligonucleotide (5' CGGCACCGCC-
GAGCCCTGGACACCA 3', bases 826-851 of the coding 
region). This probe was then used to identify a TGF-/31 
cDNA clone in a commercial Agtll human placenta library 
(Clontech, Palo Alto, CA). By restriction mapping and partial 
sequence analysis, the clone was shown to contain the 
complete coding sequence for the 390-amino acid TGF-/31 
precursor but to lack parts of the untranslated regions [439 
base pairs (bp) from the 5' end and »200 bp from the 3' end, 
data not shown). A Pvu ll-Pvu II fragment of the TGF-01 
cDN A was then used as a hybridization probe for a Southern 
blot (20) of human umbilical cord genomic DNA, digested 
with EcoRl. HindlU, or Sst I (Fig. 1). In each digest two 
bands were apparent at low stringency (2.5 x SSC, 65°C, 
lanes 1, 3, and 5); when the stringency was increased, only 
one hybridizing band remained visible (0.01 x SSC, 65°C, 
lanes 2,4, and 6). We presumed that the strongly hybridizing 
band corresponded to TGF-/31, whereas the detection of a 
weakly hybridizing second band suggested the presence of a 
related gene. Both genes were cloned by screening a genomic 
phage library constructed from the human K-562 chronic 
myelogenous leukemia cell line according to the procedures 
of Grosveld el al. (21). By varying the wash stringency, the 
TGF-/3 sequences could be distinguished from the TGF-/3-
related sequences. Restriction mapping and partial sequence 
analysis revealed that clones hybridizing at high stringency 
were derived from the gene encoding TGF-01, whereas a 
clone that hybridized only at low stringency appeared to be 
derived from a related gene. We have termed this DNA 
sequence TGF-/33 in the remainder of the text (see discussion 
below). 
To obtain a repeat-free probe for TGF-03, restriction 
fragments of the genomic clone were separated by electro-
phoresis, transferred to nitrocellulose, and then hybridized 
with either TGF-01 cDNA or total human genomic DNA. A 
BamHl-Taq I fragment was found to hybridize specifically to 
1 2 3 4 5 6 
kb 
w 
9.5- W v 
6.4- » W 
4.2-
Fic. 1. Southern blot analysis of umbilical cord genomic DNA 
digested with EcoRl (lanes 1 and 2), HinAlW (lanes 3 and 4), and Sst 
I (lanes S and 6) and hybridized with a cDNA fragment of TGF-/31. 
Lanes 1, 3, and 5: low-stringency wash. Lanes'2, 4, and 6: 
high-stringency wash. 
TGF-/31 cDNA, indicating the presence of coding sequence 
and the absence of repetitive DNA elements. This repeat-free 
probe was used to screen a Agtll human placenta cDNA 
library (Clontech, 1.2 x 106 independent clones) resulting in 
the isolation of a 1.7-kilobase (kb) cDNA clone (Fig. 2). 
Screening of a Agtll human umbilical cord cDNA library 
(Clontech, 1.5 x 10° independent clones) with a 5' EcoKl-
Bgl II restriction fragment (Fig. 2, indicated as E-B), derived 
from the placenta cDNA clone, resulted in the isolation of a 
1.9-kb cDNA. The nucleotide sequences of these two cDNA 
clones confirmed that both were derived from the same gene 
as the genomic TGF-/33 clone. On RNA analysis, however, 
the TGF-03 mRNA was found to be »3.5 kb, indicating that 
we had not obtained a full-length cDNA. 
To obtain a full-length clone, mRNA was isolated from 
A673 cells, and a cDNA library was prepared by random 
priming. Approximately 0.7 x 106 unamplified cDNA clones 
were screened with a 25-mer oligonucleotide probe (5' 
ATATAGCGCTGTTTGGCAATGTGCT 3', corresponding 
to a sequence near the 5' end of the 1.9-kb cDNA clone), and 
a single positive clone containing a 1.7-kb insert was identi-
fied. 
Analysis of the three overlapping cDNAs (Fig. 2) revealed 
a sequence of 2529 bp, with the largest open reading frame 
being 1236 bases. We found no sequence differences in the 
overlapping regions and conclude that all three clones were 
derived from transcripts of the same gene. Our sequence 
contains a complete 3' untranslated region of 1031 bp with a 
polyadenylylation signal 25 bp upstream from the poly(A) 
tract. The 5' untranslated region comprises 262 bp and lacks 
=1 kb, as judged from the size of the mRNA estimated by 
RNA analysis. The predicted amino acid sequence of TGF-/33 
shows extensive similarity to TGF-/31 and -02 (19, 22). 
Failure of the TGF-01 probe to detect TGF-02 in the original 
Southern hybridization (Fig. 1) can be accounted for by the 
fact that the Pvu ll-Pvu II TGF-/S1 cDNA fragment shows 
75% similarity with TGF-03 but only 65% similarity with 
TGF-02. Comparing TGF-Ä3 with the GenBank 48.0 nucle-
otide sequence data base' using the FASTN program (23) 
revealed no significant similarity with genes other than 
known members (see below) of the TGF-0 family. 
A Comparison of TGF-/31, -02, and -83. TGF-01 and 
TGF-/32 are produced in precursor forms of 390 and 414 
amino acid residues, respectively (19, 22). The cDNA se-
quence we have obtained for TGF-/33 (Fig. 2b) contains an 
open reading frame coding for 412 amino acids, with the first 
ATG preceded by a stop codon, 162 nucleotides upstream. 
As found with TGF-/31 (19) and -82 (22), the predicted 
initiating codon for TGF-/33 does not form part of a Kozak 
consensus sequence (24). Interestingly, six nucleotides 
downstream there is a second ATG, with an adenine at 
position - 3 , which aligns with the initiating codon in TGF-
82. Homodimers of the C-terminal 112 residues of TGF-01 
and -82 represent the biologically active forms of these 
proteins. Preceding the site of cleavage to their mature forms, 
TGF-/31 and -82 have stretches of four and five basic 
residues, respectively. In TGF-03 there are five basic resi-
dues preceding the predicted cleavage site (Fig. 3). The 
mature forms of TGF-/31 and -02 share 80/112 identical 
residues. The corresponding 112 C-terminal amino acids of 
TGF-03 exhibit 86/112 and 89/112 identical residues com-
pared with TGF-01 and -82, respectively (Fig. 3). Many 
remaining differences represent conservative substitutions. 
All three proteins show a strict conservation of the nine 
cysteine residues in this region (19, 22). The N-terminal 
domain of the precursor form of TGF-/33 exhibits =35% 
*EMBL/GenBank Genetic Sequence Database (1987) GenBank 
(IntelliGenetics, Mountain View, CA), Tape Release 48.0. 
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GAGCCCACAACCTTCGGCTCCGGGCAAATGGCTCAGATGGAGGTTTCCTTITGGAACATÏKTTTCnGCTGGCTCTGAGAAKACGGIGGTAAAGAAAG 
1610 1620 1630 1640 1650 1660 1670 1680 1690 1700 
IGTGGGIITGGTTAGAGGAAGGCTGAACTCTTCAGAACACACAGAC11TCTGTGACGCAGACAGAGGCGAYGGGGATAGAGGAAAGGGATGCIAAGTTGA 
1710 1720 1730 1740 1750 1760 1770 1760 1790 1800 
GATGIIGTGTGGCAATGGGATTTGGGCTACCCTAAAGGGAGAACGAAGGGCAGAGAATGGCYGGG1CAGGGCCAGACTGGAAGACACITCAGATCTGAGG 
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TCTGCCICIGGGTCCCTCCTCTCACCYCTCCCTCGATCATAIIICCCCTTGGACACTTGGlTAGACGCCIICCAGGTCAGGATGCACAnTCTGGAYTGT 
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G1ATAAATAAATATTTTTGGGGCATCCTG poly(A) 
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Fie 2. (A) Schematic diagram of TGF-/33 mRNA with the coding sequence boxed. The relative extension of the cDNAs obtained from 
placenta (1.7 kb), umbilical cord (1.9 kb), and A673 (1.7 kb) libraries is indicated. The dashed part of the box represents the C-terminal region 
showing the greatest similarity to TGF-01 and -02. The 5' EcoRl-Bgl II restriction fragment of the placental cDNA used to screen the umbilical 
cord library is indicated by a thick bar (E-B). (B) Nucleotide sequence and deduced amino acid sequence of a TGF-03 cDNA, determined from 
three overlapping cDNA clones. Putative glycosylation sites and the polyadenylylation signal are underlined. The predicted start of the mature 
TGF-03 is marked by an asterisk at position 1164. 
similarity with TGF-/31 and 45% similarity with TGF-02. By 
comparison, the corresponding sequences of the TGF-01 and 
-ßl precursors have 33% sequence similarity (Fig. 3). A 
homology matrix plot clearly illustrates the greater similarity 
between TGF-03 and -02 compared with TGF-01 (Fig. 3). 
Four potential glycosylation sites are contained in the N-
terminal part of TGF-/33, one of which is conserved in all 
three proteins. All three proteins also possess hydrophobic N 
termini, which probably represent presecretory signal pep-
tide sequences (25). Interestingly, both TGF-01 and TGF-03 
(but not TGF-02) contain the-fibronectin-binding sequence 
Arg-Gly-Asp (26). Given the known effects of TGF-01 on the 
extracellular matrix and wound healing (8), it is tempting to 
speculate that TGF-03 may also have therapeutic applica-
tions in this area. 
Expression of TGF-03 mRNA. The availability of a TGF-03 
cDNA clone allowed us to investigate expression of the gene 
in different human cell types. Hybridizing mRNA was found 
to be present in A673 (a rhabdomyosarcoma), A549 (a lung 
adenocarcinoma), and A-498 (a kidney carcinoma); expres-
sion of TGF-03 was found to be lower by at least a factor of 
50 than that of TGF-01. In all three cell lines, the TGF-03 
mRNA migrated *s a species of about 3.5 kb (Fig. 4). A faintly 
hybridizing band was found at 4.2 kb, which was also seen 
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FIG. 3. Homology of TGF-0S. (A) Homology matrix plots of TGF-/9 amino acid sequences. Stretches of 17 amino acids sharing at least 
50% identity between two proteins were scored as homologous. (B) Comparison of the deduced amino acid sequences of TGF-03, TGF-01, and 
TGF-/82 precursors. One-letter code for amino acids is used, and gaps have been introduced to maximize the similarities. Identical amino acids 
are boxed. The mature TGF-0 amino acid sequences start at position 315. 
with the TGF-/31 probe and may correspond to TGF-02. 
Expression of TGF-/33 was not detected by the TGF-/31 probe 
in the experiment, shown in Fig. 4/4, due to the short 
B 
# • • " « 
FIG. 4. RNA blot analysis. (A) RNA blot analysis of mRN A from 
A673, A549, and A-498 cell lines using a TGF-01 probe containing the 
complete coding region. Exposure time, 14 hr. (B) RNA blot analysis 
of mRN A from A673, A549, and A-498 cell lines using the EcoRl-Bgl 
II placenta TGF-03 probe (Fig. 2).'Exposure time, 4.5 days. (O RNA 
blot analysis of umbilical cord and A673 mRN A using the same probe 
as in B. Exposure time, 3 days. 
exposure. Interestingly, umbilical cord, which we had shown 
previously to contain multiple TGF-/3-like activities, ex-
presses the highest level of TGF-03 mRNA that we have seen 
to date (Fig. 4). Peptide antisera to TGF-03 confirm that the 
protein is present in umbilical cord extracts in fractions 
containing growth inhibitory activity (K.K.I, and S. I. 
Rayter, unpublished data). 
The TGF-0 Gene Family and Comments on Nomenclature. 
During the last few years TGF-01 and -02 have been shown 
to correspond to a number of previously described biological 
activities; these include the glioblastoma-derived T cell 
suppressor factor (22), cartilage-inducing factors A and B (27, 
28), tumor growth inhibiting factor (29), and polyergin (orig-
inally termed BSC-1-derived growth inhibitor) (30). Clearly, 
TGF-ßs are important in the regulation of cell growth. An 
inability of cells either to produce such inhibitory factors or 
to respond to them may play a critical role in transformation 
(7, 8), and members of the TGF-0 family, therefore, could 
function as antioncogenes. 
Recently, it has become apparent that the TGF-/3S belong 
to an expanding family of genes, which not only act as potent 
regulators of cell growth but also affect cell differentiation. 
These genes include those that encode multiple forms of 
activin and inhibin, which regulate secretion of follicle-stim-
ulating hormone (31, 32); the gene that encodes Mullerian 
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inhibiting substance, responsible for regression of the female 
reproductive tract during development of the male embryo 
(33); Vgl, which appears to be involved in mesoderm 
formation during Xenopus development (34); and the deca-
pentaplegic gene of Drosophila, which is associated with 
dorsal-ventral determination during embryogenesis (35). 
Given the multiple activities exhibited by the TGF-/3 gene 
family, we predict that our cDNA clone may also encode a 
protein with pleiotropic biological functions, as opposed to 
being strictly another TGI. Therefore, neither the term 
TGF-0 nor the term TGI is appropriate for this factor. Due to 
the current widespread use of the former nomenclature, 
however, we have chosen the term TGF-/33 for present 
designation. As has been proposed (30), a more appropriate 
nomenclature for this gene family is needed. One possibility 
would be the use of TGF as an abbreviation for tissue growth 
factor. Perhaps, however, such terminology should await a 
clearer definition of the in vivo physiology of these factors. 
Note Added in Proof. Partial cDNA clones for the chicken TGF-03 
have been isolated recently by Jakowlew et al. (36). The predicted 
C-terminal 112 amino acids of chicken TGF-03 share 111/112 
residues sequence identity with the human protein described herein. 
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Type ß transforming growth factors (TGF-/te) are poly-
peptides that act hormonally to control the proliferation 
and differentiation of multiple cell types. Recently, we 
reported the isolation of a cDNA encoding a new 
member of this gene family, which we have termed 
TGF-/Î3. Here we show by Southern analysis using a 
human probe specific for TGF-/I3, the presence of a 
related single copy gene in a wide range of animal 
species. Chromosomal localization of the TGF-/I3 gene 
was performed by Southern blot analysis of DNA pre-
pared from 24 human-Chinese hamster somatic cell 
hybrids using a specific TGF-03 cDNA probe. The 
human specific restriction fragments segregated only with 
human chromosome 14. For all other human chromo-
somes high discordancy scores were obtained. Using in 
situ hybridization of human metaphase chromosomes, the 
regional location could be identified. Hybridization of the 
TGF-/T3 cDNA probe resulted in specific labeling of 
chromosome 14, bands q23-24. 
Type ß transforming growth factors (TGF-/ÎS) are 
dimeric 25 kD peptides with widespread effects on pro-
liferation, differentiation, embryogenesis and tissue 
repair (for recent reviews see Massague, 1987; Sporn et 
al, 1987; ten Dijke et al, 1988a). Three closely related 
homodimeric forms of TGF-/J exist. The form that was 
described first, TGF-/S1, is the predominant species in 
many cells and is particularly abundant in human plate-
lets (Assoian et aï., 1983) and bovine bone (Seyedin et 
al, 1986). A second form of TGF-/J, TGF-/Ï2, has been 
isolated from porcine platelets (Cheifetz et al, 1987), 
bovine bone (Seyedin et al, 1987) and conditioned 
media of a variety of cell types (Wrann et al, 1987; 
Ikeda et al, 1987; Hanks et al, 1988). A rare iso-form 
containing one TGF-/Î1 and one TGF-/Î2 chain has 
been identified in porcine platelets and has been termed 
TGF-/S1.2 (Cheifetz et al, 1987). The physiological sig-
nificance of this heterodimer, if any, is presently 
unknown. Although in most systems which have been 
examined, TGF-/Î1 and -ßl have been found to exhibit 
similar biological properties; distinct effects have also 
been observed in certain assays. For example, TGF-/32, 
but not TGF-/H, has been reported to induce Xenopus 
mesoderm induction (Rosa et al, 1988), while TGF-/fl, 
appears to be a 100 fold more potent growth inhibitor 
of hematopoietic stem cells (Ohta et al, 1987). 
During the last few years, it has become apparent 
that the TGF-/ÎS belong to a rapidly growing family of 
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polypeptides which share similar structural character-
istics. Other mammalian members of the family include 
two forms of inhibin and three forms of activin, gonadal 
proteins that regulate pituitary secretion of follicle 
stimulating hormone (Ling et al, 1986 and Mason et al, 
1985); and the Mullerian inhibiting substance or MIS, a 
protein which causes regression of the female rudiments 
in the developing male reproductive system (Cate et al, 
1986). 
Recently, we reported the isolation of a cDNA clone 
for the third form of TGF-/5, which we have termed 
TGF-/S3 (ten Dijke et al, 1988b). The C-terminal 112 
amino acids of TGF-/J3 share approximately 80% 
sequence identity with TGF-/Î1 and -ßl. The C-terminal 
112 amino acids of TGF-/Î1 are identical in human 
(Derynck et al, 1985) porcine- (Derynck & Rhee, 1987), 
bovine- (Van Obberghen-Schilling et al, 1987) and 
simian species (Sharpies et al, 1987) and differ by only 
one amino acid in the murine form (Derynck et al, 
1986). Furthermore, the human (de Martin et al, 1987; 
Madisen et al, 1988) and simian (Hanks et al, 1988) 
forms of TGF-/Î2 have identical C-terminal 112 amino 
acid residues. To investigate the interspecies conserva-
tion of TGF-/S3 in mammalian and avian species, a 
human 0.25 kb TGF-/53 specific probe was hybridized 
with genomic DNA of other species (see Figure 1). In 
each digest of monkey, rat, mouse, dog, cow, sheep and 
chicken DNA, TGF-/B homologous sequences were 
identified; except for dogs, all species had one hybrid-
izing EcoRI restriction fragment. Northern hybrid-
ization of mouse mRNA visualizes a TGF-/S3 mRNA of 
similar length as the human counterpart (not shown). 
The TGF-/J3 probe used in both of the hybridization 
experiments contains sequences corresponding to the 
N-terminal percursor domain that do not cross react 
with either the human TGF-/Î1 or -ß2 sequences under 
these conditions. Following our publication of the 
human TGF-/Î3 sequence, the chicken TGF-/Î3 gene has 
also now been isolated (Jakowlew et al, 1988). The pre-
dicted C-terminal 112 amino acids of human and 
chicken TGF-/Î3 share 111/112 residues sequence iden-
tity and have one conservative substitution. The intact 
percursors show 366/412 amino acid sequence identities. 
This high degree of evolutionary conservation amongst 
the TGF-/ÎS suggests a fundamental role in normal cell 
physiology. 
Using a specific ["P]-labeled 0.45 kb TGF-03 cDNA 
probe, the DNA from a panel of 24 human x Chinese 
hamster hybrids was screened for human TGF-03 
sequences. A representative Southern blot analysis is 
shown in Figure 2. By using this particular probe 
(which contains the DNA sequence of the probe used in 
Figure 1 and an extra 180bp), two hybridizing EcoRI 
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Figure 1 Southern blot analysis of EcoRI digested DNA (10/jg) 
from different animal species (liver tissue source except Human); 
(1) Human placenta; (2) Monkey; (3) Rat; (4) Mouse; (5) Dog; (6) 
Cow; (7) Sheep and (8) Chicken. Hybridization was performed 
with a [32P]-labeled 5' EcoRI-Smal restriction fragment derived 
from the 1.7kb placenta cDNA clone (ten Dijke et al., 1988b). 
Washing of the filter was performed at 2.5 x SSC, 65"C 
. 2.0 
1.9 
• 1.6 
• 1.4 
fragments of 5.5 and 1.5 Kb could be identified in human 
DNA (Figure 2, lane f). These fragments were easily dis-
tinguishable from the two bands hybridizing in Chinese 
hamster DNA (Figure 2, Lanes a-e), thereby allowing 
the identification and chromosomal localization of the 
human TGF-/Î3 gene. The overall results of this screen-
ing are presented in Table 1. The highest correlation is 
Table I Relationship between the human TGF-/Ï3 gene and human 
chromosomes in 24 human-Chinese hamster somatic cell hybrid 
clones 
Chromosome 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
X 
No 
+ / + 
5 
2 
6 
6 
6 
6 
6 
7 
9 
5 
3 
11 
5 
12 
9 
10 
10 
5 
8 
9 
9 
9 
8 
hybrid 
+ / -
6 
1 
6 
6 
7 
4 
3 
7 
4 
3 
7 
5 
4 
0 
5 
6 
5 
4 
5 
9 
9 
7 
8 
•lones with chromosome/TGF-ßS 
gene retention 
- / + 
7 
10 
6 
6 
6 
6 
6 
5 
3 
7 
9 
1 
7 
0 
3 
2 
2 
7 
4 
3 
3 
3 
4 
-/-
6 
II 
6 
6 
5 
8 
9 
5 
8 
9 
5 
7 
8 
12 
7 
6 
7 
8 
7 
3 
3 
5 
4 
% Discordance 
54 
46 
50 
50 
54 
42 
38 
50 
29 
42 
67 
25 
46 
0 
33 
33 
29 
46 
38 
50 
50 
42 
50 
The symbols + /•• and —/.. indicate the presence and absence of the 
human chromosome. The symbols ../+ and ../— refer to the 
presence and absence of human TGF-/(3 sequences as detected by 
Southern hybridization 
-0.9 
0.8 
Figure 2 Southern blotting analysis of EcoRI digested DNA 
(15ug) from human x Chinese hamster somatic cell hybrids (Lanes 
a-e) and control HeLa cells (Lane 0. The panel of hybrid cell lines 
was generated by fusion of thymidine kinase-deficient (TK~) or 
hypoxanthine phosphoribosyltransferase deficient ( H P R T ) 
Chinese hamster cells with leucocytes from various human donors. 
Details concerning their origin and initial characterization have 
been reported previously (Geurts van Kessel et ai. 1983). The same 
batches of cell were used for DNA extraction and cytogenetic 
characterization. The 5' EcoRI-Smal restriction fragment derived 
from the 1.9kb umbilical cord cDNA clone (ten Dijke et al., 
1988b) was used as a probe. Washing was performed at 0.3 x SSC 
at 65"C. The arrows indicate hybridization with the human 
TGF-/S3 sequences, whereas arrow heads point at Chinese hamster 
hybridizing fragments. Hybrids a, c and d retained the human 
TGF-/Î3 sequences whereas the others did not (b and e) 
found with chromosome 14. All 12 of the 24 hybrid cell 
lines which contained human chromosome 14 hybrid-
ized with the TGF-/Î3 probe (Table 1, + / + column). 
No hybrids were found in the categories, in which 
chromosome 14 was present and TGF-/?3 absent or vice 
versa (Table 1, +/— and — / + column!, ' n contrast to 
the findings with all other human chromosomes. This 
result is consistent with a single location for the 
TGF-/?3 gene on chromosome 14. 
In situ hybridization of the [3H]-labeled TGF-/Î3 spe-
cific probe to metaphase chromosomes from a normal 
individual also resulted in the specific labeling of 
chromosome 14. Of 100 metaphase cells examined from 
this hybridization, 25 (25%) were labeled on region q2 
of one or both copies of the chromosome 14 homo-
logues. The distribution of labeled sites on this chromo-
some is illustrated in Figure 3; of 169 labeled sites 
observed, 37 (22%) were located on this chromosome. 
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Figure 3 Distribution' of labeled sites on chromosome 14 in 100 
normal metaphase cells From phytohemagglutinin-stimulated per-
ipheral blood lymphocytes that were hybridized with TGF-/Ï3 spe-
cific cDNA probe. (Clone p5-l;5' EcoRI-EcoRI restriction 
fragment of the TGF-/Ï3 cDNA containing nucleotides 0-715 (ten 
Dijke et ai, 1988b) subcloned into the pGem vector, Promega 
Biotec). The probe was prepared by nicktranslation of the entire 
plasmid with all four [3H]-labeled deoxynucleoside triphosphates 
to a specific activity of 1.0-2.0 x 108dpm/*g_1. In situ hybrid-
ization was performed as described previously (Le Beau et ai, 
1984). Metaphase cells were hybridized at 2.0 and 4.0 ng of probe 
per ml of hybridization mixture. Autoradiography were exposed 
for 11 days. Each dot indicates one labeled site observed in the 
corresponding band. Eighty four percent (31/37) of the labeled 
sites on chromosome 14 were located at q23-24; this cluster rep-
resented 18.3% of all labeled sites (31/169) 
These sites were clustered at bands q23-24 and this 
cluster represented 18.3% (31/169) of all labeled sites 
(cumulative probability for the Poisson distribution is 
•^0.0005). Specific labeling of bands 14q23-24 was also 
observed in hybridizations in which we used two other 
TGF-/Î3 probes (data not given). All hybridization 
experiments were repeated at least twice and gave essen-
tially identical results. It was noticeable that no hybrid-
izations of the three TGF-/i3-specific probes was 
observed at 19ql3, the chromosomal localization of 
TGF-01. 
The sequence homology between members of the 
TGF-/? gene family suggest a common evolutionary 
origin. Some related gene families are closely linked 
within the same chromosomal region; e.g., the globin 
gene family (Maniatis et ai, 1981), tumor necrosis 
factors (Nedwin et ai, 1985) and some of the interferons 
(Owerbach et ai, 1981). In contrast, TGF-03, TGF-01 
and inhibin ßA are localized on chromosome 14, 19 and 
7, respectively (Fujii et ai, 1986; Barton et ai, 1987). 
This suggests that following amplification, these genes 
have dispersed and subsequently diverged in sequence. 
The TGF-/Î3 gene maps to a region of chromosome 
14 that contains a number of characterized genes, as 
well as the breakpoints of several recurring chromo-
somal abnormalities in human tumors. Genes that have 
been mapped to this region include WARS 
(tryptophanyl-tRNA synthetase), COX4L1 (Cyto-
chrome C oxidase subunit IV-like 1), HSPA2 (heat 
shock protein 2, 70kD subunit), MTHFC (5,10-methy-
lene tetrahydrofolate cyclohydrolyase) as well as the 
FOS proto-oncogene (Ropers et ai, 1987). With respect 
to cancer-specific chromosomal abnormalities, deletions 
involving bands 14q22-24 have been observed in malig-
nant lymphomas as well as in B-cell chronic lympho-
cytic leukemia, and a recurring translocation involving 
chromosomes 6 and 14, t(6; 14) (q21; q24) has been 
observed in ovarian carcinomas (Bloomfield et ai, 
1987). Whether the TGF-/73 gene is involved in any of 
these malignancies remains to be determined. 
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Abstract 
Recently, we identified a new member of the transforming growth factor-/? (TGF-
ß) family, termed TGF-/J3. Recombinant human TGF-/S3 was expressed in Chinese 
Hamster Ovary cells by using dihydrofolate reductase gene amplification. By stepwise 
increases in the concentration of methotrexate, clones with amplified gene copy number 
and elevated expression levels were selected. Using antibodies against TGF-03 peptides, 
it was shown that the conditioned media of transfected cells contained both the mature 
and precursor forms of TGF-/J3. The TGF-/93 protein was purified to apparent 
homogeneity by ammonium sulfate precipitation, acetic acid/acetonitrile extraction of the 
pellet, followed by Biogel P60 gel filtration, immunoaffinity chromatography and reverse 
phase H PLC on C18. Biological activity was demonstrated by growth inhibition of Mv1 Lu 
mink lung epithelial cells and the stimulation of rat NRK fibroblasts cells to form large 
colonies in soft agar cultures in the presence of epidermal growth factor. Additionally, 
TGF-/J3 inhibited the growth of some tumor cell lines, while other cell types were virtually 
unaffected in their growth by TGF-#3, eg., human foreskin fibroblasts. 
Introduction 
Transforming growth factor-/? (TGF-0) was initially discovered by its ability to 
promote the anchorage independent growth of rat NRK fibroblast cells in the presence 
of TGF-o (Delarco and Todaro, 1978). However, it is now recognized that TGF-/9 is a 
multifunctional regulator of cell growth and differentiation (Sporn, er al., 1987; Massague, 
1987). For example, TGF-0 stimulates the growth of osteoblasts (Centrella, era/., 1987), 
fibroblasts (Roberts, era/., 1985) and Schwann cells (Ridley, era/., 1989) and inhibits the 
growth of many epithelial cells (Moses, era/., 1985), endothelial cells (Baird and Durkin, 
1986) andT- and B- lymphocytes (Kehrl, era/., 1986a; Kehrl, etal., 1986b). TGF-0 blocks 
adipogenesis (Ignotz and Massague, 1985), myogenesis (Massague, et al., 1986) and 
hematopoiesis (Keller, etal., 1989) and promotes chondrogenesis (Rosen, etal., 1988) 
and epithelial cell differentiation (Masui, ef a/., 1986). TGF-/7 has multiple physiological 
roles, including in embryogenesis, tissue-repair, bone remodeling, immunoregulation and 
inflammation. Potential clinical applications of TGF-0, include wound healing, bone repair 
and immunosuppression (Sporn, era/., 1987). 
TGF-/83 is a member of the structurally and functionally related family of growth 
factors. Thus far, three homodimeric isoforms have been identified in mammals, termed 
TGF-01, TGF-^2 and TGF-/83. TGF-01 and TGF-02 have been purified from several 
tissues, transformed cells and conditioned media of cell lines (Assoian, ef a/., 1983; 
Cheifetz, etal., 1987; Seyedin, etal., 1987; Wrann, etal., 1987; Ikeda, etal., 1987). The 
cDNA cloning for human TGF-/M revealed that it is synthesized as a 390 amino acid 
precursor, with a hydrophobic signal peptide at the N-terminus and the bioactive mature 
part encoded by the C-terminal 112 amino acid residues (Derynck, era/., 1985). The N-
terminal region of the TGF-/M precursor is glycosylated (Brunner, era/., 1988). Proteolytic 
processing occurs at the signal sequence and the tetrabasic cleavage site. The human 
cDNAs for TGF-/82 (de Martin, era/., 1988) and TGF-/83 (ten Dijke, era/., 1988; Derynck, 
er al., 1988) indicate that they may also be produced as larger secreted precursor 
proteins, with proteolytic processing sites at 112 amino acids from the C-terminus. The 
amino acid sequences for the three human TGF-/? isoforms are highly homologous in their 
mature domains (approximately 70-80%), whereas the homology is much reduced in the 
amino acid sequences of the N-terminal precursor regions (25-35%). Cloning of TGF-
ßs from other mammalian and avian species indicate that all TGF-/? sequences are highly 
conserved in evolution (Sporn, era/., 1987). 
Although TGF-/S1 and TGF-/82 have comparable biological activities, striking 
quantitative differences in biological activities have been reported. TGF-02, but not TGF-
ßl, induces mesoderm in Xenopus ectodermal expiants (Rosa, ef a/., 1988) and TGF-/71 
has been claimed to be a 100 fold more potent growth inhibitor of hematopoietic stem 
cells for this gene (Ohta, ef a/., 1987). Presently, little is known about the biological 
activities of TGF-/83 as the cDNA for this gene was only been recently identified (ten Dijke, 
era/., 1988; Derynck, era/., 1988). 
Recombinant TGF-01 has been overexpressed in Chinese Hamster Ovary (CHO) 
cells using dihydrofolate reductase (dhfr) gene amplification (Gentry, era/., 1987). Both 
mature and precursor forms were present in the conditioned media of the transfected 
cells. Recombinant TGF-/J1 is produced in a latent form. Acidification of the conditioned 
medium was necessary to release the noncovalently bound mature TGF-/?1 from the N-
terminal precursor region to obtain biological activity (Gentry, ef a/., 1987). 
We report here the eukaryotic expression of human TGF-03, its purification to 
apparent homogeneity, and some effects of TGF-/83 on the stimulation or inhibition of cell 
growth. Like TGF-/M and -ß2, TGF-03 appears to be a potent growth modulator of 
multiple cell types. 
Materials and Methods 
Cell Lines 
Stock cultures of cell lines were maintained at 37° C in a humidified 5% C02-95% 
air atmosphere as follows: Mv1 Lu mink lung epithelial cells, A549 lung adenocarcinoma, 
A375 melanoma, A2058 melanoma, WiDr colon adenocarcinoma, MCF7 breast cancer 
and Huf human foreskin fibroblasts in Dulbecco's modified Eagles medium (DMEM) 
supplemented with 10% fetal bovine serum (Hyclone); MG-63 osteosarcoma and MNNG 
osteogenic sarcoma in minimal essential medium (MEM) supplemented with 10% fetal 
bovine serum; G292 osteosarcoma in McCoys medium supplemented with 10% fetal 
bovine serum; K562 chronic myelogenous leukemia, KG-1 acute myelogenous leukemia; 
Hut 78 T cell lymphoma and U937 histiocytic lymphoma in RPMI supplemented with 10% 
fetal bovine serum; CHO cells deficient in dhfr were propagated in Ham F12 medium 
supplemented with 10% dialysed fetal bovine serum (Hyclone). 
General Nucleic Acid Procedures 
Purification of nucleic acids, restriction enzyme digestion, gel electrophoresis, 
transfer of DNA and RNA to nitrocellulose, labeling, and hybridization were performed 
essentially according to established procedures as described by Maniatis, ef a/. (1986). 
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Figure 1 : Schematic representation of the construction of the pCMV:TGF-#3 expression 
plasmid. 
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DNA sequencing was performed according to Sanger era/. (1977). In vitro mutagenesis 
of the flanking sequence, changing the initiation codon CACAC[ATG]A into 
CCACC[ATG]A, was performed using the method of Nakamaye and Eckstein (1986). 
TGF-&3 Expression Construct 
A 1500 bp Alul-Hgal restriction fragment of TGF-/S3 cDNA, corresponding to 
nucleotide positions 255 and 1755, respectively (ten Dijke, era/., 1988), which encodes 
the complete TGF-/83 protein was cloned into the Bluescript plasmid (Stratagene, La Jolla, 
CA) to yield the plasmid pBlue-TGF-/83. The flanking sequence of the initiation codon was 
mutagenized to a more efficient translation sequence, according to Kozak (1986), by 
changing CACAC[ATG]A into CCACC[ATG]A. Mutagenesis was confirmed by DNA 
sequencing. Subsequently, the mutagenized pBlue-TGF-#3 was cut with Kpn\ and Spel, 
two polylinker restriction sites flanking the cDNA insert. This fragment was cloned into 
the eukaroytic expression vector pORFEX (Bernard, ef a/., 1987) cut with Kpnl and Xbal. 
In this construct (pCMV:TGF-/83) the TGF-/83 cDNA sequence is transcriptionally regulated 
by the cytomegalovirus immediate early promoter (Figure 1). 
DNA Transfection and Gene Amplification 
A standard calcium phosphate-DNA precipitation method was used for DNA 
transfection (Graham and van der Eb, 1973). Both the cytomegalovirus (CMV) promoter-
driven TGF-/S3 cDNA expression plasmid (5.7 kb) and the plasmid containing the dhfr 
gene driven by its own promoter (2.5kb) were coprecipitated in a ratio of 10 //g to 0.05 
//g, respectively, and this calcium phosphate-DNA precipitate was added to 0.5 x 106 
CHO cells deficient in dihydrofolate reductase (dhfr'). Selection of transformants with the 
dhfr* phenotype was performed in alpha MEM supplemented with 10% dialyzed fetal 
bovine serum. Colonies that appeared after culturing for 10 to 14 days in selection 
medium were isolated using cloning cylinders and expanded. For gene amplification, the 
primary transfectants were selected by increasing concentrations of methotrexate (Mtx) 
in selective medium. TGF-03 expression levels of primary transfectants and levels during 
amplification were measured by RNA cytodot hybridization (White and Bancroft, 1982) 
normalizing the expression of TGF-/83 mRNA to that of actin. 
Biological Assay 
The growth of MvlLu mink lung epithelial cell is extremely sensitive to TGF-^s 
(Ranchalis, ef a/., 1987). These cells were, therefore, utilized to test conditioned media 
for biological activity of the recombinant TGF-/J3 protein. The growth inhibition assay is 
based on measurement of DNA synthesis as previously described (Iwata, et al., 1985). 
The cells were subcultured on 96-well tissue culture plates in 100 //I of complete medium 
at a density that allowed them to be in a growing state throughout the time period of the 
assay. Conditioned media samples with TGF-/S3 were acid activated by treatment with 
acetic acid (final con. 0.1M) for 30 min followed by neutralization by NaOH/HEPES and 
assayed in triplicate at several serial dilutions added to each well. The cells were 
incubated for 72 h at 37°C in a humidified 5% C02-95% air atmosphere. At the end of this 
incubation period, each well was treated for 24 h with 100 //I of complete medium 
containing 5-[125l] iodo-2-deoxyuridine, [125l]ldUr ( VCi/ml). The monolayers were washed 
once with phosphate-buffered saline, fixed for 10 min in methanol and air dried for 15 min. 
The [125l]ldUr incorporated in the cells was solubilized with 200 //I of 1N NaOH and 
incubated for 20 min at 60°C. The amount of cell growth is measured the amount of 
[125l]ldUr incorporated into the DNA of actively growing cells. Inhibition of growth was 
expressed as the percentage of decrease of [: 5l]ldUr incorporated by cells treated with 
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Figure 2: (A) Southern blot of parental CHO cells (lane 1), CHO 6.35 clone (lane 2) and 
CHO 6.35 with 20 mM Mtx (lane 3). Genomic DNA digested with Bgl II (15/yg) 
was fractionated on a 0.8% agarose gel, blotted onto nitrocellulose and 
probed with 0.6 kb Bgl II TGF-#3 cDNA. 
(B) Northern blot of parental CHO cells (lane 1), CHO 6.35 clone (lane 2) and 
CHO 6.35 with 20mM Mtx (lane 3). Total RNA (50//g) was fractionated on a 
1.2% agarose formaldehyde gel, blotted onto nitrocellulose and probed with 
0.4 kb EcoRI-Smal TGF-#3 cDNA. The position of the ribosomal 18S and 28S 
markers are indicated. 
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TGF-03 containing media samples relative to [125l]ldUr incorporated by the untreated 
control cells. 
Peptide Synthesis and Antibody Production 
Peptides 03111 (DTNYCFRNLEENC) and 03V (YLRSADTTHSTVLGLYNTLNPEAS 
ASY) corresponding to peptide sequences within the TGF-03 protein were synthesized 
on an Applied Biosystems peptide synthesizer (Model 430A) using tert-butyloxycarbonyl 
(t-Boc) chemistry. The peptides 03111 and 03V were coupled to keyhole limpet hemocyanin 
via glutaraldehyde and used for immunization of rabbits. For specificity studies of the 
TGF-03 antisera, the cognate TGF-01 peptides 01 III (DTNYCFSSTEKNC) and 01V 
(YIWSLDTQYSKVLALYNQHNPGASAAY) andTGF-02 peptides 02III (AAYCFRNVQDCNC) 
and 02V (YLWSSDTQHSRVLSLYNTINPEASASY) were also made. Antisera from the 
immunized rabbits were affinity purified using an affinity matrix composed of the respective 
peptide 03-antigen coupled to Affi-prep 10 (Bio-Rad, Richmond, CA) (Harlow and Lane, 
1989). 
Immunodetection 
Enzyme-linked immunosorbent assays were used initially to characterize the 
antibody titers. For Western blotting, proteins were fractionated on 12.5% sodium 
dodecyl sulfate (SDS) Polyacrylamide gels and transferred to nitrocellulose (0.1 //m; 
Schleicher and Schuell, Inc., Keene, NH) in 200 mM Tris, 150 mM glycin, 0.02% wt/vol 
SDS and 20% vol/vol methanol, using 0.8 mA for 15 h at 4°C (Towbin, et al., 1979). The 
blots were blocked in TBST (10 mM Tris-HCI pH 8.0, 150 mM NaCI, 0.05% Tween 20) 
containing 3% non-fat milk powder for 1 h at room temperature. Subsequently, the blots 
were incubated with affinity purified antibody (5 //g/ml) in TBST for 1 h at room 
temperature. After excess of antibody had been washed away with TBST, the blots were 
incubated with alkaline phosphatase-conjugated goat anti-rabbit IgG (Zyrhed Laboratories, 
Inc., San Francisco, CA) diluted 1:5,000 in TBST. Color was developed using 5-bromo-
4-chloro-3-indolyphosphate and nitroblue tetrazolium (Promega Corporation, Madison, Wl) 
as substrates in AP buffer (100 mM Tris-HCI pH 9.5, 100 mM NaCI, 5 mM MgCI2). 
TGF-03 Protein Purification 
Conditioned medium was prepared from transfected CHO cells grown to near 
confluence in alpha MEM supplemented with 10% dialyzed fetal bovine serum in the 
presence of 20nM Mtx in Nunc cell factories. The cells were washed with phosphate 
buffered saline (PBS) and incubated with HB CHO serum free medium (HANA Biologies, 
CA) for 2 hours to eliminate carryover of serum proteins and subsequently incubated with 
fresh HB CHO serum free medium for 48 hours. A total of six collections (2.5 titers per 
collection) were performed. The first collection of conditioned HB CHO media contained 
low levels of TGF-03 (-1 -5ng/ml) and was discarded. Maximum amounts were produced 
in the 4th through 6th collections (20-50ng/ml). Conditioned media was filtered through 
a 1 fjm glass fiber filter (Micron Separations) and prior to processing, stored in plastic 
containers at4°C after addition (with a final concentration) of 0.1 mM PMSF, 4 mM EDTA, 
1 mM EGTA, 0.02% sodium azide and 10 mM Tris HCl pH 7.5. The media was 
concentrated approximately 100 fold using a high capacity, low protein binding Millipore 
"Pellicon" membrane cartridge (Millipore PLGC Regenerated Cellulose, MW cutoff 10,000). 
The protein concentration was adjusted to 10 mg/ml and ammonium sulfate (90%, pH 7) 
was added to 45%, pH adjusted to 7.6 and incubated for 4 hours at 0°C (or overnight). 
The precipitate was pelleted by centrifugation (10,000 x g for 30 min) and the pellet left 
to drain for 10 minutes. Subsequently, the pellet was extracted with 50% (vol/vol) 
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acetonitrile/acetic acid (1M), at 0°C. Twenty five ml of extraction buffer was used per 
gram of starting protein. The suspension was centrifuged at 10,000 x g for 30 minutes 
and the supernatant further concentrated using a Minitan concentrator (Millipore). 1M 
acetic acid was added during concentration to prevent protein precipitation and change 
the buffer to 1M acetic acid. The concentrated material was chromatographed by Biogel 
P-60 gel filtration eluting with 1M acetic acid, and peak fractions (as determined by 
Western blot analysis) concentrated using the Minitan concentrator. Triton was added 
to a final concentration of 1%. The concentrate was pH adjusted to 7.5 with solid Tris 
Base (Sigma) and clarified by centrifugation at 10,000 x g for 30 minutes. This material 
was then chromatographed (at 4°C) on a/83V anti-peptide antibody affinity column (12.5 
cm x 0.8 cm), the column washed extensively with 0.1 M Tris HCl pH 7.5, 10mM EGTA, 
1mM PMSF, 1% Triton X-10Q, 1M NaCI until no protein could be detected in the eluate. 
TGF-/83 was then eluted with 50mM glycine (pH 2) into siliconized plastic vials. The TGF-
ß3 from the antibody affinity column was applied to a Waters C18 reverse phase HPLC 
column and eluted by a linear gradient of 0-60% acetonitrile 0.1% trifluoro acetic acid 
(TFA) gradient, a flow rate 0.5ml/minute and monitored at 210nm. Material was aliquoted 
and stored in the elution solvent at -20°C. Quantitation of chromatographic yields was 
accomplished by immunoblot analysis using #3III anti-peptide antibody. The yield was 
about 30-50% of starting material. Purity was assessed by Polyacrylamide gel 
electrophoresis/silver stain analysis. 
Amino Acid Analysis and Sequence Determination 
Purified TGF-/J3 was hydrolyzed with argon-purged, constant boiling 6N HCl 
containing 1% (vol/vol) phenol at 110°C for 18 hr. Amino acids were derivatized with 
phenylisothiocyanate and separated with an Applied Biosystems model 130A PTC 
analyzer. A Waters 840 systems was used for data collection and reduction. Amino acid 
sequences were determined using an Applied Biosystems model 477A sequencer. 
Cleaved amino acid derivatives were identified with an on-line Applied Biosystems model 
120A PTH analyzer. 
Mass Spectrometry 
TGF-/83 was analyzed using a Bio Ion 20 (Bio Ion AB, Uppsala, Sweden) time-of-
flight mass spectrometer with ionization by 252Cf fission fragments (Sundquist, et al., 
1984). A 100 pmol aliquot of TGF-/83 was applied to aluminized Myler, which was 
previously electro-sprayed with 100//I of nitrocellulose. The sample disc was spun-dried 
and washed with 20 JJ\ of 0.1% aquous trifluoroacetic acid (Johnsson, et al., 1986). 
Spectra were collected for 10 hr at 16000 V accelerating potential. Spectra were 
calibrated using hydrogen and sodium ions. 
NRK-Soft Agar Colony Formation 
TGF-/S3 was tested for the ability to stimulate normal rat kidney (NRK) fibroblasts 
to grow in soft agar. A soft agar under layer of 50/sl of 0.5% agar (Noble) in 10% fetal 
bovine serum containing medium was added to a well of 96 well plate. Cells were diluted 
in 0.5% agar to obtain a final agar concentration of 0.34% agar and 100//I with serial 
diluted TGF-/J3 and 10 ng/ml EGF was added on top of the soft agar underlayer. The 
cells (with factors) were incubated for 5-7 days at 37° C in a 5% C02 atmosphere. At the 
end of the assay 25 //I 0.05% solution of p-iodonitrotetrazolium violet (INT) was added to 
the well and incubated another 24 hrs at 37°C. The assay was quantitated on a Biotek 
320 plate reader at a wavelength of 540nm. 
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Figure 3: Immunoblot of TGF-/83 produced by CHO transfectant using /83III and /83V 
peptide antibodies. (A) shows gel under reducing conditions while (B) shows 
the gel under non-reducing conditions. Lanes 1-3 and 4-6 corresponds to 
conditioned media immunoblotted with /83V and /8VIII antisera, respectively. 
For peptide blocking experiment the antibody was incubated with 80-fold 
molar excess of peptide prior to incubation with the blot, lanes 2 and 5 in 
presence of cognate peptide and lanes 3 and 6 in presence of unrelated 
peptide. The positions of the mature and precursor TGF-/93 proteins are 
indicated by arrows. 
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Growth Regulation of Human Cell Lines 
Growth was determined using a modification of the monolayer assay for TGF-/? 
described by Iwata, et al. (1985). Non-leukemic cells were subcultured on 96-well tissue 
culture plates in 100//I of media at a seeding density of 2x103 cells per well. Cells were 
maintained and assayed in DMEM containing 10% fetal bovine serum and 2% L-
glutamine. Aliquots of TGF-/K3 of 25ng/ml ( - 1nM) were added to the treated cells. 
When cells in the untreated control wells were 90% confluent, cells were pulsed 24 hours 
with 1ji;Ci/ml [125l]ldUr and subsequently harvested. 
Leukemic cells (K562, KG-1, Hut 78 and U937) were seeded in 50>l of media. 
K562 was seeded at a density of 1x103 cells per well in RPMI supplemented with 10% 
fetal bovine serum. KG-1 was seeded at a density of 3.5x103 cells per well in Iscove's 
media supplemented with 10% fetal bovine serum. Hut 78 and U937 were seeded at a 
density of 3.5x103 cells per well in RPMI supplemented with 10% fetal bovine serum. Cell 
growth was determined by microscopic examination. 
Results and Discussion 
Recombinant Expression of Human TGF-/?3 
In order to express recombinant human TGF-/83, we constructed an expression 
plasmid with the TGF-03 cDNA under transcriptional control of the early cytomegalovirus 
promoter (pCMV: TGF-03, see also Figure 1). The initiation codon of TGF-/93 does not 
form part of a Kozak consensus sequence (CCACC[ATG]G), which has been shown to 
influence translation efficiency. In order to promote high yields of the recombinant TGF-
#3 protein, the flanking sequence of the initiation codon was mutagenized to a more 
efficient translation sequence according to Kozak (1986), by changing CACAC[ATG]A into 
CCACC[ATG]A. Most of the flanking 5' and 3' region of the TGF-/73 encoding sequences 
were deleted to remove upstream initiation codons that could possibly impede translation 
efficiency or destabilizing elements that decrease mRNA half-life. 
The pCMV: TGF-03 construct was cotransfected with a dhfr marker gene into CHO 
cells deficient in dhfr. A number of clones expressing the dhfr positive phehotype were 
isolated in selective medium. To enhance TGF-/Î3 expression levels, clones containing 
higher copy numbers of the TGF-/83 gene were selected by stepwise increasing the 
concentrations of Mtx. Southern and Northern blots of a primary transfectant and a 
transfectant selected at 20 nM Mtx, probed with TGF-/Î3 cDNA specific probes are shown 
in Figure 2. Both TGF-/83 gene copy number and TGF-/83 expression level increase after 
Mtx selection. 
To determine whether biologically active TGF-/S3 protein was produced and 
secreted by the transfected cells, conditioned media of transfected cells were harvested 
and tested for growth inhibitory activity against MvlLu mink lung epithelial cells. An 
increase in growth inhibitory activity was observed when cell supernatants before and 
after Mtx selection were compared (data not shown). The clone CHO 6.35 at 20 nM Mtx 
secreted about 30 ng/ml in 48 hr, as determined by this bioassay relative to a TGF-/91 
standard curve. Acidification of the conditioned media was necessary for detectable 
levels of biological activity, suggesting that TGF-/S3 is made in an inactive latent form, in 
a similar fashion as found for TGF-01 expressed in CHO cells (Gentry, era/., 1987). 
Immunodetection of TGF-A3 
Polyclonal antisera were raised in rabbits against peptides /23III and /83V, which 
correspond to different regions of the mature TGF-/73 protein. The affinity purified /J3III 
antibody exhibits greater than 300 fold specificity for the #3III peptide compared to the 
cognate peptide sequences from either the TGF-01 or TGF-/S2. Furthermore, no 
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Figure 4: Silver stain of SDS Polyacrylamide gel of purified TGF-/83 and TGF-51 under 
reducing conditions. The position of 12 kDa marker position is indicated. 
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Figure 5: 252, Cf plasma desorption time-of-flight mass spectrum of purified TGF-/J3. The 
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significant cross reactivity of this antibody has been observed against either the TGF-/91 
or TGF-/72 proteins data (data not shown). The affinity purified yS3V antibody exhibits at 
least a 400 fold selectivity for the /83V peptide compared to the corresponding peptide 
sequence from TGF-/81. However, whereas this antibody cross reacts with TGF-/82 
protein in Western blots, it immunoprecipitates and specifically neutralizes TGF-/83 
biological activity on Mv1 Lu Mink cells (data not shown). 
These antisera were used to identify TGF-/83 in Western blots of conditioned media 
from transfected cells. By analogy to the proteolytic processing as described by Gentry, 
ef a/., (1987), the processed 12 kD mature protein and the uncleaved 50 kD precursor 
protein were detected under reducing conditions. Under non-reducing conditions, the 24 
kD and 100 kD precursor homodimer forms were detected. Specificity of the detected 
bands was demonstrated by pre-adsorbing the antibodies with the respective peptide 
immunogen prior to Western blotting (Figure 3). 
As expected, based on expression data, the antibody did not detect any TGF-/83 
protein in conditioned media of the parental CHO (dhfr) cells (data not shown). 
Following cleavage of the signal peptide sequence of the precursor form of TGF-/S3, one 
would expect a protein with MW of 43 kDa (under reduced conditions), whereas a 50 kDa 
protein is detected. Based on the primary sequence of TGF-/83, there are four N-linked 
glycosylation sites, suggesting the molecular weight differences is likely due to 
glycosylation. The TGF-01 precursor fragment expressed in CHO cells was also found 
to be glycosylated (Brunner, er al., 1988). Within the cells, only the 50 kDa precursor 
TGF-/9 was detected by the TGF-/S3 peptide antibodies (data not shown). 
Purification of TGF-/93 
The CHO transfectant 6.35/20 mM Mtx was used as a cell source for the 
purification of human TGF-^3. Serum free media conditioned for 24 hours using cells 
grown to near confluence was employed as starting material. This media was filtered 
through a 1 /vm glass fiber filter to remove detached cells and was subsequently 
concentrated approximately 100 fold using a Pellicon membrane cartridge with 10.000 MW 
cutoff. Subsequently, the protein in the supernatant was ammonium sulfate (45%) 
precipitated and the pellet extracted with acetonitrile/acetic acid. This step gave 
approximately 40-fold purification with no significant loss of TGF-/93 protein. 
Subsequently, a Biogel P60 gel filtration step was employed. The fractions were analyzed 
by Western blot analysis and peak fractions of the mature TGF-/93 concentrated. This 
material was then chromatographed on a /73V anti-peptide antibody affinity column. 
Finally, TGF-/Î3 from the antibody column was purified on a reverse phase C18 HPLC 
column to remove glycine from the antibody affinity column and other contaminants. 
TGF-/83 eluted at approximately 30% acetonitrile concentration as a single peak. We were 
usually able to recover 30-50% of the starting material as homogeneous TGF-/S3. 
The purity and identity of the recombinant TGF-/83 were assessed using several 
criteria. Analytical gel electrophoresis followed by silver staining showed a single protein 
species with an apparent mol. wt. of 12 kDa under reducing conditions (Figure 4). When 
3 //g of TGF-/J3 was loaded onto a Polyacrylamide gel, no other proteins were detected, 
indicating a purity of >95% (the silver stain could detect <50 ng). Comparing TGF-/81 
and TGF-/83, shows that recombinant TGF-/83 runs at a lower apparent molecular weight 
than TGF-01 under reducing conditions. Possibly this is due to differences in binding of 
SDS to differences in conformation between the two proteins affecting the migration rate 
in the Polyacrylamide gel. The amino acid composition of purified TGF-/S3 corresponded 
with the composition based upon the predicted amino acid sequence of human TGF-/Î3. 
Direct N-terminal sequencing of 30 amino acid residues was in exact agreement with the 
predicted N-terminus of human TGF-/83 based upon the cDNA sequence, indicating that 
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Figure 6: Stimulation of normal NRK rat fibroblast growth in soft agar by TGF-03. 
Varying amounts of TGF-0 were incubated with NRK cells for 7-10 days. 
Absorbance in the wells was measured with a Biotek 320 plate reader at a 
wavelength of 540 nm. 
101 
TABLE 1 : Effects of TGF-#3 (1 nM) on Cell Proliferation in Culture 
Cell Line % Inhibition 
Human tumor cell lines 
A549 (lung adenocarcinoma) 46 
A375 (melanoma) 47 
A2058 (melanoma) 88 
WiDr (colon adenocarcinoma) 24 
MCF 7 (breast carcinoma) 57 
G292 (osteosarcoma) <5 
MG-63 (osteosarcoma) <5 
MNNG (osteosarcoma) <5 
K562 (chronic myeloid leukemia) 55 
KG-1 (acute myeloid leukemia) 50 
Hut 78 (T cell lymphoma) 50 
U937 (histiocytic lymphoma) 50 
Normal human 
Huf (foreskin fibroblasts) 
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the mature TGF-/83 is proteolytically processed after the multi-basic sequence in an 
analogous fashion to TGF-j91. 
The molecular weight for TGF-/83, as determined with a time-of-flight (TOF) mass 
analyzer utilizing high energy fission fragment bombardment, was 25430 Dalton, which 
corresponds with the predicted molecular weight according to the amino acid sequence 
predicted from the cDNA sequence (Figure 5), this indicates that human TGF-/83 
produced in CHO cells is not post-translationally modified 
Stimulation of Normal NRK Rat Fibroblasts to Grow in Soft Agar 
TGF-/83 was characterized for its ability to stimulate soft agar growth of normal rat 
fibroblasts (NRK) in soft agar, as is observed for TGF-01 and TGF-02 (Ranchalis, etal., 
1987). NRK cells were plated with various amounts of TGF-/73 in the presence of EGF. 
As shown in Figure 6, TGF-/83 is a potent stimulator of NRK soft agar growth (ED50 = 1 
ng/ml). Although induction of cells to grow in soft agar is characteristic of cell 
transformation, TGF-/? stimulation of extracellular matrix formation is thought to be 
responsible for the reversible induction of NRK growth in soft agar. 
Effects of TGF-A3 on Cells in Monolayer or Suspension 
The effect of TGF-^3 on the cell proliferation of a number of cell lines was tested. 
The cells were treated with 25 ng/ml (~1 nM) of TGF-/83, a concentration which 
completely inhibits Mv1 Lu mink lung epithelial cells. Most of the cell lines were partially 
inhibited and others (i.e., osteosarcomas) were not affected by TGF-/83. The A 2058 
melanoma cell line was the most sensitive human cell line to growth inhibition by TGF-
ß3. Dose response curves indicated that a plateau response level was reached for each 
cell line below 1 nM. Comparing the effect of TGF-/83 with TGF-01 (normalized with 
respect to protein concentration), showed that both factors have similar qualitative effects, 
with both factors reaching the same maximum inhibition level (data not shown). Partial 
inhibition might be explained by the fact that TGF-/?s affect the cell cycle. TGF-01 has 
been shown to arrest cells in the middle to late G1 phase delaying entry into S phage 
(Heimark, et al., 1986; Shipley, er al., 1985). Alternatively, the tumor cell lines may be 
heterogeneous, containing subpopulations that are resistant to growth inhibition by TGF-
ßs. 
TGF-/Ö, like TGF-/71 and TGF-/72 appears to be a potent growth modulator. 
However, based upon the activities of TGF-/?1 and TGF-/02, TGF-/83 is likely to be a 
multifunctional growth regulator, not only affecting cell growth but also differentiation and 
other cell functions. The availability of highly pure recombinant biologically active TGF-
03, as presented in this report, will allow a detailed structural and functional analysis and 
the evaluation of the multiple clinical applications of TGF-/83. 
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We have recently cloned the cDNA for transforming growth factor type ß3 (TGF-ß3), a new member of the 
TGF-ß gene family. We examined the biological effects of recombinant TGF-ß3 protein in osteoblast-enriched 
bone cell cultures. In this report we demonstrate that TGF-ß3 is a potent regulator of functions associated with 
bone formation, i.e., mitogenesis, collagen synthesis, and alkaline phosphatase activity. In a direct comparison 
between TGF-ß3 and TGF-ßl, TGF-ß3 appeared to be three- to fivefold more potent than TGF-ßl. Our cross-
linking experiments with iodinated TGF-ß showed that in osteoblast-enriched bone cell cultures, both TGF-ß3 
and TGF-ßl associated with the same three cell surface binding sites. Scatchard analysis of receptor 
competition studies indicated the presence of high-affinity binding sites for TGF-ß3 in the pkomolar range. 
TGF-ß3 showed an approximately fourfold-higher apparent affinity than TGF-ßl in overall binding. 
Type ß transforming growth factors (TGF-ßs) are multi-
functional growth modulators which play a central role in 
embryonic development, tissue repair, immunoregulation, 
fibrosis, and carcinogenesis (18, 26). The two well-described 
25-kilodalton (kDa) homodimer forms, TGF-ßl and TGF-ß2, 
share 71% amino acid sequence identity. A heterodimer, 
composed of one polypeptide chain each from TGF-ßl and 
TGF-ß2, termed TGF-ßl.2, has been found in porcine plate-
lets (6). In most assay systems, TGF-ßl and TGF-ß2 have 
similar biological properties, although dramatic differences 
have also been observed. TGF-ßl has been claimed to be a 
100-fold more potent growth inhibitor of hematopoietic stem 
cells than TGF-ß2 (20). In addition, TGF-ß2 but not TGF-ßl 
has been reported to induce mesoderm formation in early 
frog embryos (23). Differences in tissue distribution and gene 
regulation also suggest distinct biological roles for various 
TGF-ß isoforms (26). 
Recently, we identified another human form of TGF-ß, 
termed TGF-ß3. The mature bioactive form of TGF-ß3 
shares 80% amino acid sequence identity with TGF-ßl and 
83% sequence identity with TGF-ß2 (28). TGF-ß3 mRNA 
expression in human cells has been found in umbilical cord 
and in a number of mesenchymal and tumor cell lines (9,28). 
We have now expressed recombinant TGF-ß3 and purified 
this protein to homogeneity by using an immunoaffinity 
column (28a). 
TGF-ß-like activities are produced by bone cells, and 
large amounts are found in the extracellular bone matrix, 
suggesting an important physiological function of TGF-ßs in 
this tissue (4). TGF-ß stimulates cell replication and collagen 
production in cultured fetal rat bone cells (2-5) and induces 
chondrogenesis of embryonic rat mesenchymal cells (25). In 
addition, molecules with TGF-ß-like activity are released in 
vitro after bone resorption and may effect a link between the 
coupled processes of bone formation and resorption during 
remodeling (22, 27). 
The experimental paradigm we have used in this report is 
to isolate various cell populations from resected bone frag-
1
 Corresponding author. 
ments by sequential collagenase digestions (2-5). The later-
released populations are enriched for bone-forming cells 
with the biochemical characteristics associated with the 
osteoblast phenotype, such as type I collagen production, 
elevated alkaline phosphatase activity, and osteocalcin syn-
thesis (17). Studies with such isolated bone cells have shown 
that TGF-ßl is a potent regulator of cells from the osteoblast 
lineage (3). On a molar basis, TGF-ßl is one of the most 
potent mitogens thus far described for osteoblast-enriched 
cultures from fetal bone. The mitotic response to TGF-ßl is 
biphasic, with an optimal concentration below 100 pM (2-4). 
TGF-ßs, in addition, alter expression of various activities 
associated with the osteoblast phenotype: alkaline phos-
phatase activity is decreased, while the synthesis of type I 
collagen is enhanced, similar to the effects of TGF-ß in a 
number of other connective tissue systems (2, 3). 
TGF-ßl and -ß2 appear to act via binding to specific cell 
membrane receptors linked to as yet unknown intracellular 
signaling pathways. Virtually all cell types examined to date 
carry TGF ;ß receptors, with the exception of retinoblastoma 
and pheochromocytoma cells (14). The binding of TGF-ßl 
and TGF-ß2 to integral cell membrane receptors has been 
demonstrated by chemical cross-linking. Three size classes 
of ligand-receptor complexes have been identified: (i) a 
65-kDa glycoprotein; (ii) an 85- to 110-kDa glycoprotein; and 
(iii) a heterogeneous proteoglycan with an average size of 
250 kDa (2,7,16, 24,29). Current evidence suggests that the 
type I TGF-ß receptor is required for TGF-ßl's effect on 
DNA, collagen, and fibronectin synthesis (1, 24). 
The present studies were performed to assess the effects 
of human recombinant TGF-ß3 on osteoblast-enriched cul-
tures from fetal rat parietal bone and to characterize the 
specific binding of TGF-ß3 to bone cell surface proteins. 
MATERIALS AND METHODS 
Test agents. Recombinant human TGF-ß3 protein used in 
these studies was obtained from conditioned medium of 
Chinese hamster ovary (CHO) cells transfected with an 
expression plasmid containing the TGF-ß3 cDNA. The 
TGF-ß3 protein was purified to homogeneity as judged by 
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silver-stained sodium dodecyl sulfate-pojyacrylamide gel 
electrophoresis (28a). Human TGF-ßl, purified from plate-
lets, was obtained from Calbiochem (La Jolla, Calif.). TGF-
ßl (from Biomedical Technologies, Stoughton, Mass.) and 
TGF-ß3 were iodinated on ice for 15 s by a modification of 
the method of Hunter and Greenwood (11). The radiolabeled 
TGF-ß was separated from the free iodine by adsorption to 
a Waters SEP-Pak C18 cartridge, which was pretreated with 
bovine serum albumin. The iodinated,TGF-ß was eluted with 
80% acetonitrile-0.05% trifluoracetic acid. 
Cell cultures. Parietal bones dissected free of adjacent 
suture lines were obtained from 22-day-old rat fetuses (Spra-
gue-Dawley; Charles River Breeding Laboratories, Wilming-
ton, Mass.) and subjected to five sequential 20-min collage-
nase digestions as described previously (17, 30). The 
population of cells released during the first enzyme treat-
ment (population 1) is enriched with less-differentiated fibro-
blastlike cells, whereas the last three (populations 3 to 5) are 
enriched with cells expressing features characteristic of the 
osteoblast phenotype. Cells from population 1 and a pool of 
cells from populations 3 to 5 were plated at 12,500 cells per 
cm2 and cultured in Dulbecco modified Eagle medium as 
detailed previously (2, 3, 17). After reaching confluence 
(approximately 6 x 104 cells per cm2), the cultures were 
deprived of serum for 20 h; the factors of interest were then 
added to the cultures in serum-free medium and incubated 
for an additional 23 h. 
DNA synthesis. To examine the mitogenic effect of the test 
factors, cell cultures were pulse labeled with [3H]thymidine 
(80 Ci/mmol) for the last 2 h of treatment and lysed by the 
addition of 0.1% sodium dodecyl sulfate and 0.1 N sodium 
hydroxide. The insoluble material formed by precipitation 
with 10% trichloroacetic acid was collected on glass fiber 
filters, rinsed with ethanol, and measured by scintillation 
counting. Data are shown as the total amount of acid-
precipitable [3H]thymidine incorporated per 0.32-cm2 cul-
ture well. 
Protein synthesis. To measure collagen and noncollagen 
protein synthesis, 2-cm2 cultures were pulsed with 12.5 p.Ci 
of [3H]proline (125 mCi/mmol) per ml for the last 2 h of 
culture. Cells were rinsed with isotonic buffer (146 mM 
NaCl, 11 mM dextrose, 35 mM Tris hydrochloride [pH 7.4]) 
and lysed by freeze-thawing in 0.5% (vol/vol) Triton X-100 
(Sigma Chemical Co.). The homogenates were diluted three-
fold and precipitated with 10% trichloroacetic acid, and the 
acid-precipitable material was collected by centrifugation. 
The pellets were acetone extracted, dried, resolubilized in 
0.5 M acetic acid, and neutralized with NaOH. The amount 
of ('Hlproline incorporated into collagenase-digestible pro-
tein and noncollagen protein was measured as described by 
Peterkofsky and Diegelmann (21). 
Alkaline phosphatase assay. Enzyme activity was mea-
sured in extracts prepared from 2-cm2 cultures following 
sonication in 0.5% Triton X-100. Hydrolysis of p-nitrophenyl 
phosphate was measured at 410 nm after 30 min (15); data 
are expressed as nanomoles of p-nitrophenol released per 
minute per milligram of protein. 
Receptor assays. Binding of TGF-ßl and TGF-ß3 to cell 
surface-associated binding sites was examined by methods 
adapted from Massague and Like (16). Confluent cell cul-
tures (4.8 cm2) were serum deprived for 20 h, rinsed, 
incubated for 1 h at 37°C, rinsed, and incubated for an 
additional hour at 4°C in serum-free medium containing 0.4% 
bovine serum albumin. 125I-labeled TGF-ß (80 pM) in the 
presence or absence of unlabeled TGF-ßl or -ß3 was then 
added for 3 h at 4°C; the cultures were rinsed with cold 
isotonic buffer and cross-linked by a 15-min incubation at 
4°C with 0.5 mM disuccinimidyl suberate. Subsequently, 
cells were extracted, and the amount of bound ligand was 
determined in a gamma counter and electrophoresed on 
7.5% Polyacrylamide gels. Bound [125I]TGF-ß was visual-
ized by autoradiography as reported previously (2). 
Statistical methods. Data for effects on DNA and collagen 
synthesis and alkaline phosphatase activity are shown as the 
means ± standard error of the mean (SEM) and are repre-
sentative of at least three independent determinations. Bind-
ing studies were performed with at least two separate 
batches of [125I]TGF-ßl or [125I]TGF-ß3 and are repre-
sentative of at least two independent determinations. 
RESULTS 
Effects of recombinant TGF-ß3 on DNA synthesis rates, 
collagen production, and alkaline phosphatase activity. We 
examined the effects of recombinant human TGF-ß3 and 
human platelet-derived TGF-ßl in osteoblast-enriched cul-
tures obtained from fetal rat parietal bone (Fig. 1). The 
protein concentrations of TGF-ß3 and TGF-ßl were normal-
ized by using both the colloidal gold assay (Collaborative 
Research, Bedford, Mass.) and intensity of silver staining on 
an SDS-polyacrylamide gel. Analogous to our previous 
reports with native and recombinant TGF-ßl (2, 3), recom-
binant TGF-ß3 had a biphasic stimulatory effect on DNA 
synthesis, enhanced collagen synthesis, and decreased alka-
line phosphatase activity in osteoblast-enriched cultures 
after 23 h of treatment. TGF-ß3 was more potent than TGF-
ßl , with an approximately three- to fivefold-lower concen-
tration needed for similar half-maximal effects in all three 
assays. 
Relative effects of TGF-ß3 on DNA synthesis in osteoblast-
and fibroblast-enriched bone cell populations. Earlier studies 
with isolated bone cells have revealed that TGF-ßl was a 
potent mitogen for cells within the osteoblast lineage, 
whereas minimal effects were seen in less differentiated 
fibroblast-enriched cultures from fetal rat bone (3). In the 
present studies, we observed that both TGF-ßl (data not 
shown) and TGF-ß3 (Fig. 2) enhanced the rate of DNA 
synthesis to a greater extent in osteoblast-enriched cultures 
than in fibroblast-enriched bone cell cultures. In contrast, 
fetal bovine serum greatly increased the level of DNA 
synthesis in both cell populations (Fig. 2). 
Receptor binding of TGF-ß. Cross-linking studies have 
demonstrated that TGF-ßl associates with three distinct 
FIG. 1. Effect of TGF-ß3 (•) and TGF-ßl (O) on DNA synthesis (a), collagen synthesis (b), and alkaline phosphatase activity (c). 
Osteoblast-enriched cultures from fetal rat parietal bone were cultured to confluence and then serum deprived for 20 h prior to a 23-h 
treatment with either TGF-ß3 or TGF-ßl at the concentrations shown, (a) DNA synthesis rates were measured by labeling cells with 
t3Hlthymidine for the last 2 h of culture; acid-insoluble material was assayed by scintillation counting, (b) Collagen synthesis was measured 
by labeling with pHlproline for the last 2 h of culture; acid-insoluble cell extracts were digested with nonspecific protease-free bacterial 
collagenase, and radioactivity was determined in the enzyme-released supematants. (c) Alkaline phosphatase activity was measured in cell 
extracts by hydrolysis of p-nitrophenyl phosphate to p-nitrophenol (PNP). Data are the means ± SEM of four to six replicate cultures per 
condition. 
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FIG. 2. Effect of TGF-ß3 (a) and fetal bovine serum (b) on DNA synthesis of osleoblast-enriched (populations 3 to 5) (•) and 
fibroblast-enriched (population 1) (O) cells. Confluent cell cultures were serum deprived for 20 h prior to a 23-h treatment with TGF-ß3 or 
fetal bovine serum (FBS) at the concentrations shown. DNA synthesis rates were measured by labeling cells with [3H]thymidine for the last 
2 h of culture; acid-insoluble material was assayed by scintillation counting. Data are the means ± SEM of four replicate cultures per 
condition. 
classes of integral cell surface binding sites. We and others 
have previously reported TGF-ß ligand-receptor complex 
types I, II, and III on fetal rat bone cells that correspond to 
bands of 65, 85, and >200 kDa when analyzed by Polyacryl-
amide gel electrophoresis (2, 24). The type III receptor is 
most prominently labeled, followed by the type II and type I 
receptors, with approximate labeling ratios of 5:2:1, respec-
tively. When r l"l]TGF-ßl and [125I]TGF-ß3 binding to 
osteoblast-enriched cultures was compared by these meth-
ods, we observed an identical labeling pattern by both 
ligands, and similar labeling ratios among the three binding 
sites (Fig. 3). Competition binding studies between [125I] 
TGF-ßl (80 pM) and 40 to 2,560 pM unlabeled TGF-ßl and 
TGF-ß3 demonstrated that TGF-ß3 bound with a three- to 
fourfold-greater affinity (Fig. 4), and a significant displace-
ment was observed for each receptor class (Fig. 5). The 
LIGAND program (19) was used to analyze the competition 
binding data and indicated an overall dissociation constant 
(Kd) of 200 pM for TGF-ßl and an overall inhibition constant 
(AT,) of 50 pM for TGF-ß3. 
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FIG. 3. Cell surface-associated binding of [ l2 'I)TGF-ßl and |125I) 
TGF-ß3. A confluent monolayer of osteoblast-enriched cell culture 
was affinity labeled by incubation in the presence of [ l25l]TGF-ßl 
(lane a) or [I25I]TGF-ß3 (lane b). followed by treatment with 
disuccinimidyl suberate. Detergent-soluble cell extracts were dis-
played by gel electrophoresis and autoradiography. The positions of 
the three labeled TGF-ß receptor types are indicated (in kilodal-
tons). 
DISCUSSION 
In the present studies we observed that TGF-ß3 produces 
biochemical effects in fetal rat bone-derived cell cultures 
analogous to those of T G F - ß l (2^t ) . Like T G F - ß l , TGF-ß3 
enhances D N A and collagen synthesis and decreases alka-
line phosphatase activity in osteoblast-enriched cul tures 
from fetal rat bone , but has minimal effects on D N A synthe-
sis in fibroblastlike cells from the same t issue. As in our 
present and earlier studies with T G F - ß l (2-4), the mitogenic 
effect of T G F - ß was biphasic, with significantly less activity 
at higher T G F - ß concentra t ions . This may result from com-
plex interactions between signals generated at different 
binding sites in these cultures. At lower T G F - ß levels, the 
FIG. 5. Relative displacement at cell surface binding sites by 
TGF-ßl and TGF-ß3 in osteoblast-enriched cultures form fetal rat 
bone. Confluent cell cultures were serum deprived for 20 h, rinsed, 
and incubated with 80 pM [125I]TGF-ßl in the absence or presence 
of unlabeled TGF-ßl and TGF-ß3 for 3 h at 4°C. The cell lysates 
were fractionated by electrophoresis on 7.5% Polyacrylamide gels, 
and the bound ligand was visualized by autoradiography. Lane a, 
No addition; lanes b to f, unlabeled TGF-ßl at 80, 160, 320, 640, and 
1,280 pM, respectively; lanes g to I, unlabeled TGF-ß3 at 40, 80, 160, 
320, 640, and 1,280 pM, respectively. 
signal generated through the higher-affinity complex would 
predominate ; at higher T G F - ß concent ra t ions , the moderat -
ing effect of a separate counteract ing signal, p roduced by 
binding to the lower-affinity site, might then become evident . 
A more complete unders tanding of the intracellular signals 
induced by T G F - ß occupancy at each binding site will be 
required to address this quest ion directly, however . 
Receptor-binding studies indicate that in osteoblast-en-
riched cell cul tures , T G F - ß 3 associates with each of the 
three binding sites previously demonst ra ted with T G F - ß l 
and T G F - ß 2 . The higher affinity of T G F - ß 3 compared with 
1000 2000 3000 
TGF-8 (pM) 
FIG. 4. Competitive binding between TGF-ßl and TGF-ß3 in osteoblast-enriched cultures form fetal rat bone. Confluent cell cultures were 
serum deprived for 20 h, rinsed, and incubated with 80 pM | l 2 5l]TGF-ßl in the presence of unlabeled TGF-ßl (O) or unlabeled TGF-ß3 ( • ) 
for 3 h at 4°C. The cells were lysed, and the amount of bound radioligand was determined in a gamma counter. The maximum amount of [l2sl] 
TGF-ßl bound in the absence of unlabeled competitor was 7,100 cpm, or 3.8% of its input concentration. The values shown are the average 
for duplicate culture wells and are representative of two separate experiments. 
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TGF-ßl correlates well with the relatively'greater biological 
activity of TGF-ß3. 
Differences in activity and binding between TGF-ß3 and 
TGF-ßl observed in these experiments could be due to 
subtle species sequence variations and the heterologous 
nature of the assay systems, i.e., human TGF-ßs have been 
analyzed with rat cells. This is doubtful, however, since 
TGF-ß3 and TGF-ßl are highly conserved through evolu-
tion. For example, the human and chicken mature polypep-
tide sequences are identical for TGF-ßl, and there is only a 
single conservative amino acid substitution for TGF-ß3 (8,9, 
12, 13, 28). Another explanation for these findings could be 
the sources from which each of these TGF-ß preparations 
were acquired. TGF-ßl, purified from human blood plate-
lets, was obtained commercially, and recombinant TGF-ß3 
was purified to homogeneity from cell culture medium. We 
believe this second possibility is also unlikely due to the 
inherent stability of these proteins and because we have 
observed similar results with multiple preparations of the 
TGF-ßs. 
Recently, Graycar et al. (10) found that recombinant 
TGF-ß3 has similar biological activities to TGF-ßl and -ß2, 
but with different relative potencies depending on the cell 
type. Consistent with our data presented in this report and 
our observation on TGF-ß3 growth inhibition of mink cells 
(K. K. Iwata, unpublished data), TGF-ß3 has been found to 
be more potent than TGF-ßl in inhibiting DNA synthesis of 
mink cells and keratinocytes and more potent in stimulating 
DNA synthesis in AKR-2B cells (10). Receptor competition 
with [125I]TGF-ßl showed that TGF-ßl competed more 
effectively than TGF-ß3 in AKR-2B cells (10). In contrast, 
we observed that TGF-ß3 competed more effectively than 
TGF-ßl in osteoblast cultures, an effect more consistent 
with its relatively greater biochemical potency. These differ-
ences could be due to experimental factors such as cell 
types, cell density, and method of radiolabeling. 
Unlike our present results with TGF-ß3, analogous studies 
comparing porcine blood platelet-derived TBF-ßl and TGF-
ß2 (R and D Systems, Inc., Minneapolis, Minn.) showed no 
consistently different effects on DNA synthesis or any 
correlation between mitogenic activity and ligand occupancy 
at type I TGF-ß-binding sites in fetal rat osteoblast-enriched 
cultures (M. Centrella, unpublished results). This suggests 
that each of the TGF-ßs differentially couples to binding 
sites and/or differs in the proportion of receptor ligand 
interaction resulting in postreceptor signals, but this possi-
bility will require a better understanding of the nature of the 
TGF-ß receptor that mediates increased DNA synthesis in 
these cells. 
The precise role and mutual interactions of specific growth 
regulators in bone metabolism, such as the TGF-ßs, fibro-
blast growth factors, platelet-derived growth factors, insulin-
like growth factors, and the bone morphogenetic proteins, 
have yet to be determined. However, all TGF-ß isoforms 
examined to date are potent mitogens for osteoblast-en-
riched cultures from fetal rat bone and enhance bone matrix 
protein synthesis (2-5, 22, 25, 27, 31; this study). Bone 
grows rapidly during development and early life. In addition, 
bone is continuously remodeled throughout the life span by 
cellular events that incorporate bone resorption and subse-
quent bone formation. Furthermore, in contrast to the heal-
ing process that occurs in most other connective tissues, 
bone repair involves the formation of new bone rather than 
scar tissue. TGF-ß may stimulate precise steps in bone 
formation during each of the three physiological processes 
(development, remodeling, and fracture repair). It is possi-
ble, therefore, that different members of the TGF-ß gene 
family may have a more important or direct role in each of 
these processes. It will be of great interest to understand the 
role of the various TGF-ß isoforms in normal and aberrant 
bone formation, to determine how the different TGF-ß 
isoforms may be used in the treatment of metabolic bone 
disease, and how to utilize TGF-ßs therapeutically to accel-
erate the process of fracture repair. 
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Characterization of the three mammalian transform-
ing growth factor-/? (TGF-0) isoforms, TGF-01, -02, 
and -/S3, indicates that TGF-03 is somewhat more po-
tent (EDB0 = 0.5 pM versus 2 pM) than TGF-01 and 
TGF-02 as a growth inhibitor of the MvlLu mink lung 
epithelial cell line. In the fetal bovine heart endothelial 
(FBHE) cell line, however, TGF-01 and -03 are at least 
50-fold more potent than TGF-02 which is a very weak 
growth inhibitor (ED50 > 0.5 nM). Thus, as growth 
inhibitors, TGF-01 and -03 resemble each other more 
than TGF-02. The presence of serum a2-macroglobulin 
in the FBHE cell assays decreases the biological po-
tency of TGF-0S, in particular TGF-02. This effect of 
a2-macroglobulin, however, is not sufficient to explain 
the low responsiveness of FBHE cells to TGF-02. Eval-
uation of the role of TGF-0 receptors as determinants 
of cell-specific responsiveness to TGF-0 isoforms indi-
cates that TGF-01, -02, and -03 have similar affinity 
for the membrane proteoglycan, betaglycan. They dif-
fer, however, in their ability to bind to receptor types 
I and II which are implicated in TGF-0 signal trans-
duction. TGF-01 is similar, albeit not identical, to TGF-
03 and much more potent than TGF-/S2 as a competitor 
for binding to the overall population of receptors I and 
II in all cell lines tested. A subset of receptors I and II 
has been identified in MvlLu cells which has high 
affinity for TGF-02 (KD - 1 0 pM) and binds this factor 
at concentrations that are biologically active in MvlLu 
cells. This receptor subset could not be detected in 
FBHE cells, suggesting that cell-specific differences in 
the level of high affinity TGF-02 receptors may lead 
to cell-specific differences in responsiveness to this 
isoform. Thus, despite their structural and biological 
similarities, TGF-01, -02, and -03 diverge in their 
ability to bind to receptors in a manner that correlates 
with their potency as growth inhibitors. 
Transforming growth factor-0 (TGF-0)1 is a term that 
refers to the dimeric products of various genes, five to date, 
identified in vertebrates by isolation of the proteins or by 
* This work was supported by National Institutes of Health Grant 
CA 34610 and by a collaborative research agreement between Pfizer, 
Inc. and Oncogene Science, Inc. The costs of publication of this 
article were defrayed in part by the payment of page charges. This 
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ance with 18 U.S.C. Section 1734 solely to indicate this fact. 
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1
 The abbreviations used are: TGF-0, transforming growth factor-
0; DMEM, Dulbecco's modified Eagle's medium; '!sI-dU, 'î5I-iodo-
deoxyuridine; a2M, a^-macroglobulin; Hepes, 4-(2-hydroxyethyl)-l-
piperazineethanesulfonic acid; FBHE, fetal bovine heart endothelial; 
PAI-1, plasminogen activator inhibitor-1. 
cDNA cloning (for reviews see Refs. 1 and 2). TGFs-0 are 
secretory polypeptides that act as paracrine inhibitors of cell 
proliferation, regulators of cell differentiation, immunosup-
pressors, and regulators of cell adhesion and extracellular 
matrix deposition. The three isoforms identified in mammals 
are TGF-01, -02, and -03. TGF-01 and -02 have been purified 
from various natural sources, and their biological activity and 
receptor interactions are known with some detail (1, 2). The 
cDNAs for human and chick TGF-03 have been isolated (3-
5), and the human recombinant protein has been recently 
purified to homogeneity (6, 7). Expression of these TGF-0 
isoforms is active throughout embryonic development and 
into adulthood (8-11). Histochemical localization studies have 
shown expression of TGF-01, -02, and -03 in discrete regions 
of many tissues with characteristic temporal and spatial pat-
terns (1, 2). Physiologically, TGFs-0 are thought to play a 
major role in morphogenetic events during émbryogenesis, 
adult tissue recycling, and repair. 
The retention of various TGF-0 isoforms through evolution 
is of interest. The extent of identity between the sequences 
of TGF-01, -02, and -03 is relatively high, ranging from 71% 
(01 versus 02) to 76% (02 versus 03) (12). Even more remark-
able is the level of conservation of the individual TGF-0 
isoforms. There is >97% identity between the mature TGF-
01 sequences from various mammalian and avian species, and 
the same is true for TGF-02 and -03 (1, 2). Arguably, the high 
degree of conservation of the mature TGF-0 sequences reflects 
the existence of evolutionary pressure to conserve distinct 
biological properties in each TGF-0 isoform. Indeed, TGF-01 
and -02 can show marked differences in biological potency in 
certain cell types (13-17), although their biological potencies 
are similar in many other cell types (6, 14, 18,19). 
The relationship between receptor binding affinity and 
biological potency of the various TGF-0 isoforms, however, 
has been unclear. Binding of TGF-01 and TGF-02 to most 
mammalian cells is mediated by two coexisting cell surface 
glycoproteins of 53 kDa (type I) and 70-85 kDa (type II), 
respectively, and by the JV-glycosylated core of betaglycan, a 
200-400-kDa cell surface proteoglycan (1). Based on the phe-
notype of a panel of TGF-0-resistant MvlLu cell mutants, it 
is thought that receptor components T and II are involved in 
signal transduction since both components are frequently lost 
in the mutants (20, 21). However, receptor components I and 
II have much higher affinity for TGF-01 than for TGF-02 
(13,14, 18, 22). This marked difference has been paradoxical 
in cells that respond equally well to TGF-01 and TGF-02. By 
studying the basis for the differential response of cells to 
TGF-01, -02, and -03, we have identified a previously un-
known level of TGF-0 receptor heterogeneity that may clarify 
this paradox. 
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EXPERIMENTAL PROCEDURES 
Growth Factors—TGV-ßl and -ß2 were purified to homogeneity 
from bovine bone (23). Porcine TGF-ß2 (18) was purchased from 
R&D Systems. TGF-ß3 was purified to homogeneity from serum-free 
medium conditioned by Chinese hamster ovary cells expressing a 
transfected human TGF-/33 cDNA, as previously described (7). Ho-
mogeneity of the TGF-ß preparations was assessed by silver staining 
of electrophoresis gels overloaded with TGF-ß samples. Quantitation 
of these TGF-ß preparations was done by amino acid analysis and by 
comparison with TGF-ß standards on silver-stained electrophoresis 
gels. 
Cell Lines—Stock cultures of cell lines were maintained at 37 °C 
in a humidified 5%/95% C02:air atmosphere as follows: FBHE fetal 
bovine heart endothelial cells (American Type Culture Collection, 
CRL 1395) in Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% bovine calf serum (GIBCO) and 100 ^g/ml endo-
thelial cell mitogen (Biomedical Technologies); MvlLu mink lung 
epithelial cells (American Type Culture Collection) in minimal essen-
tial medium supplemented with nonessential amino acids and 10% 
fetal bovine serum (GIBCO); BRL-3A Buffalo rat liver cells (Ameri-
can Type Culture Collection) in DMEM supplemented with 10% 
bovine calf serum; and LeE9 rat skeletal muscle myoblasts (24) in 
DMEM supplemented with 20% fetal bovine serum. 
DNA Synthesis (Growth Inhibition) Assays—For growth inhibition 
assays (25), MvlLu cells were seeded in 24- or 48-well multicluster 
dishes at a density of 30,000 cells/cm2 in medium supplemented with 
0.2% fetal bovine serum and 10 DIM Hepes, or 15,000 cells/cm2 in 
medium supplemented with 10% fetal bovine serum for experiments 
shown in Fig. 2B. After cells had attached (2-4 h), the medium was 
replaced with fresh medium containing the indicated concentrations 
of TGF-ß. Cultures were incubated for 24 h, the last 2 or 4 h in the 
presence of 0.5 ,uCi/ml 12SI-deoxyuridine (lï5I-dU; Du Pont-New Eng-
land Nuclear). Incorporation of m I -dU into DNA was measured as 
previously described (25). 
FBHE cells were seeded in 24-well multicluster dishes at a density 
of 50,000 cells/well in DMEM supplemented with 10% calf serum 
unless otherwise indicated. 12-15 h later, medium was replaced with 
0.5 ml of the same fresh medium containing the indicated concentra-
tion of TGF-ß. Cultures were incubated for 48 h, the last 18 h in the 
presence of 1 fiCi/m\ mI-deoxyuridine, and incorporation of 125I-dU 
into DNA was measured. 
TGF-ß Receptor Assays—Bovine TGF-ßl, porcine TGF-ß2, and 
human recombinant TGF-ß3 were iodinated by the chloramine-T 
method as previously described (14). Affinity labeling of confluent 
cell monolayers with 125I-TGF-ßl, -ß2, or -ß3 and disuccinimidyl 
suberate was done as previously described (26). 
Preparation of a2-Macroglobulin-depleted Serum—Rabbit anti-hu-
man a2M antibody (4.2 mg) (Sigma) was immobilized by overnight 
incubation at 4 "C with 0.4 ml of protein A-Sepharose (Pharmacia 
LKB Biotechnology Inc.) in phosphate-buffered isotonic saline con-
taining calcium and magnesium and then washed with 5 volumes of 
the same solution. This immobilized anti-a2M preparation bound up 
to 10 mg of bovine a^M/ml of beads. Control beads were prepared 
with rabbit preimmune serum. Fetal bovine serum (GIBCO) (1 ml of 
serum/0.3 ml of beads) was incubated with immobilized a2M antibody 
overnight at 4 "C to remove endogenous a2M. Efficiency of depletion 
was assayed by Western immunoblot using anti-a2M antibody and 
iasI-protein A, and known amounts of bovine a2M (Boehringer Mann-
heim) as standards. 
RESULTS 
Growth Inhibitory Activity of TGF-ßl, -02, and - 0 3 — M v l L u 
mink lung epithelial cells a n d F B H E cells are po ten t ly growth 
inhibi ted by T G F - 0 1 bu t differ in thei r growth inhibi tory 
response to TGF-02 (Ref. 17 and Fig. 1). U n d e r normal assay 
condit ions, TGF-02 is as po t en t as T G F - 0 1 in M v l L u cells 
but is much less po t en t t h a n T G F - ß l in F B H E cells (Fig. 1). 
W e selected these two cell l ines t o de te rmine t h e activity of 
recombinant T G F - 0 3 as a growth inhibi tor us ing a D N A 
synthesis assay. T G F - 0 3 was somewhat more po t en t (ED5o ~ 
0.5 pM) t h a n T G F - ß l a n d T G F - 0 2 (ED 5 0 = 2 pM) a s a D N A 
synthes is inhibi tor in M v l L u cells. In F B H E cells, T G F - 0 3 
(ED«» = 35 pM) was somewha t less po ten t t h a n T G F - ß l <ED6o 
= 7 pM) bu t much more po t en t t h a n T G F - ß 2 (Fig. I ß ) . T G F -
TGF-ß, pM TGF-ß, pM 
FIG. 1. Inhibi t ion of 1 2 5I-dU incorpora t ion into DNA by 
T G F - ß l , -ß2 , and - 0 3 . Sparse cultures of MvlLu cells in medium 
containing 0.2% fetal bovine serum or FBHE cells in medium con-
taining 10% calf serum were incubated for 24 h (MvlLu) or 48 h 
(FBHE) with the indicated concentrations of TGF-ßl ( • ) , TGF-ß2 
(O), or TGF-ß3 ( • ) . Incorporation of 125I-dU into DNA was then 
measured and is expressed as the percent decrease relative to the 
value in parallel cultures that did not receive TGF-ß. Data are the 
mean of triplicate values ± S.E. 
02 was a very poor (ED50 > 2 nM) inhib i tor of D N A synthes is 
in F B H E cells under the condi t ions of th i s assay. 
R I B a n d S l B are m u t a n t M v l L u cell clones defective in 
type I T G F - ß receptor b inding and T G F - ß receptor signaling, 
respectively (20). R I B and S l B cells, which are res is tant to 
T G F - ß l and 02, were no t growth- inhibi ted by T G F - 0 3 (da ta 
no t shown) suggesting t h a t t he same receptors and signaling 
pa thways were involved in t he growth inhibi tory action of 
these th ree T G F - ß isoforms. 
Effect of Serum Factors and Cell-specific Determinants on 
the Potency of TGF-ß Isoforms—MvlLu cell growth inhibi t ion 
assays as those shown in Fig. LA were normally done in the 
presence of a very low (0.2%) serum concent ra t ion whereas 
t he F B H E cell growth inhibi t ion assays were carried out in 
t h e presence of 10% bovine calf se rum due t o cell viability 
requi rements . T o search for possible causes of t he differential 
response to T G F - ß l , -02, and -03 in F B H E cells, we investi-
gated whe ther bovine se rum factors p resen t in t he F B H E cell 
growth inhibi t ion assay could selectively decrease t he potency 
of T G F - 0 2 . W h e n fetal bovine se rum was used ins tead of 
regular calf se rum in t he F B H E cell assay, T G F - 0 1 and -03 
were still 50-fold more po t en t t h a n T G F - 0 2 as growth inhib-
itors; however, a s t ronger growth inhibi tory response to T G F -
02 was observed under these assay condi t ions (ED 5 0 = 400 
pM) (Fig. 2A) as compared with assays performed in the 
presence of bovine calf se rum (see Fig. I ß ) . Growth inhibi t ion 
assays were carried out with M v l L u cells in t he presence of 
high se rum concen t ra t ions to de te rmine whe ther serum fac-
to rs might also differently affect t he potency of various T G F -
0 isoforms in these cells. In t he presence of serum, T G F - 0 1 
was 3-fold more po t en t t h a n T G F - 0 2 in M v l L u cells (Fig. 
2B). In no case, however, was t he difference in potency 
be tween T G F - 0 1 and T G F - 0 2 in M v l L u cells as m a r k e d a s 
in F B H E cells (compare Figs. L4 and 2B with Figs. I B and 
2A), 
a2M is an a b u n d a n t se rum componen t t h a t can bind T G F -
0 (27-30) and has higher affinity for T G F - 0 2 t h a n for T G F -
01 (30). Addit ion of 200 fig/ml exogenous a2M ( the concen-
t ra t ion of a 2 M t h a t would be provided by the presence of 
approximate ly 1% calf serum or 12% fetal bovine serum in 
120 
TGF-ß Isoforrrk and Receptor Subsets 
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FIG. 2. Effect of serum on inhibition of ,Ml-dU incorpora-
tion into DNA by TGF-01, -02, and -03. A, sparse cultures of 
FBHE cells in medium containing 10% fetal bovine serum, or B, 
MvlLu cells in medium containing 0.2% bovine calf serum { ), 
10% fetal bovine serum < ) or 5% fetal bovine serurrt plus 5% 
bovine calf serum ( ) were incubated for 48 h (FBHE) or 24 h 
(MvlLu) with the indicated concentrations of TGF-01 (•) or TGF-
02 (O). Incorporation of 125I-dU into DNA was then measured and is 
expressed as the percent decrease relative to the value in parallel 
cultures that did not receive TGF-0. Data are the mean of triplicate 
values ± S.E. 
the assays)2 markedly decreased the growth inhibitory re-
sponse of MvlLu cells to TGF-02 but not to TGF-01 (Table 
I). 
To determine the effect of a2M on the responsiveness of 
FBHE cells, the growth inhibitory response to TGF-01 and 
-02 was assayed in the presence of 10% fetal bovine serum 
that had been depleted of a2M by treatment with Sepharose-
bound anti-a2M antibody. This treatment depleted 90% or 
more of the a2M present in fetal calf serum (data not shown)2 
and yielded a <10 jig/ml final concentration of a2M in the 
assays. Fetal calf serum that had been treated with Sepharose-
bound preimmune rabbit IgG was used as a control. Although 
depletion of a2M increased somewhat the growth inhibitory 
response to TGF-02, TGF-02 was still much less potent than 
TGF-01 under these assay conditions (Table I and data not 
shown). Thus, cellular determinants or medium components 
other than a2M appeared to be the major cause of the low 
2
 Based on quantitation of a2M by Western immunoblot (see "Ex-
perimental Procedures"). 
responsiveness of FBHE cells to TGF-02 in growth inhibition 
assays. 
High Affinity TGF-02 Receptor Subset in MvlLu Cells— 
The ability of TGF-01, -02, and -03 to bind to cell surface 
receptors was compared by performing binding saturation 
experiments with MvlLu cells using radiolabeled derivatives 
of each TGF-0 isoform. Cells were incubated with increasing 
concentrations of 125I-radiolabeled TGF-01, -02, or -03, fol-
lowed by the addition of disuccinimidyl suberate to affinity-
label and individually examine each TGF-0 binding compo-
nent. Binding to receptor types I and II was détectable with 
5 pM concentrations of all three radiolabeled TGF-0 isoforms 
(Figs. 3 and 4A). However, a marked difference in receptor 
saturation patterns emerged as the concentration of radiola-
beled ligands was increased. Thus, saturation of the type II 
receptor component by 125I-TGF-01 or 12sI-TGF-03 was half-
maximal at 25 pM and continued to increase as the concen-
tration of these ligands was increased up to 250 pM. In 
contrast, binding of 125I-TGF-02 to this receptor component 
reached a maximum at 25 pM (Figs. 3 and 4A). Furthermore, 
the maximal labeling intensity of receptor types I and II 
reached with this ligand was only about 25% of that reached 
with either 125I-TGF-01 or 125I-TGF-03 (Fig. 3). 
Similarly, BRL-3A rat epithelial cells subjected to affinity 
labeling saturation experiments with 125I-TGF-01 and -02 also 
showed a limited (10% of total) subset of receptor types I and 
II that bound 125I-TGF-01 and -02 with high affinity and a 
larger subset that bound with high affinity only 12SI-TGF-01 
(Fig. 48). In contrast to these three cell lines, FBHE cells 
and LgEs rat skeletal muscle myoblasts failed to provide 
evidence for the presence of a subset of high affinity TGF-02 
receptors (data not shown). 
125I-Labeled TGF-01, -02, and -03 showed only limited 
differences in their ability to saturate betaglycan in MvlLu 
cells. Binding to betaglycan increased as the concentration of 
these ligands was increased to 250 pM, with 125I-TGF-02 
displaying a somewhat higher affinity than I25I-TGF-01 and 
125I-TGF-03 (Fig. 3). 
Receptor Competition Patterns of TGF-01, -02, and -03— 
The next series of experiments examined the ability of native 
TGF-01, -02, and -03 to compete with tracer radioligands' for 
binding to cell surface receptor components. TGF-01, 02 and 
03 competed effectively against 125I-TGF-01 for binding to 
betaglycan in MvlLu cells. Half-maximal inhibition of label-
ing was obtained with concentrations of TGF-01, -02, or -03 
in the 100-250 pM range (Fig. 5). However, the three TGF-0 
isoforms differed in their ability to compete for receptor types 
TABLE I 
Effect of a2M on cell responsiveness to TGF-ßl and TGF-ß2 
Cell Une 
MvlLu 
FBHE 
Fetal bovine serum in the assay 
0.2 
0.2 
10, untreated 
10, preimmune IgG-treated' 
10, anti-o2M IgG-treated' 
aï-Macroglobulin 
ligjml ff 
200' 
(~170)J 
(-170) ' 
(<10C 
Growth 
TGF-01* 
86 ± 9 
94 ± 1 
90 ± 1 
85 ± 1 
87 ± 4 
inhibition0 
% 
TGF-02* 
8 8 ± 4 
33 ± 10 
27 ± 10 
42 ± 8 
57 ± 7 
° Growth inhibition refers to percent decrease in mI-dU incorporation into DNA as compared with control 
cultures that did not receive TGF-ß. Assays were performed in triplicate. The results shown are representative of 
three separate experiments. 
fcThe concentrations of TGF-01 and TGF-02 used were 2.5 pM (MvlLu cells) or 50 pM (FBHE cells). 
c
 Final concentration of exogenously added aaM. d
 Estimated final concentration of a2M contributed by serum present in the assays. 
*• Fetal calf serum was treated with either Sepharose-bound preimmune IgG or Sepharose-bound anti-a^M IgG. 
See text for details. 
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"lTGF-91 '"iTGF-fla '"l-TGF-03 
»25 50250 5 Z5 50Z50 5 25 50250 
0 5 25 50 250 
FIG. 3. Receptor saturation patterns of TGF-01, -02, and 
-03 in M v l L u cells. A, cells were affinity-labeled with the indicated 
concentrations of '"I-TGF-01, l25I-TGF-02, and m I -TGF-03. Shown 
are autoradiograms of Polyacrylamide electrophoresis gels containing 
detergent extracts of the affinity-labeled cells. Autoradiographic ex-
posure of individual panels were adjusted in order to compensate for 
differences in specific activity of the three '"I-TGF-0 preparations 
used. B, a repeat of the experiment with a more detailed range of l25I-
TGF-02 concentrations. The positions of receptor types I, II, and 
betaglycan {BG) as well as the molecular mass in kilodaltons of 
protein standards run in parallel are indicated. 
I and II. As previously reported (18), labeling of these receptor 
components by 125I-TGF-01 was reduced to half or less by the 
presence of 25 pM TGF-01 but was only minimally affected 
by 500 pM TGF-02 (Fig. 5). The previously untested isoform, 
TGF-03, competed for the type I receptor with a potency 
similar to TGF-01. However, TGF-03 competed for the type 
II receptor with half or less of the potency of TGF-01 (Fig. 
5). Similar TGF-0 binding competition patterns were ob-
served with FBHE cells and two additional cell lines, BRL-
3A cells (14) which have a TGF-0 receptor profile similar to 
MvlLu cells and LeEg cells (31) which have a receptor profile 
similar to FBHE cells (Fig. 6). 
Despite its limited ability to compete with 125I-TGF-01 or 
-03 for receptor types I and II, TGF-02 competed very effec-
tively for the receptor subset that bound 125I-TGF-02 in 
MvlLu cells (Fig. 7). TGF-01 and -03 were also potent com-
petitors for this receptor subset (data not shown). Taken 
together, the experiments described in Figs. 3-7 showed that 
the subset of receptor types I and II that have high affinity 
for TGF-02 had properties that made it undetectable when 
TGF-02 was used as a competitor of heterologous ligands 
(TGF-01 or -03) in binding assays. 
DISCUSSION 
Growth Inhibitory Activity of Three TGF-ßl Isoforms—The 
purpose of this study was, in part, to evaluate the biological 
properties of the newly isolated recombinant factor, TGF-03. 
As it has been recently noted (6) and the results with MvlLu 
cells here confirm, cell lines that respond well to both TGF-
ß\ and TGF-02 also respond well to TGF-03. These responses 
are to low picomolar concentrations of TGF-0, and if differ-
ences in the potency of various TGF-0 isoforms exist they are 
limited to less than 10-fold. Although limited, these differ-
ences in potency could be physiologically important. 
Vascular endothelial cells that are strongly growth-inhib-
200 
so-
so. 
20. 
0. 
Typel r" 
O iaS|-TGF-B1 
•
 125l-TGF-62 
Type II r» 
FIG. 
I-TGF-B, pM 
4. TGF-0 receptor saturation patterns in M v l L u and 
BRL-3A cells. A, the intensity of the autoradiographic bands cor-
responding to receptor types I and II in Fig. 3A was determined by 
densitometry. B, the intensity of the autoradiographic bands corre-
sponding to receptor types I and II in BRL-3A cells affinity-labeled 
with the indicated concentrations of l25I-TGF-01 and l2SI-TGF-02 
was determined by densitometry. 
A TGF-81. pM TGF'BZ. pM TGF 63, pM S 
0 25 SO 100 250 400 0 25 SO 100 250 S00 0 25 SO 100 250 500 
FIG. 5 Receptor competition patterns of TGF-01, -02 , and 
-03 in M v l L u cells. A, cells were affinity-labeled with 25 pM l iSI-
TGF-01 in the presence of the indicated concentrations of TGF-01, 
-02, or -03. Shown are autoradiograms of Polyacrylamide electropho-
resis gels containing detergent extracts of the affinity-labeled cells. 
B, cell-associated radioactivity after incubation with 25 pM IÏSI-TGF-
01 in the presence of the indicated concentrations of TGF-01 (•) , 
-02 (O), or -02 (O). Data are expressed as' percent relative to the value 
in control cells incubated with 12SI-TGF-01 alone. The apparent 
difference in mobility of betaglycan in the TGF-03 panel compared 
with the TGF-0Î and -02 panels is due to the fact that the samples 
were run in separate gels. 
ited by TGF-01 but not TGF-02 (Ref. 17 and Fig. 1) provide 
a more informative system to compare TGF-ß isoforms. The 
results show that TGF-03 is as potent a growth inhibitor for 
FBHE cells as is TGF-/31 and is at least 50-fold more potent 
than TGF-02. Thus, TGF-03 is more similar to TGF-01 than 
to TGF-02 as a growth inhibitor in this cell system. Although 
these three TGF-0 isoforms have a similar high degree of 
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TGF-81 TGF-B2 TGF-63 
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TGF-61 TGF-B2 TGF-A3 
W&& % 
\mm -• TGF-B. pM 
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TGF-ßl TGF-82 TGF-63 
FIG. 6. Receptor competition patterns of TGF-ßl , -ß2, and 
-ß3 in various cell lines. Experiments were carried out as described 
in Fig. 3, except that the cell lines used were FBHE bovine heart 
endothelial cells {A), L6E9 rat myoblasts (B), and BRL-3A rat liver 
cells (C). The inset in each panel depicts cell-associated radioactivity 
after incubation with 25 pM '"I-TGF-ßl in the presence of the 
indicated concentrations of TGF-/51 ( • ) , -02 (O), or -03 <D). Data are 
expressed as in Fig. 3. 
J1-TGF-B1 
I 
• «mm« 
mmmmm 
• • » 
0 100 300 1000 3000 0 100 300 1000 3000 0 100 300 1000 3000 
TGF-R2. pM TGF-B2, pM TGF-B2. pM 
FIG. 7. Ability of TGF-02 to compete with three 12BI-labeled 
TGF-ß isoforms for receptors on MvlLu cells. Cells were affin-
ity-labeled with 25 pM concentrations of mI-TGF-p*l, mI-TGF-ß2, 
or 12SI-TGF-03 in the presence of the indicated concentrations of 
TGF-02. Shown are autoradiograms of Polyacrylamide electrophore-
sis gels containing detergent extracts of the affinity-labeled cells. 
amino acid sequence identity with each other (1-5) some 
structural feature(s) common to TGF-ßl and TGF-ß3, but 
not TGF-ß2, allow these two factors to be potent growth 
inhibitors for vascular endothelial cells. 
a2M is an abundant serum component that can bind and 
inactivate TGF-ß (27-30). a-M binds TGF-ß2 better than 
TGF-ßl (30). The results of our experiments based on either 
adding a2M to cell cultures or depleting a2M from serum with 
immobilized anti-a2M antibody confirm that a2M can selec-
tively decrease the responsiveness of MvlLu cells to TGF-ß2 
but fail to demonstrate a major role for this protein as a 
selective antagonist or inactivator of TGF-/32 in FBHE cell 
growth inhibition. Many assays in which TGF-ßl and TGF-
ß2 show similar potency have been carried out in the presence 
of serum (14, 19, 23). Even in the presence of serum MvlLu 
cells are far more sensitive to growth inhibition by TGF-ß2 
than FBHE cells are. This indicates that the responsiveness 
to distinct TGF-ß isoforms is strongly influenced by cell-
specific determinants. 
Subsets of TGF-ß Receptors with Distinct Binding Properties 
as Determinants of Cellular Responsiveness to TGF-ß Iso-
forms—The present results address one additional issue of 
importance; the results provide evidence for specific subsets 
of TGF-ß receptors I and II that have distinct binding prop-
erties. This new evidence relates to previously unresolved 
questions about receptor interaction with various TGF-ß iso-
forms. 
The phenotype of a large panel of TGF-ß-resistant MvlLu 
cell mutants implicates receptor types I and II as components 
of the signal-transducing TGF-ß receptor complex (20, 21). 
The mutants have lost all known responses to TGF-ßl, -ß2, 
and -ß3. With high frequency, the mutations affect receptors 
I and II; betaglycan is apparently not affected (20, 21). Fur-
thermore, TGF-ß-resistant cell mutants lacking receptors I 
and II were isolated when either TGF-ßl or TGF-ß2 was used 
in the mutant selection protocol (20, 21). The phenotype of 
these TGF-ß-resistant cell mutants thus implicates receptors 
I and II as mediators of multiple responses to various TGF-ß 
isoforms. Initially, however, these findings seemed paradoxi-
cal because MvlLu and other cells respond similarly to var-
ious TGF-ß isoforms, yet they bind TGF-ß2 less avidly than 
other isoforms. How could TGF-ß2 act via these receptors if 
its ability to bind to them is much lower than that of TGF-
ßl or TGF-ß3? 
A resolution of this issue is suggested in the present study 
by the detection of a subset of type I and II receptors that has 
high affinity for TGF-ß2. This receptor population can be 
readily detected in MvlLu cells and BRL-3A cells by receptor 
labeling saturation assays using 125I-TGF-ß2 or by receptor 
labeling competition assays using TGF-ß2 to compete with 
I25I-TGF-ß2. The low picomolar concentration range of TGF-
ß2 (ED» ~ 10 pM) that saturates these high affinity receptors 
is close to the concentration range (ED50 = 2 pM) that induces 
the biological response of MvlLu to this factor. It remains to 
be determined how the subset of high affinity TGF-ß2 recep-
tors is generated. However, both receptor subsets are lost in 
certain TGF-ß resistant MvlLu cell mutants (20, 21) sug-
gesting that the high affinity and the low affinity TGF-ß2 
receptor subsets represent different receptor states rather 
than separate gene products. 
The limited ability of TGF-ß2 to compete with 12JiI-TGF-
ßl or 12SI-TGF-ß3 for the total pool'of receptor components I 
and II and the weak receptor labeling intensity obtained with 
125I-TGF-ß2 could be explained by the low affinity of TGF-ß2 
for the larger receptor subset, which is in agreement with 
previous conclusions (18). The receptors I and II that have 
high affinity for TGF-ß2 could not be properly detected by 
competition experiments using TGF-ß2 against a heterolo-
gous ligand (1MI-TGF-/31 or mI-TGF-ß3) or by mathematical 
analysis of equilibrium binding data, given the coexistence of 
multiple types of TGF-ß binding sites on the cell. The role of 
the larger receptor population that apparently has high affin-
ity for TGF-ßl and TGF-ß3 but not TGF-ß2 is unclear. We 
note that the concentration of TGF-ßl and TGF-ß3 required 
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t o sa tu ra te th i s pool of " spare" receptors is a t least 1 order of 
magni tude higher t h a n t h e concen t ra t ion needed t o sa tu ra t e 
t h e biological response in M v l L u cells. 
Interest ingly, we could no t detect type I or II receptors with 
a high affinity for TGF-|82 in F B H E cells which are res i s tan t 
t o growth inhibi t ion by TGF-/S2. T h e s e m a r k e d differences in 
receptor b inding between cell l ines may play a n impor t an t 
role in t he physiology of t he T G F - ß sys tem. Cell-specific 
differences in levels of high affinity TGF-j82 receptors migh t 
de te rmine cell-specific differences in responsiveness to dis-
t inc t T G F - ß isoforms. Ano the r character is t ic of F B H E is the i r 
lack of detectable betaglycan, a m e m b r a n e proteoglycan t h a t 
b inds T G F s - ß via its JV-glycosylated core pro te in (32-34) . 
Betaglycan can be released by cells a n d deposi ted in to ext ra-
cellular matr ices (35). W o r k is in progress t o de te rmine if 
betaglycan selectively affects t he responsiveness t o TGF-/32 
or cont r ibutes to t he cell 's abili ty to express t h e receptor 
subset with high affinity for T G F - 0 2 . 
Cell-specific differences in responsiveness to TGF-/S iso-
forms might also be dic ta ted by the na tu re of each individual 
response. In th is regard, it is impor t an t to no te t h a t F B H E 
cells did not d iscr iminate be tween the th ree T G F - ß isoforms 
when a relatively shor t - t e rm effect, up-regulat ion of p lasmin-
ogen act ivator inhibi tor-1 (PAI-1) , was assayed.3 In F B H E 
cells, th is response was faster (tw = 2-4) t h a n the growth 
inhibi tory response, which required exposure to TGF-/3 for a t 
least 24 h. Evidence from T G F - ß receptor-defective cell mu-
t a n t s suggests t h a t growth inhibi t ion a n d PAI -1 induct ion are 
media ted by the same type of receptors (20, 21). I t is possible, 
then , t h a t a very low level of high affinity TGF-/Î2 receptors 
exist in F B H E cells which might be sufficient to media te t he 
PAI -1 response bu t be too low to be detectable a n d t o media te 
t he growth inhibi tory response. 
In conclusion, the p resen t results indicate t h a t despi te 
cer ta in s t ruc tura l a n d functional similari t ies, TGF-/3 isoforms 
1, 2, and 3 can diverge significantly in thei r potency as growth 
inhibi tors in vitro, the i r recognit ion by receptors , and thei r 
susceptibili ty t o an tagonism or inact ivat ion by extracel lular 
factors. T h e biological differences between T G F - ß l , -02, a n d 
-03 are likely to be physiologically impor t an t as suggested by 
the str ict conservat ion of t he individual p r imary sequences of 
these factors in ver tebrates . 
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CHAPTER NINE 
Mesoderm Induction in Early Xenopus Embryos 
by Transforming Growth Factor-/83 
Peter ten Dijke 
Mesoderm Induction in Early Xenopus Embryos by Transforming Growth Factor-/?3. 
Peter ten Dijke 
Oncogene Science, Inc., Manhasset, New York, USA 
Abstract 
The differentiation of mesoderm in Xenopus appears to depend upon inductive 
interactions from the vegetal endoderm upon the overlying ectoderm. Members of the 
TGF-0 and FGF family can mimic and possibly act in vivo as mesoderm inducers. Human 
TGF-03 was tested and its potency compared with TGF-/71 and TGF-02 for mesoderm 
inducing activity on expiants of Xenopus blastula ectoderm. TGF-#3 was active in this 
assay, but less potent than TGF-/92. As shown previously, TGF-01 acting alone had no 
effect upon mesoderm induction. When TGF-/83 was assayed for induction of muscle 
formation, it was found to synergize with basic FGF and to be more potent than TGF-/?1 
in this respect. 
Introduction 
TGF-/?s form a family of related secreted 25 kDa peptides, which affect proliferation 
and differentiation of many cell types (Roberts and Sporn, 1990). To date, five vertebrate 
homodimeric isoforms of IGF-ß have been described by cDNA cloning or protein 
purification (Kondaiah, ef a/., 1990). Three human homodimeric isoforms have been 
identified, termed TGF-/91 (Derynck, era/., 1985), TGF-02 (de Martin, ef a/., 1987) and 
TGF-03 (ten Dijke, era/., 1988; Derynck, etal., 1988). Activities forTGF-01 and TGF-/92 
have been characterized in numerous assays. Not much is known about the biological 
activity of TGF-/S3, since it has only recently become available for study. Recombinant 
TGF-/?3 was expressed in Chinese Hamster Ovary (CHO) cells and purified to apparent 
homogeneity (Graycar, etal., 1989; ten Dijke, era/., 1990a). The three TGF-/9s appear 
to have similar biological activities, but different potencies depending on the cell type and 
assay used (Jennings, etal., 1989; Ohta, etal., 1987; Tsunawaki, etal., 1988; Graycar, 
ef a/., 1989; ten Dijke, ef a/., 1990b). All three TGF-0S associate with the same three cell 
surface binding sites (ten Dijke, etal., 1990b). 
TGF-£s are highly conserved between mammals and amphibians. The interspecies 
sequence conservation is higher (>95%) than the intraspecies conservation (Kondaiah, 
etal., 1990), suggesting an evolutionary pressure to conserve these differences, possibly 
for functional reasons. Differences in gene regulation resulting in characteristic temporal 
and spacial expression patterns (Roberts and Sporn, 1990) also suggest distinct biological 
roles for various TGF-0 isoforms. 
Immunohistochemistry (Heine, ef a/., 1987) and in situ hybridization (Wilcox and 
Derynck, 1988; Lehnert and Akhurst, 1988; Pelton, etal., 1989; Akhurst, etal., 1990; 
Fitzpatrick, etal., 1990) clearly implicate TGF-/?'s in development. Moreover, TGF-^s are 
part of a superfamily that include inhibins and activins, mullerian inhibiting substance, 
bone morphogenetic proteins, the Drosophila Decapentaplegic gene product {DPP-C), 
Xenopus Vg-1 gene product and related murine VgR-1 gene product, which all play 
important regulatory roles in development (Roberts and Sporn, 1990). 
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In amphibian embryogenesis mesoderm is formed and patterned from cells of the 
animal region by signals originating in the vegetal region (Nieuwkoop, 1969). Mammalian 
TGF-^2 alone has been reported to induce mesoderm in isolated Xenopus animal cap 
expiants (Rosa, ef a/., 1988) whereas mammalian TGF-01 can only enhance the 
mesoderm inducing activity of fibroblast growth factor (FGF)(Kimelman and Kirschner, 
1987). Recently, XTC/MIF, a potent mesoderm inducing factor isolated from the Xenopus 
XTC cell line was shown to be homologous to the mammalian activin A (Smith, ef a/., 
1990; van den Eijden-Van Raaij, era/., 1990). The TGF-/9 family of growth factors induce 
a variety of dorsal mesodermal cell types including muscle, mesenchyme and 
mesothelium and notochord, the most dorsal mesodermal tissue (Smith, ef a/., 1988; 
Rosa, ef a/., 1988). The FGF family of growth factors, including acidic FGF, basic FGF, 
embryonal carcinoma-derived growth factor, and protein products of basic FGF and int-
2 oncogenes, are capable of inducing ventral type mesoderm differentiation in animal pole 
expiants. In FGF induced expiants notochord is rarely observed (Slack, ef a/., 1987; 
Kimelman and Kirschner, 1987; Paterno, etal., 1989; Slack, ef a/., 1989). 
The present comparative studies were performed to assess the mesoderm 
inducing potential of mammalian TGF-0 isoforms, in particular TGF-/Ï3, using Xenopus 
animal cap expiants and isolated cells. 
Materials and Methods 
Growth Factors 
Human TGF-/?1 and porcine TGF-02 were purchased from R&D Systems, Inc., 
Minneapolis, MN. TGF-/K3 was purified to apparent homogeneity from serum-free medium 
conditioned by Chinese hamster ovary cells expressing a transfected human TGF-/S3 
cDNA, as previously described (ten Dijke, ef a/., 1990a). Xenopus basic FGF was 
prepared by bacterial expression followed by conventional and HPLC heparin columns. 
Embryos 
Female Xenopus laevis were induced to lay eggs by injection of 500 i.u. human 
chorionic gonadotrophin in 0.5ml phosphate-buffered water (Chorulon, Intervet) into the 
dorsal lymph sac. The eggs subsequently obtained were fertilized using macerated 
Xenopus testes. Following rotation, eggs were dejellied using 2.5% wt/vol cysteine 
hydrochloride (adjusted to pH 7.8-8.1 with NaOH). Eggs were then washed thoroughly 
and allowed to develop in Petri dishes coated with 1.5% wt/vol Noble agar (Difco) in 1/20 
normal amphibian medium (NAM) salts (Slack, 1984) with 2 mM-sodium phosphate pH 
7.5. 
Embryo operations 
Operations were carried out on stage-8 embryos in NAM (Slack, 1984) or half-
strength NAM containing 5 mM-sodium phosphate pH 7.5 (referred to here as NAM/2). 
Hair loops and electrolytically sharpened tungsten needles were used to cut out discs of 
tissue from the center of the animal pigmented hemisphere. 
Mesoderm induction assays and histology 
Expiants were transferred to wells of Terasolin plates (Sterilin) containing 2//I of 
type 1 agarose (Sigma) and 10-15//I of sample in NAM/2, containing 1mg/ml bovine 
serum albumin (BSA) in 2-fold serial dilutions of the factors. Expiants were maintained 
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Figure 1 
Effect of TGF-/83 on the development of Xenopus ectodermal explants. (A) section 
through control expiants after 3 days of culture, which consists entirely of a solid mass 
of epidermis (epi). (B) and (C) sections through TGF-/83 treated expiants after 3 days of 
culture, showing formation of loose mesenchyme (mes) and muscle (mus). 
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The process of wound healing begins im-
mediately following surface lesions or 
when skin proteins become exposed to 
radiation, chemical damage or extreme 
temperatures. Wound repair requires 
close control of degradative and regenera-
tive processes, involving numerous cell 
types and complex interactions between 
multiple biochemical cascades. Growth 
factors released in the traumatized area 
promote cell migration into the wound 
area (Chemotaxis), stimulate the growth of 
epithelial cells and fibroblasts (ontogene-
sis), initiate the formulation of new blood 
vessels (angiogenesis), and stimulate ma-
trix formation and remodeling of the af-
fected region. Animal studies have shown 
that exogenously added growth factors 
can accelerate the normal healing process. 
Growth factors have also been used suc-
cessfully in humans to treat previously 
incurable wounds. The most intensively 
studied growth factors are EGF, FGFs, 
PDGF, TGF-a, and TGF-ßs. Each of these 
factors is currently the focus of intense 
commercial development. 
M ost growth factors were initially named after the biological activity that lead to their isola-tion. Later, several of these factors were found to be multifunctional, not only affect-
ing cell growth but differentiation, embryogenesis, in-
flammation, tissue repair, and immune response. Hence, 
potential therapeutic applications of growth factors in-
clude such diverse areas as bone repair, cancer and 
immunomodulation'. In this review, however, we have 
focused specifically on their role as potent pharmacologi-
cal agents in soft tissue repair. 
BIOCHEMISTRY OF GROWTH FACTORS 
Epidermal growth factor (EGF). EGF is synthesized as a 
larger precursor protein (Mr= 128 kDa), which is proteo-
lytically processed into the mature form of 53 amino acid 
residues (Mr=5.7 kDa)2. EGF is a member of a family of 
structurally related proteins including TGF-a (see below), 
amphiregulin and poxvirus growth factors (Table 1)'. 
Human EGF was first isolated from urine and named 
urogastrone by its ability to inhibit gastric acid secretion4. 
Murine EGF was isolated from salivary glands and found 
to stimulate precocious eyelid opening and tooth eruption 
in newborn mice* and to be mitogenic for a large number 
of cell types, including epithelial, fibroblastic and endo-
thelial cells6. EGF has also been shown to be chemotactic 
for epithelial cells'. The receptor for EGF is a transmem-
brane protein (Mr= 170 kD) with tyrosine kinase activity*. 
Transforming growth factor-a (TGF-a). TGF-a is also 
synthesized as a transmembrane precursor (160 amino 
acid), which is proteolytically processed into a peptide of 
50 amino acid residues (Mr=5.7 kDa)9. Both TGF-a and 
EGF bind to the same receptor and share similar biologi-
cal activities10. TGF-a was originally characterized by its 
ability to act synergistically with transforming growth 
factor-ß (see below) to induce anchorage independent 
growth of normal rat kidney (NRK) fibroblasts in soft agar 
and was therefore thought to be involved in malignant 
transformation". The presence of TGF-a in a variety of 
human tumors and in cell lines transformed by chemical 
carcinogens and viral oncogenes supported this initial 
hypothesis. However, the role of TGF-a in human neopla-
sia is unclear, since TGF-a expression is also found in 
activated macrophages and in other normal tissues. 
Platelet-derived growth factor (PDGF). PDGF is a heat-
stable protein (Mr=S0 kDa) that was first purified from 
blood platelets12. Treatment of PDGF from platelets with 
reducing agents results in the loss of biological activity" 
and yields two polypeptide chains: the A-chain (124 
amino acid residues) and the B-chain (140 amino acid 
residues). The PDGF B-chain corresponds to the proto-
oncogene v-sis, the transforming gene of simian sarcoma 
virus14, suggesting an autocrine role for PDGF-like pro-
teins in neoplasia. PDGF is a potent mitogen for cells of 
mesenchymal origin (e.g. fibroblasts and smooth muscle 
cells), but has no effect on the growth of epithelial or 
endothelial cells15, which lack PDGF receptors. At low 
concentrations, PDGF is chemotactic for fibroblasts16 and 
has been shown to be both chemotactic and activating for 
monocytes and neutrophils17-18. As in the case of the EGF 
family, the receptors for PDGF possess intrinsic protein-
tyrosine kinase activity19. 
Transforming growth factor-ß (TGF-/3). In their ma-
ture form, TGF-ßs are acid- and heat-stable disulfide-
linked homodimeric proteins (Mr=25 kDa), with each 
homodimer consisting of 112 amino acid residues20. Two 
homodimeric forms of TGF-ß have been identified (TGF-
ßl and -ß2), which share significant (>70%) amino acid 
sequence homology21-22. Recently, we reported a new 
form of TGF-ß, designated TGF-ß3, which is currently 
being developed at Oncogene Science for wound healing 
and other clinical indications25. TGF-ßs are released in 
biologically inactive latent forms. Most cells have specific 
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HEALED WOUND 
high affinity receptors for TGF-ßl and ß22». Whether 
TGF-33 binds to the same or distinct receptors remains to 
be determined. TGF-ßs were characterized originally by 
their ability to act synergistically with EGF or TGF-o to 
induce anchorage independent growth of NRK cells". 
TGF-ßs, however, have been found to produce multiple 
biological effects including mitogenesis, growth inhibition, 
Chemotaxis and induction or inhibition of differentiation, 
depending upon the cell or tissue type, and the presence 
or absence of other growth factors20. Although the TGF-
ßs share several biological features, it is becoming appar-
ent that the different forms of TGF-ß also possess distinct 
biological activities and targets24. Most of the published 
work on TGF-ßs and wound healing refers to TGF-ßl. 
Thus, unless specifically indicated, the use of the term 
TGF-ß in this review refers to TGF-ß 1. Other mammalian 
members of the TGF-ß family20 (see Table 1), include two 
forms of inhibin and three forms of activin, gonadal 
proteins that regulate pituitary secretion of follicle stimu-
lating hormone; Mullerian inhibiting substance (MIS), 
which causes the regression of the female Mullerian duct 
as part of the development of the male embryo; and bone 
morphogenic proteins (BMP), a group of polypeptides 
involved in the induction of cartilage and bone forma-
tion25. 
Fibroblast growth factor (FGF). FGFs are members of a 
family of single-chain proteins of 14-18 kDa, which bind 
tightly to heparin. Two well defined forms of FGF are 
acidic FGF (isolated from brain and retina)2627 and basic 
FGF (isolated from brain and pituitary)28. Acidic FGF 
(aFGF) is a nonglycosylated protein of 140 amino acids 
1 Soft tissue repair pathways. 
(Mr= 15.6 kDa) with a pi of 5.6-6.029. Basic FGF (bFGF) is 
a nonglycosylated protein of 146 amino acids (Mr= 16.4 
kDa) with a pi of 9.630. In most systems examined, bFGF 
is more stable and exhibits a 10-fold greater potency than 
aFGF31. Both forms of FGF bind to the same receptor. 
FGFs are mitogenic for cells of mesodermal origin, such as 
fibroblasts, vascular endothelial cells, vascular smooth 
muscle cells, myoblasts, keratinocytes, chondrocytes and 
osteoblasts51. Other members of the FGF family include 
the products of the int-2 and hst proto-oncogenes32-35. 
THE WOUND HEALING PROCESS 
The process of wound healing can be divided into three 
main overlapping stages: inflammation, formation of 
granulation tissue, and matrix formation and remodeling. 
A schematic representation of these stages is shown in 
Figure 1. 
Inflammation, Tissue injury results in the release of blood 
components into the wound site. Contact of the blood 
plasma with tissue protein and the basement membrane 
activates the clotting cascade. The clot traps plasma pro-
tein and blood cells into a fibrin gel thereby inducing 
hemostasis and providing a matrix for the influx of 
inflammatory cells. Thrombin, formed during the clotting 
cascade, stimulates release of alpha granules from aggre-
gated platelets. These alpha granules contain locally act-
ing growth factors such as TGF-ß, PDGF and FGF. The 
combination, concentration and timing of growth factor 
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release and activation at the site of injury regulate the 
complex process of wound healing by controlling cell 
proliferation, Chemotaxis and activation of a variety of 
cellular responses. 
Platelet aggregation and blood clot formation cease as 
the stimuli for initiation dissipate. This cessation involves 
(i) the generation of protein C (which degrades coagula-
tion factors V and VII54), (ii) the release of plasminogen 
activator (which initiates clot lysis'5), and (iii) the produc-
tion of prostaglandins from smooth muscle cells (which 
inhibit platelet aggregation and PDGF production, there-
by providing a feedback control mechanism). The pro-
duction of growth inhibitors at various steps in the wound 
healing process may therefore be essential for restraining 
cell growth in the presence of mitogenic factors. 
Neutrophils, attracted by a variety of chemotactic fac-
tors, function mainly to remove contaminating bacteria 
from the injury site. However, they are not essential to 
wound healing as neutropenia does not interfere with the 
healing process36. Macrophages, like neutrophiles, re-
move pathogenic organisms and tissue debris, including 
effete neutrophils. The influx of monocytes and their 
conversion to macrophages is critical for the initiation of 
tissue repair. Both cell types are most numerous irt the 
wound site between 3 and 5 days following injury. Macro-
phages release a variety of biologically active substances, 
including further amounts of TGF-ß and PDGF, which 
facilitate the recruitment of additional inflammatory cells, 
augment macrophage-mediated tissue debridement and 
initiate granulation tissue formation (see below). TGF-ß 
has been shown to be three orders of magnitude more 
potent than PDGF as a chemoattractant for both mono-
cytes and fibroblasts37'8. TGF-ß can also stimulate endo-
thelial cell PDGF production. In addition, TGF-ß, PDGF 
and TGF-ot have been reported to stimulate their own 
production, thus providing a way to amplify and sustain 
their respective physiological effects39-41. 
After an injury site has been sterilized during inflam-
mation, the secreted products of the activated macro-
phages may become damaging to healthy cells and tissue. 
At this stage of wound healing, the suppression of macro-
phage activities may be critical for protecting the sur-
rounding healthy tissue, and for the transition between 
inflammation and granulation tissue formation. In this 
regard, therefore, it is interesting to note that TGF-ßs 
have also been reported to deactivate superoxide produc-
tion from macrophages42. 
Granulation tissue formation. Granulation tissue con-
sists of a dense population of fibroblasts, macrophages 
and neovasculature embedded in a loose matrix of colla-
gen, fibronectin and hyaluronic acid. TGF-ß has a major 
role in granulation tissue formation. It increases the 
expression of genes associated with extracellular matrix 
formation (ECM), such as fibronectin, the fibronectin 
receptor, various types of collagen and protease inhibi-
tors. TGF-ß has been shown to enhance the contraction of 
a collagen matrix by fibroblasts43, suggesting its possible 
involvement in connective tissue contraction. In response 
to growth factors such as PDGF and TGF-ß, the fibro-
blasts proliferate, migrate into the wound site, and then 
undergo a series of phenotypic changes to become myofi-
broblasts, which have characteristics similar to smooth 
muscle cells. The myofibroblasts align themselves along 
the radial axis of the newly deposited extracellular matrix 
within the wound. The myofibroblasts then form interac-
tions with other cells and the extracellular matrix to 
generate a contractive force that aids in wound closure. 
Endothelial celts in the wound proliferate and form new 
blood vessels (angiogenesis) to supply the injured site with 
nutrients and oxygen. This nutrient supply is essential for 
11 Growth factor families. 
FAMILY MEMBERS 
Epidermal Growth Factor 
(EGF) 
Platelet-derived growth 
factor (PDGF) 
Transforming growth 
factor-ß (TGF-ß) 
Fibroblast growth factor 
(FGF) 
Insulin-like growth factor 
(IGF) 
EGF 
Transforming growth factor-a 
(TGF-a) 
Vaccinia growth factor (VGF) 
Shope fibroma growth factor 
(SFGF) 
Myxoma growth factor (MGF) 
Amphiregulin (AR) 
PDGF-AA 
PDGF-AB 
PDGF-BB 
TGF-ß 1 
TGF-ß2 
TGF-ßS 
lnhibins 
Acüvtns 
MuUerian inhibiting substance 
(MIS) 
Bone morphogenk proteins 
(BMPs) 
Acidic FGF 
Basic FGF 
Art gene product 
int-2 gene product 
IGF-1 
IGF-II 
Insulin 
Relaxin 
TAMI2 Potential 
wound healing. 
CATEGORY 
Burns 
Surgery 
Ulcers 
herapeutic applications of growth factors in 
SPECIFIC APPLICATIONS 
Thermal burns 
Chemical burns 
Surgical incisions 
Dental surgery 
Eye surgery 
Decubital (bed sores) 
Venous stasis 
Diabetic 
Peptic 
Other Indications Skin crafts 
Bone fractures 
Osteoporosis 
Psoriasis 
Veterinary uses 
synthesis, deposition and organization of the extracellular 
matrix. Basic FGF is a potent mitogen for vascular endo-
thelial cells, derived from either large vessels or capillar-
ies44. FGF also stimulates endothelial cells to produce a 
urokinase type plasminogen activator, a protease implicat-
ed in neovascularization. In addition, bFGF regulates the 
synthesis and deposition of various extracellular matrix 
components45. Heparin sulfate, a structural component of 
the ECM, may function to stabilize FGFs. since it protects 
both bFGF and aFGF from acid or heat inactivation and 
potentiates their mitogenic activity46. It has been suggest-
ed that when FGFs are released they become an integral 
part of the ECM45. The hydrolysis of ECM by heparitin-
ase, an inducible enzyme produced by activated platelets 
and macrophages4748, could subsequently lead to solubili-
zation of biologically active heparin sulfate-FGF complex-
es. Although TGF-ßs are not mitogenic for endothelial 
cells, they are potent angiogenic agents in vivo. This is 
probably due to their ability to chemoattract macrophages 
and to stimulate macrophages to secrete angiogenic pep-
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tides49 and to their direct affect on capillary formation50. 
Re-epithelialization. Within hours of injury, re-epithe-
lialization begins to restore the integrity of the damaged 
surface. Re-epithelialization begins with the migration of 
epithelial cells from the free edges of the tissue across the 
wound. Within 24 hours, epithelial cells at the original 
edge of the wound begin proliferating, thereby generat-
ing more cells for migration. EGF and other members of 
the EGF family are chemotactic and mitogenic for epithe-
lial cells6-7. Once re-epithelialization is complete, the epi-
thelial cells revert to their non-migrating phenotype and 
become attached to the basement membrane through 
hemidesmosomes.
 t 
Matrix formation and remodeling. The third phase of 
wound healing is the gradual dissolution of granulation 
tissue with devascularization and the loss of cells, fibronec-
tin and type III collagen. The granulation tissue is re-
placed with connective tissue consisting of a framework of 
collagen and elastin fibers providing tissue strength and 
elastic properties, respectively. This framework then be-
comes saturated with proteoglycans and glycoproteins. 
Remodeling involves the synthesis of new collagen and the 
degradation of old collagen. The production of collagen 
and proteinase inhibitors is stimulated by TGF-ß20, while 
the production of collagenases by fibroblasts is stimulated 
by PDGF51. The final outcome of matrix formation and 
remodeling is the scar tissue. 
ANIMAL MODELS AND CLINICAL STUDIES 
Wound healing involves complex interactions, process-
es, and numerous cell types, which cannot be completely 
duplicated in vitro. Excluding infection or other complica-
tions, the normal process of wound healing often results 
in complete restoration of tissue function. However, exog-
enously added growth factors can dramatically accelerate 
the healing process in vivo, suggesting that they are 
normally present in rate limiting concentrations. More 
importantly, situations exist in which wound healing is 
impaired and fails to respond to conventional therapy. 
These include chemotherapy, venous stasis and diabetic 
ulcers (Table 2). 
Subcutaneous implants. Several animal models have 
been developed to gauge the efficacy of growth factors in 
wound healing. A porous subcutaneous chamber is often 
used as an in vivo model for the healing of deep wounds. 
Chambers of stainless steel wire mesh or polyvinyl alcohol 
sponges are inserted into the backs of rats. The animal 
encapsulates the chamber with connective tissue, defining 
a dead space in which growth factors can be injected. The 
chambers are removed after one to two weeks and the 
infiltrated granulation tissue is examined by biochemical 
and histological techniques. While PDGF, FGF, EGF, and 
TGF-ß have all been demonstrated to stimulate granula-
tion tissue formation using this model system, TGF-ß 
appears to be the most effective52-54. To examine the 
intrinsic role of growth factors in wound healing, the 
presence of endogenous growth factors in wound cham-
ber models has also been determined. Macrophages isolat-
ed from wound chambers were found to express elevated 
mRNA levels for TGF-a, TGF-ß, PDGF, and IGF-155. 
The concentration of TGF-ß was found to peak during 
the phase of wounc) healing associated with maximal 
fibroblast proliferation and collagen synthesis54. 
Surface wounds and burns. Epidermal lesions can be 
classified as either partial or full thickness wounds. Partial 
thickness wounds extend to the dermis and heal by 
epidermal regeneration, using the wound edges as start-
ing points for regrowth. Full thickness wounds extend 
into the subcutaneous tissue and heal predominantly by 
granulation tissue formation, re-epithelialization and 
wound contraction. Pig skin is often used as a model due 
to its similarities with human skin. Growth factors are 
most often applied topically in a cream or ointment and 
healing is measured by the extent of epidermal regenera-
tion and histological evaluation. Experiments using pig 
skin have shown that repeated doses of EGF accelerated 
the rate of healing two-fold56. 
Incisional model. Full thickness linear incisions in rat 
skin is analogous to surgical wounds in humans, involving 
both epidermal and dermal healing. A single application 
of a collagen suspension containing either TGF-ß or 
PDGF to the site of incision in rat skin, increased the 
healing rate57-58. 
Impaired healing model. The efficacy of any wound 
healing factor is more easily demonstrated in animals with 
impaired wound healing. Defective wound repair can be 
induced by chemotherapy, steroids, or streptozotocin. 
When the effects of EGF, PDGF, TGF-ß and insulin on 
wound healing were compared in adriamycin treated rats, 
TGF-ß was found to be the most effective growth factor59. 
PDGF and EGF alone had no effect. A combination of 
EGF, PDGF and TGF-ß resulted in an almost complete 
reversal of adriamycin inhibition of wound healing. EGF 
was shown to prevent methyl prednisolone induced inhi-
bition of wound healing in a wound chamber model60. 
PDGF restored wound healing in streptozotocin-induced 
diabetic rats, whereas insulin had no effect. A combination 
of PDGF and insulin, however, stimulated a more rapid 
increase in collagen deposition than PDGF alone61. These 
animal models indicate that the repair process in the 
various forms of defective healing requires different 
growth factors and combinations of growth factors for 
optimal healing. 
Angiogenesis models. Growth factor stimulation of 
new blood vessel formation in vivo can be determined in 
assays using the avascular rabbit cornea, the hamster 
cheek pouch and the chick chorioallantoic membrane. All 
three assays are scored by blood vessel growth toward the 
angiogenic factor but are difficult to quantitate. Concor-
dant with the in vitro observations, FGF's are potent 
angiogenic factors in all three assays45. As discussed 
previously, TGF-ß is a strong growth inhibitor of capillary 
endothelial cells in vitro, but a potent angiogenic factor in 
vivo*9. Thus, extrapolations between in vitro and in vivo 
can not always be made. 
Clinical studies. EGF, the most studied growth factor, 
is currendy in clinical trials and under development for a 
number of indications such as topical administration for 
wound and burn healing, in opthalamology to accelerate 
healing of corneal surface abrasions and corneal trans-
plants after cataract removal, and in the treatment of 
gastric ulcers. Preliminary human clinical data shows that 
the mixture of growth factors in platelets can restore 
healing in patients with chronic nonhealing ulcers due to 
diabetes, chronic venous stasis, systemic lupus erythema-
tosus or rheumatoid arthritis62*63. This demonstrates the 
therapeutic potential of combinations of growth factors 
for in vivo wound healing. Apart from synergism, multiple 
growth factors will probably be necessary for the complete 
repair of a wound involving multiple tissues. 
Delivery methods and formulation. As the efficacy of 
growth factors for wound healing indications is estab-
lished, delivery methods and formulation criteria will 
become critical issues for the commercial development of 
the growth factor. Bandages, gels and lotions are current-
ly being used for topical applications of growth factors to 
the area of soft tissue wounds. For ophthalmic applica-
tions, eye drops could be used to deliver growth factors. 
The sustained release of growth factors may be more 
effective than separate applications. Although EGF in 
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saline solution was unsuccessful in certain wound healing 
models, EGF in slow release formulations, such as multila-
mellar liposomes or collagen gels, has been shown to 
enhance the re-epithelialization and tensile'strength of 
wounds64. Moreover, collagen gels are biodegradable and 
may also enhance the stability of the growth factor. 
Biodegradable film made of collagen or fibronectin could 
function as a delivery vehicle, provide protection and act 
as a substrate for epithelial cell migration and adhesion. 
As previously mentioned, the presence of specific growth 
factors at defined times is required for the optimal healing 
of wounds. An ideal vehicle, therefore, would release 
growth factors at different rates so that the wound would 
receive the optimal stimulating and Inhibitory signals at 
the proper time over the entire course of the healing 
process. 
CONCLUDING REMARKS 
Growth factors are essential throughout the initial 
events following injury and throughout later stages of 
wound repair affecting matrix remodeling and increasing 
the tensile strength of the scar. Simple topical application 
of these factors has been shown to increase the rate of 
wound healing in several model systems and combinations 
of factors appear to work synergistically. The controlled 
release of growth factors into the injury site will probably 
be necessary to prevent overstimulation and excessive 
scaring. Crude platelet extracts, containing multiple fac-
tors, have been shown to have significant therapeutic 
effects on patients with refractory wound healing. The 
exact contributions of each factor and the interactions 
between different factors are currently areas of intensive 
academic and industrial research. Understanding the nor-
mal healing process is essential in order to optimize 
intervention in the repair process by the addition of 
exogenous growth factor formulations. Growth factor 
research may also lead to the development of novel 
molecules which can inhibit the abnormal growth of 
cancer cells. A more detailed knowledge of growth factor 
receptor structure and function, regulation of growth 
factor genes, and activation of latent forms, may lead to 
the second generation of wound healing agents. 
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CHAPTER ELEVEN 
Concluding Remarks and Prospects 
CONCLUDING REMARKS AND PROSPECTS 
Growth Factors are multifunctional 
The aim of the work described in this thesis was to identify novel human growth 
inhibitory proteins that specifically inhibit the growth and/or cause terminal differentiation 
of tumor cells. This research resulted in the isolation and characterization of human TGF-
/83 (Chapter 4). TGF-03 was shown to inhibit the growth of several (but not all) types of 
tumor cells (Chapter 6). Additionally, TGF-/S3 was found to stimulate cell proliferation of 
osteoblasts (Chapter 7) and rat kidney fibroblasts in soft agar (Chapter 6). TGF-/S3 was 
also shown to have an effect on the differentiation on certain target cells, as it induced 
mesoderm formation in Xenopus ectoderm expiants (Chapter 9). These results indicate 
that the effect of TGF-/83 is not strictly growth inhibitory but multifunctional. The particular 
effect of TGF-/73 on a cell appears to be determined by the cell type, the physiological state 
of the cell, the presence or absence of other growth factors and binding proteins, and the 
surrounding microenvironment (eg. extracellular matrix and type of adjacent cells). In 
general growth factors appear to have pleiotropic effects (Roberts and Sporn, 1988). 
These multifunctional characteristics clearly implicate the necessity of a tight control of 
growth factor activities in vivo. This requirement may have driven the need to evolve 
multiple members of a gene family, with different expression and activation patterns, the 
levels of which are rapidly regulated in vivo in response to a variety of control signals. 
Growth Factor Families 
As the amino acid sequences of more growth factors are elucidated, it is apparent 
that a number of factors are structurally related and can be grouped into families (Chapter 
2). TGF-ySs are a family of growth factors of which five different genes, to date, have been 
identified in vertebrates. Thus far, three homodimeric isoforms, TGF-01, TGF-/J2 and TGF-
03 have been described in mammals. Each of the mammalian TGF-/8S is produced as a 
larger precursor protein which is proteolytically processed into a 112 amino acid mature 
form. The biologically active mature forms of the TGF-/8S share between 70-80% sequence 
identity, with a strict conservation of all nine cysteines (Chapter 4). A comparison of TGF-
£1 and TGF-/93 at the gene level reveals a conservation of all intron-exon junctions with the 
exception of the first intron, suggesting that the two genes are the result of an ancestral 
gene amplification (Derynck, etal., 1988). 
The interspecies amino acid sequences within the mature domain of individual TGF-
ß family members is virtually complete (nearly 100%) conservation. The intraspecies 
divergence between the different TGF-y? family members is much higher (approximately 70-
80%). On this basis, it is reasonable to assume that each family member within an 
organism in vivo may be functionally distinct. Indeed, significant differences in both 
biological potency and receptor affinities between JQF-ß isoforms on certain cell types 
have been observed in vitro (Chapters 7, 8 and 9; Ohta, era/., 1987; Cheifetz, etal., 1987; 
Rosa, etal., 1988; Jennings, etal., 1988). However, thus far no unique receptor forms that 
are isoform specific have been identified. 
Different physiological roles for the multiple isoforms of TGF-0 is also suggested by 
differential transcriptional regulation, with each isoform being controlled by unique gene 
regulatory promoter/enhancer elements. Recently, in a collaboration with Rosemary 
Akhurst and colleagues (University of Glasgow, UK), we have shown by in situ hybridization 
on tissue sections the expression of TGF-/?1, TGF-/?2 and TGF-/J3 in discrete regions of 
many tissues with characteristic temporal and spatial expression patterns (Gatherer, etal., 
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1990). Similar differential expression patterns were found in human and murine 
embryogenesis, suggesting an evolutionary pressure on preserving the gene regulatory 
elements of the individual TGF-/8s and possible functional difference between different TGF-
ßs in vivo. 
Differences in post-transcriptional regulation may represent yet another mechanism 
for distinct regulation of TGF-/te leading to different in vivo activities. The tetrabasic 
proteolytic cleavage site for TGF-01 is different from TGF-/82 and TGF-/83. Recombinant 
expression of TGF-/M and TGF-/92 in CHO cells indicated that the TGF-/01 precursor is 
more efficiently processed than the TGF-02 precursor (Madisen er al., 1990). The 
precursor domains of the TGF-/te show only 27% sequence identity. These domains may 
confer biological specificity in tissue targeting. Furthermore, as TGF-/8S are produced in 
an inactive form in which the N-terminal precursor remnant (also termed latency associated 
peptide) is complexed with the mature protein, the physiological activation mechanism may 
be specific for the different latent TGF-0 complexes. The activity of TGF-/7S can also be 
modulated by TGF-/9 binding or inactivating proteins. TGF-/7S bind to the soluble form of 
betaglycan (Massague et al., 1990) and to the proteoglycan decorin (Yamaguchi ef a/., 
1990). In addition, in serum, a complex between o2-macroglobulin and mature TGF-y9 can 
be isolated, which is inactive (O'Conner-McCourt and Wakefield, 1987; Huang era/., 1988). 
It has been proposed that o2-macroglobulin may function as an in vivo scavenger providing 
a clearance mechanism to restrict the action range of IGF-ß. Comparing the affinities of 
o2-macroglobulin for TGF-/te show that TGF-/92 binds with a higher affinity than TGF-/S1 
(Danielpour and Sporn, 1990). 
The structural and regulational differences between the TGF-/7s are likely to result 
in different physiological roles. It will be important to address this more directly by (i) 
immunohistochemical studies with, for example, isoform specific antibodies that distinguish 
between active and latent TGF-/?, (ii) pharmacological studies with the latent/mature TGF-
/8s, (iii) cloning of the TGF-/? receptors, allowing studies for a better understanding of TGF-
ß signaling and in vivo receptor localization, and (iv) experimental manipulation of in vivo 
expression and action of TGF-0S using transgenic animals. 
Embryogenesis, Wound Healing and Cancer 
There is growing evidence that many of the events which occur in embryogenesis 
are recapitulated in wound healing and cancer. Processes like mitogenesis, Chemotaxis, 
angiogenesis and formation and remodeling of connective tissue that occur during 
embryogenesis involve mechanisms similar to those in the processes of wound healing and 
cancer. The products of proto-oncogenes and growth factors, including TGF-/9s 
(discussed below), play a critical role in these processes as signaling mediators (Chapters 
2 and 3). It has been proposed that one of the key differences between physiological 
processes like embryogenesis and wound healing, versus pathological processes like 
tumorgenesis, is the activity of proto-oncogene products or growth factors being expressed 
out of context, ie. at the wrong time or in the wrong cell type. Not surprisingly, therefore, 
a wound has been compared to a tumor that heals itself (Haddow, 1972; Dvorak, 1986). 
Immunohistochemical studies using TGF-/S1 antibody in the developing mouse 
embryo suggest that TGF-/S1 functions in the remodeling of embryonic tissue (Heine era/., 
1987). Staining with the TGF-/S1 antibody was most intense during morphogenesis of 
mesenchyme derived tissues, such as connective tissue, cartilage and bone. This 
correlates well with the role of TGF-/te in wound healing and tissue repair, where TGF-/7s 
can serve as potent stimulators of extracellular matrix formation, angiogenesis and growth 
stimulators of fibroblasts and osteoblasts. Intradermal treatment with TGF-/? induces the 
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formation of granulation tissue (Roberts étal., 1986), which is a characteristic phase during 
wound repair (Chapter 10). Strikingly, granulation tissue and tumor stroma consist of the 
same elements, including inflammatory cells, neovasculature and connective tissue 
(Roberts et al., 1988). Tumor cells often secrete higher levels of TGF-y9 than their normal 
cellular counterparts (Derynck etal., 1987; Jakowlew etal., 1988; Niitsu era/., 1988) which 
may, via paracrine effects, stimulate stromal elements surrounding the tumor and thereby 
create a favorable microenvironment for rapid tumor growth. In rouse sarcoma virus(RSV)-
infected chickens wounding can act as a tumor promoter with TGF-/7 being the mediator 
in this process (Sieweke et al., 1990). In the RSV-infected chickens, TGF-0 is present 
locally after wounding (and not in control tissue) and subcuteneous injected TGF-0 in RSV-
infected chickens can substitute for wounding, leading to tumor formation (Sieweke etal., 
1990). Additionally, TGF-/& may play roles in tumorigenesis in other manners. Some 
tumor cells have lost their growth inhibitory responsiveness to TGF-/9s (Chapter 6; Keller 
et al., 1989; Kimchi et al., 1988) which may lead to abnormal growth. TGF-£s may also 
contribute to tumorigenesis and metastasis by their potent immunosuppressive activity 
(Kehrl, et al., 1986 a, b). The secretion of TGF-/9 by tumor cells may decrease the host 
immune surveillance. Glioblastoma patients are severely immune suppressed, and the 
causative agent appears to be high levels of TGF-/82 secreted by the tumor cells (Wrann 
etal., 1987). 
Growth factors and their cellular response systems appear to play a key role as 
signaling agents in embryogenesis, wound healing as well as cancer. As the underlying 
mechanisms are the same, the results from one field of study may lead to a concomitant 
understanding of the other research areas. 
Therapeutic Applications of Growth Factors 
TGF-/8S as therapeutic agents, show promise for multiple conditions, including 
wound healing, bone repair, immunosuppression, anti-inflammation and as adjuvant cancer 
therapy for chemo- and radioprotection (Chapters 3 and 10). Clinical trials with TGF-/te are 
underway for treatment of psoriasis and ulcers. Currently, we are evaluating the use of 
TGF-#3 to reduce chemotherapy associated cytotoxicity. In the treatment of neoplastic 
disease the toxicity of chemoterapeutic drugs to the hematopoietic system is a major 
limiting factor. In collaboration with Bayard Clarkson and colleagues (Memorial Sloan-
Kettering Cancer Center, USA) we found that TGF-/Ö at pico Molar concentrations 
completely inhibits the growth of human hematopoietic stem cells (Strife et al., 1990). 
Growth inhibition of over twenty different tumor cell lines, however, required a dose of 
TGF-/J3 that is approximately three orders of magnitude higher. Some tumor cells did not 
respond to TGF-y? at all (K.K. Iwata and P. ten Dijke, unpublished results and Chapter 6). 
Assuming this is not an artifact due to the differences between primary cells and cultured 
cell lines, it should be possible to use TGF-/83 to protect the stem cell proliferation in vitro, 
while using cell-cycle specific cytotoxic agents to purge the bone marrow cells of residual 
tumor cells prior to the autologous bone marrow transplants. Recently, Goey ef a/., 
demonstrated that TGF-01, injected as a single bolus into the femoral artery of mice (5 
(jg/mouse) produced a suppression of multipotential progenitor cells, in a reversible 
manner, suggesting that TGF-£s may prove useful as chemoprotective agents in vivo. If 
this were possible in cancer patients, TGF-/0S could dramatically decrease the side effects 
of conventional chemotherapy, as well as allowing the implementation of a significant more 
aggressive chemotherapeutic regimen. 
A small number of growth factors have already entered the clinic and shown to be 
efficacious, sometimes with no significant side effects (Bronchud and Dexter, 1989). Many 
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more growth factors are being evaluated as potential therapeutics. However, it will entail 
a further understanding of the molecular and cellular mechanisms that determine their 
(patho)-physiological roles and pharmacological activity before most growth factors can be 
used as therapeutic agents. 
As growth factors act in combinations in vivo, an effective cocktail of growth factor 
may exist for specific therapeutic indications. Moreover, the presence of any one specific 
growth factor may only be required at defined times as the differentiation state and 
microenvironment changes during treatment. Furthermore, understanding the mode of 
action of each effect of multifunctional growth factor through structure-function studies may 
allow for the design of analogs with a more restricted action range. Alternatively, growth 
factor analogs (receptor antagonists) can possibly be identified that bind but do not 
activate the receptor thereby blocking growth factor action. Analysis of growth factor 
binding sites with inactivating (scavenger) proteins may lead to analogs with a prolonged 
in vivo half life and overcome problems with high or multiple dose requirements. 
Additionally, the growth factor (receptors) may be used as research tools in high 
throughput screens for synthetic drug discovery of agonists or antagonists. Thus, we can 
use molecular biological techniques not only to isolate and produce large amounts of 
growth factors, but also to modify growth factors or to format them into drug screens to 
obtain more effective pharmaceuticals. In the near future, growth factor-based therapies 
are likely to have a major impact on medicine and may replace many existing therapies and 
provide solutions to illnesses that are currently not amenable to effective treatment. 
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CHAPTER TWELVE 
Summary/Samenvatting 
SUMMARY 
During development and tissue homeostasis, an intricate communication network 
exists to control cell growth and differentiation. Polypeptide growth (inhibitory) factors play 
an important part in inter-cellular signaling and trigger a complex intracellular transduction 
cascade, which ultimately leads to the nucleus and affects the expression of target genes. 
The induction or repression of these genes will determine if the cell divides or remains 
quiescent. A number of growth factors and their signal transducing mediators are products 
of either proto-oncogenes or anti-oncogenes. 
Recent years have seen a rapid accumulation of information on the role of growth-
stimulating regulators, while limited progress has been made to identify growth inhibitors. 
The aim of the research described in this thesis was to identify and study human growth 
inhibitory proteins, which could lead to a better understanding of the mechanisms of normal 
growth control. Additionally, such information could result in new strategies for diagnosis, 
therapeutic intervention and prevention of growth related diseases. This thesis, in 
particular, describes the cloning and characterization of one such growth inhibitor, 
transforming growth factor-/83 (TGF-/83). However, as with many other growth regulators, 
TGF-/S3 exhibits multifunctional properties, such as stimulating cell growth and affecting 
other cellular functions. 
Chapters 2 and 3 review the molecular aspects of growth control and the TGF-^s, 
respectively. Chapters 4 through 9 describe the experimental work on TGF-03: molecular 
cloning, chromosomal localization, recombinant expression, protein purification, biological 
characterization and receptor binding. The therapeutic applications of growth factors for 
wound healing are discussed in Chapter 10. 
The TGF-/te are a family of dimeric 25 kDa proteins (three homodimeric isoforms in 
mammals), with widespread effects on many cell types, including regulation of proliferation 
and differentiation and stimulation of extra cellular matrix formation. Physiologically, they 
are thought to play a role in multiple processes, including the morphogenetic events during 
embryogenesis, wound healing and bone remodeling (Chapter 3). 
The third member of the TGF-0 family was identified from cDNA libraries by 
differential hybridization with a TGF-01 cDNA probe. The TGF-/83 cDNA revealed an open 
reading frame encoding a protein of 412 amino acids, with strong similarity to TGF-01 and 
TGF-/ff2 sequences. By analogy to TGF-01 and TGF-02, we predicted the TGF-/83 
precursor to be proteolytically processed to a C-terminal mature segment of 112 amino 
acids. The N-terminal precursor segment contains four potential glycosylation sites and 
a tetra peptide RGDL, which could play a role in cellular adhesion. At the N-terminus there 
is a stretch of hydrophobic amino acid residues that probably correspond to the core of 
the signal peptide, as is found for TGF-01 and TGF-/92. Northern analysis indicates that 
TGF-/83 is expressed as a single mRNA species of -3.5 kb in multiple cell lines and 
tissues, including umbilical cord (Chapter 4). 
TGF-/J3 is highly conserved in evolution, as the presence of a related single copy 
gene was detected in a wide range of animal species. The same high degree of 
conservation is found for TGF-/M and -ß2, suggesting that all TGF-/?s play essential roles 
in physiology. The TGF-/83 gene was mapped to human chromosome 14 by Southern blot 
analysis of human-Chinese hamster somatic cell hybrid lines using a probe specific for 
TGF-/Ö. Using in situ hybridization of human metaphase chromosomes, the regional 
location of TGF-/83 on chromosome 14 to bands q23-q24, was identified. All members of 
TGF-/? superfamily have been mapped on different chromosomes (or arms) suggesting that 
after gene amplification, these genes have dispersed and subsequently diverged in 
sequence during evolution (Chapter 5). 
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Recombinant TGF-/J3 was expressed in Chinese Hamster Ovary (CHO) cells, using 
dihydrofolate reductase (dhfr) gene amplification. Using TGF-03 peptide antibodies, it was 
shown that in the conditioned media of transfected cells, both the mature as well as 
precursor forms of TGF-/83 were present. The recombinant TGF-^3 protein was purified 
to apparent homogeneity using immunoaffinity chromatography. TGF-/J3 stimulated the 
growth of normal rat kidney (NRK) cells in soft agar (in the presence of epidermal growth 
factor) and inhibited the growth of multiple tumor cell lines (Chapter 6). 
TGF-/J3 was also shown to be a potent regulator of functions associated with bone 
formation, ie. mitogenesis, collagen synthesis and alkaline phosphatase activity in 
osteoblast-enriched bone cell cultures. TGF-/33 has somewhat more potent effects than 
TGF-/S1 on these cells. Crosslinking experiments with iodinated TGF-/? showed that in 
osteoblasts, both TGF-/Ö and TGF-01 associate with three cell surface binding proteins 
(also termed receptor types I, II and betaglycan) with affinities in the pico Molar range 
(Chapter 7). 
Comparing the biological activity of the three mammalian homodimeric isoforms 
revealed that TGF-/K3 is 4 fold more potent than TGF-01 and TGF-/92 as a growth inhibitor 
of the MvlLu mink lung epithelial cell line. However, in the FBHE fetal bovine heart 
endothelial cell line, TGF-01 and TGF-/83 are at least 50-fold more potent than TGF-/Î2 as 
growth inhibitors. TGF-/8S differ in their binding to receptor types I and II, which are 
implicated in signal transduction. TGF-/91 and TGF-/Ö are much more potent than TGF-
02 as competitors for binding of 125l-labeled TGF-01 to receptors I and II, which does not 
correspond with their potency on mink cells. We demonstrated the presence of a subset 
of type I and II receptors that have a high affinity for TGF-02 in mink cells, but not in FBHE 
cells, that may lead to cell-specific differences in responsiveness to this isoform (Chapter 
8). 
TGF-/K3 induced the mesoderm formation in expiants of Xenopus blastula ectoderm, 
and it was found to be less potent than TGF-/J2, whereas TGF-/?1 alone showed no 
mesoderm induction. TGF-/S3 showed synergism with basic FGF and was more potent 
than TGF-/91 in this respect. The result that TGF-y9s can substitute for amphibian 
mesoderm induction signals suggests a role for these factors in mammalian early 
development (Chapter 9). 
The in vitro effects of growth factors (including TGF-/?s) suggest many potential 
therapeutic applications, including tissue regeneration, wound healing, immunomodulation 
and for the treatment of cancer. Some growth factors are already in clinical trials and have 
been shown to be efficacious (Chapters 10 and 11). 
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SAMENVATTING 
De cellulaire groei en differentiatie worden tijdens de embryonale ontwikkeling en 
weefsel-homeostasis gecontroleerd door een ingewikkeld communicatienetwerk. Een 
belangrijke rol in de inter-cellulaire signaalgeving wordt vervuld door polypeptide 
groeifactoren. Deze factoren kunnen na cellulaire uitscheiding met sterke affiniteit zich 
specifiek binden aan de op het celoppervlak gelegen herkenningseiwitten (receptoren) en 
vervolgens kunnen ze een ingewikkelde intra-cellulair transductie-cascade induceren. De 
signalen bereiken uiteindelijk de celkern, waar de expressie van een selectief aantal genen 
verandert. De inductie of repressie van deze genen is bepalend of celdeling optreedt, of 
de cel in een rustende toestand blijft. Een aantal bemiddelaars, betrokken in de inter-en 
intra-cellulaire signaal-mechanismen, zijn producten van proto-oncogenen of anti-
oncogenen. 
In de laatste jaren is een grote hoeveelheid informatie verzameld over de rol van 
groeistimulerende factoren. Er is echter weinig voortgang gemaakt bij het onderzoek naar 
factoren betrokken zijn bij de groeiremming. De identificatie en karakterisering van 
groeiremmers is noodzakelijk voor een beter begrip van de regulatie-mechanismen 
betrokken bij de normale groei. Bovendien kan deze kennis mogelijk worden toegepast 
in de ontwikkling van nieuwe strategieën voor het stellen van de diagnose, therapeutische 
interventie en preventie van groei-gerelateerde ziekten. Dit proefschrift beschrijft de 
klonering en karakterisering van een dergelijke groeiremmer, transforming growth factor-
ßß (TGF-/?3). TGF-/S3 heeft echter niet alleen een groeiremmende activiteit, maar vertoont 
zoals veel andere groeiregulatoren een multi-functioneel gedrag. 
De hoofdstukken 2 en 3 geven respectievelijk een overzicht van de moleculaire 
aspecten van groeiregulatie en TGF-/?'s. De hoofdstukken 4 tot en met 9 beschrijven het 
uitgevoerde experimentele werk aan TGF-#3 : de moleculaire klonering, chromosomale 
lokalisering, recombinante expressie, eiwitzuivering, biologische karakterisering als een 
groei- en differentiatie-regulator en de receptorbinding. In hoofstuk 10 worden tenslotte 
de therapeutische toepassingen van groeifactoren voor wondheling behandeld. 
TGF-/?'s vormen een familie van dimere 25 kDa eiwitten (drie homodimere iso-
vórmen in zoogdieren) met een grote verscheidenheid aan biologische effecten, 
waaronder de regulering van celdeling en differentiatie en de stimulering van 
extracellulaire matrix-vorming. TGF-/?'s vervullen mogelijk een functie in meerdere 
fysiologische processen, waaronder de morphologische gebeurtenissen tijdens de 
embryogenese, wondheling en de opbouw en afbraak van been (hoofdstuk 3). 
Het derde lid van de TGF-/? familie werd geïsoleerd uit een cDNA-bank door 
differentiële hybridisatie met een TGF-£1 -probe. Het TGF-#3 cDNA bevat een open 
leesraam, koderend voor een eiwit van 412 aminozuren met sterke sequentie-homologie 
met TGF-01 en TGF-02. We voorspelden, naar analogie van TGF-01 en TGF-^2, dat het 
TGF-/S3 precursor-eiwit proteolytisch wordt gesplist tot een carboxy terminaal biologisch 
actief segment van 112 aminozuren. Het amino-terminale uiteinde bevat vier potentiële 
glycosyleringsplaatsen en een tetrapeptide RGDL, hetgeen een rol zou kunnen spelen in 
de cellulaire adhesie. Het amino-terminale uiteinde is rijk aan hydrofobische aminozuren 
en correspondeert waarschijnlijk met een signaal-peptide, analoog aan TGF-/ÊM en TGF-
ß2. Northern blot analyse van diverse cellijnen en weefsels geeft aan dat de TGF-/93 in 
deze cellen gekodeerd is door een enkel mRNA-transcript van 3.5 kb (hoofdstuk 4). 
Het TGF-/73 gen werd gelokaliseerd op het menselijke chromosoom 14 door 
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Southern blot analyse van mens-chinese hamster somatische cel-hybriden, 
gebruikmakend van een specifieke probe voor TGF-/J3. Met behulp van in situ hybridisatie 
met een TGF-/83-probe op humane metafase chromosomen werd de regionale locatie van 
TGF-/83 op chomosoom 14, band q23-q24, bepaald. Alle leden van de TGF-/9 familie 
liggen op verschillende chromosomen, wat erop wijst dat na genvermeerdering deze 
genen zijn verspreid en gedurende de evolutie vervolgens in sequentie gedivergeerd zijn 
(hoofdstuk 5). 
Recombinant TGF-/?3 werd tot expressie gebracht in eierstok cellen van een 
chinese-hamster (CHO), gebruikmakend van dihydrofolate reductase (dhfr) 
genvermeerdering. Met behulp van TGF-/73 peptide-antilichamen werd aangetoond dat 
geconditioneerd media van getransfecteerde cellen, zowel de gesplitste (25 kDa), alswel 
de precursor (100 kDa) vorm van TGF-#3 bevatte. Het recombinant TGF-/S3 eiwit werd 
gezuiverd tot ogenschijnlijk homogeniteit, gebruikmakend van immuno affiniteits-
chromatografie. Gezuiverd TGF-/Î3 stimuleert de groei van normale niercellen van een rat 
in zachte agar (in aanwezigheid van epidermal growth factor) en remt de groei van 
meerdere tumorcellijnen (hoofdstuk 6). 
TGF-/83 is ook een sterke regulator van functies, geassocieerd met been-vormtng, 
zoals celproliferatie, collageenvorming en basische fosfatase-activiteit. In osteoblast 
verrijkte beencelcultures blijkt TGF-/73 iets meer biologisch actief te zijn dan TGF-/?1. 
Kruisbinding-experimenten met radioactief gelabelde TGF-/?'s geven aan dat in 
Osteoblasten zowel TGF-/?3 alswel TGF-/?1 associëren met drie membraaneiwitten 
(receptor types I en II en betaglycan) met een affiniteit in de orde van pico-molair 
(hoofdstuk 7). 
Vergelijking van de biologische activiteit tussen de drie zoogdier homodimere TGF-
ß isovormen geeft aan dat voor MvILu minklong-epitheelcellen TGF-#3 een 4 keer zo 
grote groeiremmende werking heeft als TGF-/?1 en TGF-/?2. TGF-/?1 en TGF-/S3 remmen 
echter de groei van FBHE foetale-koehart-endotheelcellen 50 keer zo sterk als TGF-/?2. 
De TGF-0's verschillen in affiniteit voor de receptortypes I en II, die zijn betrokken in 
signaal-doorgeving. TGF-/71 en TGF-#3 zijn meer kompetitief dan TGF-/?2 van de 
receptorbinding van 125l-gelabeled TGF-/Î1, hetgeen niet correspondeert met hun relatieve 
groeiremmende activiteit voor mink-cellen. Wij hebben aangetoond aan dat een bepaalde 
subgroep van type I en II receptoren met een sterke affiniteit voor TGF-/S2 aanwezig is in 
mink-cellen, maar niet in FHBE-cellen. Dit zou de celspecifieke verschillen in gevoeligheid 
voor deze isovormen kunnen verklaren (hoofdstuk 8). 
TGF-/S3 vertoont ook mesoderm-inducerende activiteit voor cellen van Xenopus 
blastula-ectoderm. TGF-/73 blijkt hierin minder actief te zijn dan TGF-/?2. TGF-/71 alleen 
vertoont geen mesoderm-inducerende activiteit. Zowel TGF-/?1 alswel TGF-/?3 vertonen 
synergie met basische FGF,waarbij TGF-/?3 meer biologisch actief is dan TGF-/?1. De 
waarneming dat de TGF-/ff's mesoderm kunnen induceren in Xenopus, wijst ook op een 
mogelijke rol voor deze factoren in de vroege embryonale ontwikkeling van zoogdieren 
(hoofdstuk 9). 
De in vitro effecten van groeifactoren (waaronder TGF-/?'s) wijzen mogelijk op 
verschillende therapeutische toepassingen, waaronder weefselregeneratie, wondheling, 
immuno-modulatie en op de genezing van kanker. Sommige groeifactoren worden 
inmiddels al toegepast in de kliniek en blijken effectief te zijn zonder nadelige 
neveneffecten te vertonen (hoofdstukken 10 en 11). 
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